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1. Introduction 
Influenza is an infectious disease. The most common symptoms are chills, fever, sore throat, 
muscle pains, severe headache, coughing, fatigue and general discomfort. In serious cases, 
influenza causes pneumonia, which can be fatal, particularly for the young and elderly. 
Typically, influenza is transmitted through the air by coughs or sneezes, creating aerosols 
containing the virus. Furthermore, influenza can be transmitted by direct contact with bird 
droppings or nasal secretions, or through contact with contaminated surfaces. Influenza 
spreads around the world in seasonal pandemics, resulting in deaths of between 250,000 and 
500,000 people every year, up to millions in some pandemic years
1
. The most effective way 
to prevent the disease or severe outcomes from the illness is vaccination. 
 
1.1 Expression systems for the production of recombinant vaccines 
The success of a vaccine is governed by three critical factors, namely safety, cost and 
efficacy. Ideally, vaccines should be free of sight effects, lack residual pathogenicity and 
should have no potential for reversion to virulence. With respect to cost, all expenditures 
related to research, licensing and production must be taken into account and balanced against 
market demand. In terms of efficacy, they should offer protection from disease, which 
depends in large part on their ability to trigger immune response appropriate to the pathogen 
targeted. With the advent of molecular cloning techniques in the 1970s, large-scale production 
of recombinant subunit antigens became possible using heterologous protein expression 
systems, such as Escherichia coli (E. coli) and yeast. The ability to produce large amounts of 
purified antigen in non-pathogenic, single-celled organisms had advantages with respect to 
cost and safety, and led quickly to the development of successful vaccines for humans and 
animals
2,3
. 
By the mid-1980s, genetic engineering techniques made an alternative approach possible, 
namely, alteration of genes for virulence determinants to produce rationally attenuated 
pathogens. These altered organisms could be "marked" in such a way that they could be 
distinguished from wild type pathogens, thus making them useful in eradication programs. 
Shortly thereafter, genetic engineering techniques facilitated the application of viral and 
bacterial vectors as delivery systems for candidate vaccine antigens. This approach led e.g. to 
the development of successful vaccines for rabies using vaccinia and canarypox as life vectors 
for the delivery of the rabies virus G-glycoprotein
4
. Finally, in the 1990s, plasmid expression 
Introduction  2 
vectors (so called "DNA vaccines") encoding microbial antigens offered another promising 
approach toward vaccine development
5
. Referred to broadly as genetic immunization, this 
method has been found to be highly effective against a wide range of pathogens, is low in cost 
and at least theoretically safe
3
. 
When compared with live agents and DNA vaccines, recombinant subunit antigens have clear 
advantages from a licensing and regulatory standpoint. Additionally, once expressed, 
recombinant antigens can be rapidly purified using for instance affinity tags and administered 
to animals at high concentration levels. Furthermore, the supplementation with new 
generation vaccine adjuvants, have enhanced the immunity in vertebrate hosts
3
. When using 
especially the E. coli system for the expression of recombinant antigens, missfolding and an 
incorrect processed protein that lack conformational epitopes required for the production of 
neutralizing antibodies depicts a problem
6,7
. Similarly, the formation of protein aggregates 
(inclusion bodies) commonly seen following overexpression in bacterial systems is 
detrimental to native 3-dimensional structure of the vaccine candidate
6
. While more complex 
eukaryotic systems (insect and mammalian tissue culture cells) are more accurate from the 
standpoint of protein folding and processing, they are more cost intensive
3
. 
Despite its obvious strength and clear success with some antigens, E. coli remains 
problematic, particular for viral and metazoan membrane proteins. Established alternatives to 
E. coli include yeast based expression systems, and cultures of insect cells where 
overexpression is performed applying baculovirus vectors. Among the fungi, Baker´s yeast 
(Saccharomyces cerevisiae), and methylotropic strains of yeast such as Pichia pastoris 
(P. pastoris) are most efficient with respect to yield. Furthermore, yeasts are capable of 
secreting proteins into the extracellular space, and are clearly superior to bacteria with respect 
to protein folding. Nevertheless, certain post-translational modifications, in particular N- and 
O-linked glycosylation patterns, vary with those seen in higher cells, with potential 
implications for antigenicity and immunogenicity. Additionally, studies with the 
G-glycoprotein from rabies virus have clearly demonstrated that a majority of the protein 
expressed in S. cerevisiae is insoluble and non-immunogenic
8
. Insect cells on the other hand, 
provide a more natural environment for the expression of recombinant proteins produced in 
higher eukaryotes including viral antigens
3
, so that the G-glycoprotein expressed in Sf9 insect 
cells did provide protection
9,10
. Additionally, the expression of hemagglutinin what is 
applicable for a vaccine, from the influenza A virus was successfully reached using the insect 
cell/baculovirus production technology
11-14
. More recently, plants have emerged as another 
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promising alternative since they are the largest and most economical biomass generators. 
They possess an eukaryotic posttranslational modification machinery similar to that of 
mammals, and they do not harbor human pathogens
15
. The hemagglutinin produced in 
icotiana benthamiana plants applying an avian influenza virus hemagglutinin showed 
antigenicity in vitro and immunogenicity in vivo
16,17
. 
Additionally, virus propagated in mammalian cell-derived tissue culture has been reported to 
be representative of the natural virus
18
. Hence, mammalian cell-derived influenza vaccine has 
been shown to provide equivalent or better protection in animal models than egg-derived 
vaccine
18-20
, and in clinical trials has been shown to be both safe and efficacious
21,22
. Three 
continuous cell lines are currently in use, Madin-Darby canine kidney (MDCK) cells
21-25
, 
African green monkey kidney (VERO) cells
20,25-27
, and the human retina PER-C6 cells
28
. 
MDCK cells are favored because of higher yields
25
, but this adherent cell line has to be grown 
in cost intensive bioreactor infrastructure like in a microcarrier culture
24
. Another 
disadvantage, using MDCK cells, is the tumorigenicity when injected into 
immunocompromized mice
29
. 
None of the expression systems, currently available for recombinant protein production, is 
ideal. The variety of systems being in development and the large number of basic approaches 
for the improvement of existing expression platforms shows the necessity of optimization in a 
broad range and documents the requirement of recombinant vaccines. The number and 
complexity of the proteins will require an equally portfolio of production methods. For this 
purpose, a large interest in new production systems exists, which could be used for a 
multitude of proteins as well as for a unique protein. 
 
1.1.1 Production of influenza vaccines 
Influenza A viruses represent a continuous pandemic threat and are responsible for a highly 
contagious, acute viral respiratory disease, which causes significant morbidity and mortality 
worldwide each year
30-36
. Influenza disease impacts every year up to 10 % of the world´s 
population, that is up to 500 millions of people
37
. Vaccination has been the most effective way 
to prevent the disease. Although, classical egg-derived influenza vaccines can be sufficiently 
produced in quantities that are needed in an inter-pandemic seasonal influenza situation, they 
may be insufficient in case of pandemic influenza. Current influenza vaccines include a single 
isolate of three antigenetically distinct influenza virus subtypes, two influenza A virus strains 
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(H1N1 and H3N2), and a single influenza B virus isolate. Annual reformulation in an attempt 
to antigenetically match the circulating strains for each of the three subtypes is a 
time-consuming process
37
. Furthermore, various studies have shown that the passage of virus 
in hen´s eggs can alter the composition of the hemagglutinin making it different from the wild 
type virus
38-40
, so that immune responses do not correspond exactly with the structure of the 
circulating clinical virus making the vaccine less efficacious
19
. This increases the need to 
produce a recombinant vaccine. 
Influenza A virus is a negative-sense single-stranded RNA virus belonging to the 
Orthomyxoviridae family. The virion consists of a host cell-derived envelope, which is lined 
on the inner side by the matrix protein M1 (Figure 1). On the surface there are multiple copies 
of hemagglutinin (HA), which are responsible for attachment to the host cell surface 
receptors, and neuraminidase (NA), which causes the release of new virus particles from the 
host cell
41
. HA is a trimeric glycoprotein that consists of two subunits, HA1 and HA2. While 
HA1 is responsible for receptor recognition, HA2 triggers the membrane fusion. The fusion 
domain or fusion peptide of HA consists of a hydrophobic sequence located at the N-terminus 
of the HA2 subunit. Under resting conditions at neutral pH, the fusion domains are buried in 
hydrophobic pockets at the interfaces between monomers in the HA trimer
42
. Under fusion 
conditions at low pH values the fusion peptide becomes exposed and inserts into the target 
membrane
43
. The HA2 chain contains a transmembrane domain near its C-terminus that 
anchors HA in the viral envelope. The transmembrane domain and the fusion peptide are the 
only segments of HA that interact direct with the lipid bilayers of the host membranes
44
. 
Nevertheless, both full-length as well as transmembrane domain-truncated HA were tested to 
induce antibody responses in vivo. Although, for both versions, antibody responses were 
detected, but depending on the influenza strain, there were higher responses for the 
untruncated version
45
. 
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Figure 1: Schematic diagram of an influenza A virus virion. 
Two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), and the M2 ion-channel protein are 
embedded in the viral envelope, which is derived from the host´s plasma membrane. The ribonucleoprotein 
complex comprises a viral RNA segment associated with the nucleoprotein (NP) and three polymerases (PA, 
PB1 and PB2). The matrix (M1) protein is associated with both ribonucleoprotein and the viral envelope and is 
coded by the M-gene. This gene also encodes the M2 ion channel The NS gene encodes two different 
non-structural proteins
46
. 
 
Currently, influenza vaccines are generated in embryonated hen's eggs. Virions are harvested 
from the egg allantoic fluid, chemically inactivated and treated with detergent. Either a whole 
virion preparation is generated, or the HA and NA proteins are partially purified to produce 
split-product, subvirion, or subunit vaccines
47
. This system served well for over 50 years, but 
there are some disadvantages as the need of millions of high quality fertile eggs. 
Alternatively, cell culture based methods have been established for faster and higher yield 
production. However, biosafety issues and difficulties with growth and yield of certain 
isolates may cause constraints during the cell culture based production. Besides whole virus 
vaccines, subunit vaccines comprising HA and virus like particles (VLPs) are considered as 
alternative strategies and have been shown successfully to induce neutralizing immune 
response
48-57
. Recently, the three hemagglutinin proteins needed for the vaccine were 
produced in a non-transformed, non-tumorigenic continuous cell line (expresSF
+®
 insect cells) 
grown in serum-free medium. Each of the three recombinant HAs were expressed in this 
insect cell line using a viral vector from baculovirus. The individual HAs are extracted from 
the cells with buffer and detergent and further purified by using a combination of filtration 
and column chromatography
11
. This method shows a new recombinant production process. 
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Nevertheless, high costs due to the patent situation of the system represents a disadvantage of 
the baculovirus based expression platform. 
Recently, the expression system based on the common pond-water ciliate 
Tetrahymena thermophila (T. thermophila) has shown considerable promise for the 
development of recombinant subunit vaccines
58,59
. With hundreds of cilia, dense core 
granules, and alveolar sacs, its metabolism is geared to the production of membrane and 
secretory proteins. This feature is unique to ciliates, and distinguishes Tetrahymena from all 
other systems currently used for heterologous protein expression. For all these reasons, 
T. thermophila is predestinated for the production of an influenza vaccine. 
 
1.2 Tetrahymena thermophila 
Tetrahymena belongs to the phylum Ciliophora and is placed in the class 
Oligohymenophorea, subclass Hymenostomatia. The genus Tetrahymena was named in 1940, 
and includes several morphologically distinct species but also includes a large group of 
morphologically indistinguishable sibling species, originally named T. geleii and later named 
T. pyriformis. The T. pyriformis sibling-species swarm includes some species that lack 
micronuclei and other, sexual, species with micronuclei. In 1976 the original name of the 
entire assemblage, T. pyriformis, was assigned to one of its amicronucleate member, and the 
other species were given Latin binomial names like Tetrahymena thermophila
60
. 
T. thermophila is a large and complex cell yet a rather small and simple ciliate. Its normal 
dimension is about 50 µm in length and 20 µm in maximum width. What is distinctive about 
ciliates, including T. thermophila, is nuclear dualism and the arrangement of structures in the 
surface region (cortex) of the cell. T. thermophila possesses a diploid micronucleus (MIC) 
possessing two complete haploid genome sets capable of both mitosis and meiosis, plus a 
macronucleus (MAC) that is made up of multiple copies of a rearranged subset of the 
complete MIC genome (Figure 2). The germline MIC is mostly inert transcriptionally, 
whereas the somatic MAC is transcriptionally active
60
. The internal (endoplasmic) structure is 
unremarkable, except for a hypertrophy of the phagosomal compartment (food vacuoles) and 
the presence of an osmoregulatory system, the contractile vacuole that also is involved in 
ionic balance. A complex structural order is found in the cell surface region
61,62
. Underneath 
the plasma membrane, eight distinct structural systems are presented in an ordered array. 
From the outside in, these systems are: flattened membrane-enclosed cortical alveoli, 
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trademarks of the alveolate evolutionary lineage, 18 to 21 longitudinal microtubule bands, a 
continuous membrane skeleton (epiplasm), and ciliary units (basal bodies) with associated 
microtubular and fibrillar elements, longitudinal aligned in 18 to 21 rows
are longitudinal arrays of dense
parallel to the rows of basal bodies and secretory granules
endoplasmic reticulum
62
, and arrays of small Golgi elements
mitochondria. Finally, three unique cell
cortical array. A complex oral apparatus, made up of four compound ciliary elements (hence 
Tetra-hymena) embedded within an elaborate fibri
end of the cell. An elongate cell
along the same ciliary row as the oral apparatus. Two (rarely one or three) contractile vacuole 
pores lie side by side near the posterior end of the cell, to the cell´s right of the oral
meridian and external to the contractile vacuole
Figure 2: Electron micrograph and schematic diagram of 
The schematic diagram shows the anterior end of the cell
of the cell that faces the viewer. Seven of the tot
dots next to longitudinally oriented microtubule bands. Cilia are drawn emerging from the basal bodies of one of 
the ciliary rows and omitted from the other rows.
 
The plasma membrane of Tetrahymena
the outer alveolar membrane and the inner alveolar membrane which line the cortical 
alveoli
60
. The plasma and ciliary membranes appear as a typical double layer in cross section, 
 
60
-core granules (mucocysts), arrays of mitochondria lined up 
63
, flattened lamellae of the 
64
, both underneath the 
-surface landmarks are superimposed on the repeated 
llar substructure, is located near the anterior 
-anus or cytoproct is situated near the posterior end of the cell 
60
. 
Tetrahymena thermophila
65,66
. 
 that is oriented upwards, and the ventral (oral) surface 
al of 18-21 ciliary rows are seen, with basal bodies shown as 
 
 is continuous with the ciliary membrane but not with 
7 
. Continuing, there 
-cytoproct 
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with the outer layer denser
62
. An external polysaccharide surface coat is indicated by 
ruthenium red staining
67
. 
The membrane skeleton of Tetrahymena, called epiplasm, is a continuous and apparently 
amorphous dense layer that underlies the inner membrane of the cortical alveoli. Exposure to 
detergent at high ionic strength results in extraction of all microtubular structures, leaving a 
residue consisting primarily of intact membrane skeleton
68
. This cell "ghost" is a closed 
envelope that still retains the shape of the cell, indicating that the membrane skeletal layer has 
considerable rigidity, although it must be sufficiently elastic to allow Tetrahymena cells to 
alter their shape dramatically while moving through media of high viscosity
69
. The 
membrane-skeleton is separated by the circumciliary rings from the terminal plates that 
penetrate the distal end of the basal bodies. The three together form a structurally continuous 
layer
70,71
. 
 
1.2.1 Inward and outward traffic 
Tetrahymena, a ciliated organism, is an attractive model for trafficking studies because it 
possesses at least three secretory pathways, namely regulated phagocytosis, constitutive 
secretion of lysosomal enzymes, and regulated exocytosis via dense core granules 
(mucocysts)
60
. Tetrahymena forms large food vacuoles (phagosomes) at the inner end of a 
complex oral apparatus and defecates their remaining contents at a specialized cytoproct
72
. 
Lysosomes were characterized long ago in T. thermophila as a heterogeneous class of 
compartments containing lysosomal enzymes, the acid hydrolases, many of which are 
constitutively secreted into the culture medium
73-75
. In later studies, lysosomal enzymes were 
identified at two sites – food vacuoles (phagolysosomes) – and bound to the exterior surface 
of the plasma and ciliary membranes; they were interfered at a third site, believed to be small 
lysosomal vesicles
76
. 
Lysosomal enzymes, synthesized at the endoplasmic reticulum (ER), pass through the Golgi 
apparatus, and are sorted by so far unknown signals to the lysosomes. Vesicles of a pool may 
fuse with incoming phagosomes to form phagolysosomes, which are intracellularly processed, 
and whose residual contents finally are egested. Alternatively, vesicles from this pool may 
fuse with the plasma membrane at so far unknown sites, releasing soluble enzyme forms into 
the culture medium. By this pathway also membrane-bound forms of lysosomal enzymes may 
be incorporated into the plasma membrane
76
. 
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The plasma membrane of Tetrahymena overlays the alveolar membrane, where it includes 
invaginations that penetrate the cortical alveoli and the tightly adherent membrane skeleton. 
These invaginations are traditionally named "parasomal sacs" and are found just anterior to 
basal bodies in the ciliary rows
77,78
. They are also found near basal bodies of the 
membranelles and undulating membrane of the oral apparatus
79
. The parasomal sacs have a 
fuzzy coat on the cytoplasmic side, therefore called coated pits. These coated pits are the only 
places apart from the cytoproct where the plasma membrane is in regular contact with the 
internal cytoplasm
80
. The cortical alveoli and the underlying membrane skeleton are 
interposed
62
. Hence, these coated pits have been postulated to be sites both of exocytosis and 
of endocytosis
61,81
. 
Numerous ciliates and some flagellates possess cortically located membrane-bounded 
organelles that discharge their contents upon stimulation
82
. These Tetrahymena dense core 
granules (DCG; mucocysts) are ellipsoidal membrane-bounded structures, about 1 µm long, 
with a dense crystalline substructure
83
. Their tips commonly penetrate between cortical 
alveoli to abut against the plasma membrane, probably with membrane-skeleton interposed
84
. 
About 4500 of these structures are arrayed in approximately 40 longitudinal files, half of them 
along the ciliary rows and the other half along "secondary meridians" situated halfway 
between the ciliary rows at alveolar junctions
61,62
. Extrusion of the contents of Tetrahymena 
DCGs begins with the fusion of DCGs membrane with the plasma membrane at a site marked 
rosette of intramembraneous particles in the plasma membrane. The contents are expelled 
after membrane fusion, producing a latticework of filaments connected in a three-dimensional 
network (mucin)
82
. True mucins are highly glycosylated proteins bearing hydrated 
carbohydrate chains, whereas Tetrahymena mucins seem to contain little or no carbohydrates. 
Secretion by DCGs exhibits dependence on Ca
2+
 at two distinct stages. The first stage is the 
triggering of the membrane fusion, where a Ca
2+
 ionophore enter the cell an liberate Ca
2+
 
from intracellular stores such as the cortical alveoli
85
. The second stage, the activation of the 
rearrangement of the proteins of the DCGs, requires extracellular Ca
2+
 in millimolar 
concentrations. The rearrangement results from Ca
2+
 binding to these proteins subsequent to 
exocytosis
86
. When a large number of DCGs discharge simultaneously following stimulation, 
the secretion product merges to produce a thick layer that forms a capsule surrounding the 
cell
87
. The function of this secretion might be protection against predators. Chemically, the 
matrix of the DCG of T. thermophila is made up of no more than a dozen major proteins, 
which were named granule lattice proteins (Grlp)
88,89
. Five members were initially identified 
starting with isolation of the most abundant DCG content
89
. Biochemical analysis of Grl1p 
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indicated that conformational changes could underlie the crystalline expansion, whereas gene 
disruption suggested that Grl1p itself might be present throughout the entire core, because no 
visible ordered structure was formed in its absence
86
. Granules formed in such ∆GRL1 cells 
did not undergo rapid expansion upon exocytosis
89
. Screening for exocytosis-defective 
mutants among cells transformed with an antisense library, a novel family member, Grl8, was 
identified
90,91
. Granules lacking Grl8p, like those lacking Grl1p, had no discernable organized 
structure. Recent results showed that six GRL genes (GRL1, 3, 4, 5, 7 and 8) each play a 
non-redundant role in core formation
92
. But only the ∆GRL3, ∆GRL4, and ∆GRL7 lines were 
each completely defective in Alcian blue-stimulated capsule formation
92
. 
 
1.2.2 Genetics of Tetrahymena 
Ciliates characteristically possess two nuclei, a somatic macronucleus (MAC) and a germline 
micronucleus (MIC)
93
. Tetrahymena reproduces asexually by transverse cell division. During 
this asexual growth, all gene expression occurs in the MAC, which is thus considered the 
somatic nucleus. The MAC is polyploid and divides nonmitotically, with apparently random 
distribution of chromosome copies that behave as if acentromeric. In contrast, the MIC is 
diploid and contains five pairs of chromosomes, that are metacentric and are distributed 
mitotically
94-96
. In the course of cell division, phenotypic or allelic assortment takes place. 
The model for allelic assortment assumes, that daughter cells consists of about 45 copies of 
each MAC and there is no control on the specific allele distribution to the daughter MAC
97,98
. 
For any allelic pair in a heterozygote, the end point of this process is a MAC containing only 
one of the two alleles, what may result in a change in phenotype
99
. The MAC genome derives 
from that of the MIC, but the two genomes are quite distinct. During MAC differentiation, 
several types of developmentally programmed DNA rearrangements occur
100
. One 
rearrangement is the deletion of segments of the MIC genome known as internally eliminated 
sequences (IESs). Approximately 6,000 IESs are removed, resulting in the MAC genome 
being an estimated 10 % to 20 % smaller than that of the MIC
101
. A second programmed 
DNA rearrangement is the site-specific fragmentation at each location of the 15-base pair (bp) 
chromosome breakage sequence (Cbs)
102-104
. During fragmentation, sections of the MIC 
genome containing each Cbs, as well as up to 30 bp on either side, are deleted
105
. Telomeres 
are then added to each new end
106
, generating some 180 to 250 MAC chromosomes
107,108
. 
One process that occurs during MAC differentiation is the amplification of the number of 
copies of the MAC chromosomes. The minichromosome that contains two mirrorimage 
Introduction  11 
(palindromic) copies of the rRNA genes of the MIC, which encodes the 5.8S, 17S, and 26S 
rRNAs, is maintained at an average of 9,000 copies per MAC
109
. Six other chromosomes that 
have been examined are each maintained at an average of 45 copies per MAC
110
. The MIC 
first moves out to the cell periphery and undergoes mitosis. 
The sexual reproduction process is called conjugation. This process depends on three 
conditions. Firstly, cells of two different mating types must be present. Secondly, cells of both 
mating types must have attained sexual maturity. Thirdly, cells have to be in a state of 
incipient starvation, what means that the cells have been shifted into a nutritionally inadequate 
medium
111
. In mating pairs, each MIC undergoes meiosis, followed by the exchange of 
haploid products across mating junction (Figure 3). Fusion of the gametes in each cell 
generates a diploid zygotic nucleus that then undergoes mitosis. One daughter retains the 
diploid chromosome configuration and functions as the new MIC, and the other daughter 
differentiates to become the new somatic MAC. The old MAC is apoptotically destroyed. The 
two conjugating cells then separate, becoming the exconjugants, and begin to divide 
vegetatively. Using specialized strains or experimental manipulations, the normal 
developmental program for zygote formation can be perturbed. These alternative pathways 
have been harnessed to develop true heterokaryons in which the MIC and the MAC are 
genetically unrelated. Recessive lethal mutations can be stably propagated in the homozygous 
state in the transcriptionally silent MIC of heterokaryons. Mass mating between mutant 
heterokaryons generates homogenous populations of progeny that are homozygous for the 
mutant allele
112
. 
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Figure 3: Conjugation of T. thermophila
113
 
Conjugation starts with two meiotic divisions of the micronucleus (MIC) (1). Three of the haploid nuclei migrate 
to the posterior section of the cell and are disintegrated. The fourth nucleus undergoes postmeiotic mitosis (2). 
This leads to the development of two haploid daughter nuclei, followed by a substitution of one nucleus each (3) 
and the fusion with the other nucleus. A zygotous nucleus (synkaryon) arises (4). The synkaryon divides two 
times mitotically to four diploid products (5). One of the posterior located nuclei disintegrates, the second 
becomes the new MIC. The other two nuclei develop to the new MAC/anlagen (6). At this point of time the 
mating pairs divide and the old MAC is eliminated. The first division of these exconjugants leads to a division of 
the MIC. Four genomic identic daughter cells are formed, with each a MIC and a MAC (karyonides). 
 
Tetrahymena was the first member of the phylum Ciliophora to have its complete somatic 
(MAC) genome sequenced
107,108
. The amplified MAC genome consists of about 104 Mb, that 
contain more than 27,000 protein coding genes. Purified MAC genomic DNA of the 
Tetrahymena strain SB210, an inbred strain B derivate that has been extensively used for 
genetic mapping and for the isolation of mutants, was sequenced by the whole genome 
shotgun method to 9 x coverage and assembled into 2,955 contigs and 1971 scaffolds that 
appear to represent a highly accurate and complete draft genome sequence
107,108
. A performed 
gene prediction resulted in 27,424 putative protein-coding genes, over four times more than 
the most commonly studied unicellular eukaryotic model organism, 
Saccharomyces cerevisiae, and even more than many metazoans
107,108,114
. A first analysis of 
expressed sequence tags (ESTs) provided direct evidence that over 40 % of the predicted 
genes are indeed transcribed into mRNA and has allowed extensive refinement of the gene 
models
107
. About 15,000 genes match genes of other organisms. In addition to that, the 
genome analysis also elucidated that a huge number of genes are based on gene duplication 
mechanisms. This is especially true for genes that play a role in structural complexity, 
sensing, response to environmental conditions and using of different resources. The 
sequenced genome analysis of T. thermophila once more illustrates the complexity of this 
single cell eukaryotic microorganism
107,108,115
. Since the initial shotgun assembly, finishing 
efforts have succeeded in closing numerous sequencing and physical gaps. In addition, 
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MIC/MAC comparative genomic hybridization (CGH) has identified 763 small scaffolds as 
probable MIC DNA contaminants. These results in a reduced number of MAC contigs and 
scaffolds to 1,826 and 1,117, respectively
107
. These efforts also confirmed, that the MAC 
genome shows a low repetitiveness and the absence of sequences highly related to invasive 
DNA elements
107,108
. 
Tetrahymena, like many ciliates, uses an alternative genetic code, in which UGA is the only 
stop codon and UAA and UAG encode glutamine, resulting in longer potential open reading 
frames in the genomic sequence
116,117
. T. thermophila expresses a tRNA predicted to decode 
this only Tetrahymena stop codon into Selenocystein, the so called 21
st
 amino acid
107,108,118
. 
Although Tetrahymena can use all 64 codons, it does not use all. The most significant aspect 
of the codon usage in this species is that the AT-rich codons tend to be used more frequently 
than others
119
. In fact the AT pull is so strong in coding regions that amino acid composition 
of proteins is shifted toward those coded by codons with high AT codons, as seen in other 
species with extreme AT bias
120
. Also non-coding regions show high AT contents. The bias in 
codon usage is larger in highly expressed genes and these genes are less AT rich. The 
nucleotide positions before start codons is A-rich, and C is significantly avoided after stop 
codons
121
. Alternative splicing appeared to be rare in Tetrahymena, as also reported for 
Paramecium
122
. 
 
1.2.3 Tetrahymena as a heterologous expression system 
The ciliate Tetrahymena thermophila has been successfully used as a model system in 
molecular and cell biology. Fundamental discoveries such as ribozymes, telomeric repeats, 
telomerases or the function of scan RNA were first studied in this eukaryotic 
microorganism
100,107,108,123-129
. T. thermophila displays many characteristics that predestinates 
it to create safe vaccines. As a complex eukaryote, it has clear advantages over bacteria in 
terms of protein folding, processing and targeting. Besides, the apathogenicity as well as the 
high biological safety of this eukaryotic organism (GRAS-status, generally regarded as safe) 
are important points. There is no evidence that Tetrahymena contain any viruses, 
endoparasites or DNA sequences with oncogenetic potential. Therefore, the low levels of 
regulatory cGMP guidelines are, because of minor requirements for technical and personnel 
equipment, economical important
59
. The differences between humans and ciliates during 
evolution resulted in significant differences concerning the codon bias and the whole genome 
organization, indicating that it is implausible that ciliates could be a host for human 
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pathogens. In addition, nothing has been reported about toxins. T. thermophila can be used 
easily in lab-scale. A method for freezing Tetrahymena cells was developed, what is an 
important item for long term storage
130
. In addition, simple bioreactor infrastructure can be 
used and several foreign proteins have been expressed, suggesting that T. thermophila has the 
potential to become an excellent expression host
59,131,132
. It can grow very well in a variety of 
inexpensive axenic media, including skimmed milk, with generation times in the 2 to 3 hours 
range and optimally 1.4 hours
131
. Typically, cultures remain in rapid-exponential growth 
phase up to 2 x 10
5
 cells per milliliter and can reach cell densities of 2 x 10
6
 cells per milliliter 
or more
133
. Up-scalability is one of the most important problems in producing vaccines, 
because millions of vials are necessary to start and continue vaccination programs, as for 
example has already been done for measles, influenza or the hepatitis B virus. 
High-level expression of i-antigens from Ichthyophthirius multifiliis has recently been 
achieved in the Tetrahymena system using a strong inducible promoter
134
. These proteins are 
targeted to the plasma membrane in their correct 3-dimensional conformation
59
. Later on, it 
could be demonstrated that the GPI-anchored circumsporozoite protein of the malaria parasite 
Plasmodium falciparum, was expressed and targeted to the surface of T. thermophila
58
. The 
expression of a functional human protein was shown by the Cilian AG. It was successfully 
demonstrated that the expression and secretion of a human enzyme, the DNaseI, is possible. 
This recombinant human enzyme, expressed in Tetrahymena, was active, indicating that also 
disulfide bridges were correctly formed. Furthermore, a detailed N-glycan structure of the 
recombinant enzyme was presented, illustrating a very consistent glycosylation pattern
113,135
. 
This glycosylation pattern is more conform, than the pattern of higher eukaryotic cells, than 
the yeast glycosylation pattern (Figure 4). 
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Figure 4: N-glycosylation pattern of different expression systems
113
. 
The glycosylation pattern of a recombinant protein is expression host specific. While T. thermophila produces a 
consistent mannose terminated oligo-glycosylation pattern, the yeast based expression system shows N-glycans 
of the high mannose type. Recombinant proteins produced using mammalian cell culture based systems, contain 
a complex N-glycan feature with terminal galactose, N-acteylglucosamine or sialic acid residues. 
 
The nuclear dimorphism of the ciliates offers different possibilities of manipulating the 
organisms properties
136
. Altering the phenotype ultimately needs direct or indirect genetic 
engineering of the vegetative MAC. A basic requirement for the heterologous protein 
expression, is the technique to transform the expression host. A variety of DNA 
transformation techniques have been successfully applied to a broad range of organisms. For 
Tetrahymena, microinjection has been used to transform both the polyploid MAC of 
vegetative Tetrahymena and the newly formed MAC anlagen of conjugating cells
137
. 
Electroporation of vegetatively growing cells yielded a lower level of macronuclear 
transformation
138,139
. However, high frequency macronuclear transformation was obtained 
when transformation vectors were introduced directly into macronuclear anlagen of 
conjugating cells
140
. Conjugant electrotransformation (CET) yields efficient macronuclear 
transformation using high copy number vectors containing selectable markers and has been 
used to develop new vectors
141
. Later on, the efficient method for the mass transformation of 
the MAC and the MIC in T. thermophila using biolistic bombardment was developed
136
. By 
bombarding mating cells of Tetrahymena, it was possible to generate macronuclear 
transformants at a rate equivalent to the transformation frequencies obtained using CET. Also 
genetically stable micronuclear transformants and stable macronuclear transformants after 
allelic assortment were generated
136,142
. The first transformation approaches were based on the 
use of plasmids that take advantage of the vast amplification of the rDNA gene during 
anlagen/MAC development
143
. However, episomal presence of the plasmid depends on the 
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presence of antibiotics in the culture medium and the plasmids often recombinate 
homologously and non-directionally into the endogenous rDNA
113,144
. The stable integration 
of expression or knock out cassettes into the diploid MIC provides a second method to 
manipulate the ciliates genome, because after conjugation of two different mating types the 
old MACs disintegrate and new ones form that carry the new information derived from the 
recombinant MIC. The advantage is that one obtains stable clones that can be crossed via 
classical Mendelian genetics to combine various properties of different T. thermophila 
strains
145
. But this approach is elaborative and time consuming. Furthermore, it has been 
shown that scan RNAs derived from the old MAC epigenetically control the genome 
rearrangement of the new developing MAC
100,129,146
. Thus this RNAi like mechanism may 
cause problems due to partial deletion of foreign expression cassettes in the developing MAC. 
Recently, it was developed a knock out/ knock in system (pKOI) that is based on the stable 
integration into the endogenous gene locus of the bifunctional dihydrofolate reductase and 
thymidylate synthase (DHFR-TS)
142,147
. This system is based on the MAC manipulation and 
an allelic or phenotypic assortment process, based on the randomized distribution of the MAC 
chromosomes units (ARPs) during mitosis
147
. The main advantage of this system is that a 
stable knock out can be monitored by the complete loss of the DHFR-TS activity, resulting in 
an auxotrophy for thymidine
142,147
. Thus, this marker system allows the propagation of 
recombinant T. thermophila cells without the rDNA sequences, and transformants after the 
allelic assortment are stable, and do not need the addition of antibiotics
142,147,148
. 
Consequently, today there are episomal high-copy vectors including a rDNA origin or 
integrative vectors available
143,144,149-151
. So far, ciliate expression vectors rely on large double 
rDNA origin stretches to ensure a stable propagation in T. thermophila cells or on large 
flanking integration sites of non coding regions that are necessary for a proper and efficient 
homologous recombination into the gene loci of the MIC or MAC. In both cases the 
AT-richness of these functional DNA sequences cause problems in handling and cloning
142
. It 
was shown for the vector system of ciliates that a Cre-recombinase system is applicable. It 
allows the independent construction of expression cassettes using a small plasmid (donor 
vector) on the one hand side and the preparation of different T. thermophila vectors with 
integration sites (acceptor vector) on the other hand side. As a second step, expression 
cassettes can be easily shifted from the donor plasmid into various acceptor backbone 
constructs
142
. 
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For the selection of transformed Tetrahymena, the vector backbones code for a paromomycin 
resistance. Recently, a new neomycin resistance cassette has been developed that was 
optimized for the codon usage of T. thermophila. Using this optimized neo gene, a new 
resistance marker cassette has been constructed, that results when used for transformation in a 
ten times more drug resistant transformants
152
. Furthermore, a beta-tubulin marker, that uses 
the resistance to the mitotic toxin taxol, was established, and a novel blasticidin resistance 
gene was applied for the selection of transformants
58,142
. The selection of transformants 
without antibiotics was initialized by the development of thymidine auxotrophic strains. 
Furthermore, regulation of the expression of a recombinant protein can be regulated using 
constitutive as well as inducible promoters
59,134,144,153,154
. It was demonstrated that a region 
approximately 0.9 kb of the cadmium inducible MTT1 promoter was capable of driving 
high-level gene expression in T. thermophila
113,134,142
. Metallothioneins (MTs) are ubiquitous 
proteins with the capacity to bind heavy metal ions, mainly cadmium, zinc or copper. The 
MTT5 promoter region for instance, also binds other metal ions efficiently, like lead or zinc 
and is mainly expressed during conjugation induced under starvation conditions
155
. The 
MTT2 and MTT4 mainly bind copper
156,157
.  
To further enhance the expression yield a protease deficient strain was created. Additionally, 
hypersecretory strains for the acidic hydrolase Phospholipase A1 were developed
158,159
. The 
use of proprietary signal and pro peptides enables the targeting
135,147
. The recombinant 
proteins are led into the cytosol (intracellular expression), into the medium (expression and 
secretion) or to the surface (surface display)
58,59,113,135
. All these tools together, the 
ciliate-expression system is a promising molecular and cellular biological system to analyze 
putative vaccines that can be developed to an excellent platform for production of influenza 
vaccines. 
 
1.3 Scope of this thesis 
In this work, T. thermophila should be applied to develop a system for the production of an 
influenza vaccine. 
For this purpose, expression cassettes for three different hemagglutinins of two influenza A 
and one influenza B virus strain should be designed and assembled, including a gene 
optimization for the three sequences that adopt the endogenous codons to the codons preferred 
for the expression in Tetrahymena. 
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Following, these three different hemagglutinins should be produced and characterized using 
the T. thermophila expression platform. 
Afterwards, an up-scaling process should be applied for one of these three hemagglutinins 
including an optimization process for this special protein. Finally, a purification process 
should be evaluated for one of these hemagglutinins. 
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2. Materials 
2.1 Organisms 
2.1.1 Escherichia coli (E. coli) strains 
ElectroMax
TM
 DH10B
TM
 Cells 
Genotype: F-mcrA ∆ (mrr-hsdRMS-mcrBC) Ф 80lacZ∆M15 ∆lacX74 recA1 endA 1ara 
D139∆(ara,leu)7697 galU galKλ
-
rpsL nupG 
 
The E. coli strain was purchased from Invitrogen GmbH, Karlsruhe, Germany. 
 
2.1.2 Tetrahymena thermophila-strains 
T. thermophila B 1868/4 Genotype: Wild type; mating type: IV 
T. thermophila B 1868/7  Genotype: Wild type; mating type: VII 
T. thermophila B 2086/1   Genotype: Wild type; mating type: II 
 
The strains B 1868/4 and B 1868/7 of T. thermophila were purchased from ATCC, Manassas, 
VA, USA. The strain B 2086/1 was kindly provided by P. J. Bruns (1998). 
 
2.2 Media for E. coli 
LB medium     10 g/L peptone 
  5 g/L yeast extract 
  5 g/L NaC1 
  in distilled water, pH 7.5 
 
LB agar plates    15 g/L agar 
  in LB medium 
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SOC medium     Invitrogen GmbH, Karlsruhe, Germany 
 
2.3 Media for T. thermophila 
Proteose peptone (PP 1 %)   10 g/L 
      in distilled water 
 
Skimmed milk medium    20 g/L skimmed milk powder 
  5 g/L yeast extract 
  1 mL/L Ferrous sulphate/chelate solution  
   (Sigma F0518) 
  10 g/L glucose monohydrate 
  in distilled water, pH 7.0 
The glucose was autoclaved separately and after cooling down it was added to the medium 
aseptically. 
 
Supplemented proteose peptone medium (SPP) 
      5 g/L proteose peptone 
  5 g/L yeast extract 
  1 mL/L Ferrous sulphate/chelate solution 
  2 g/L glucose monohydrate 
  in distilled water, pH 7.0 
The glucose was autoclaved separately and after cooling down it was added aseptically to the 
medium. The proteose peptone was substituted with wheat peptone (5 g/L) for the 
supplemented wheat peptone medium. 
 
2.4 Buffers and solutions 
Main buffers 
Blot buffer I     300 mM Tris, pH 10.8 
  20 % (v/v) methanol p. A. 
  in distilled water 
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Blot buffer II     25 mM Tris, pH 10 
  20 % (v/v) methanol p. A. 
  in distilled water 
 
Blot buffer III     25 mM Tris, pH 10 
  40 mM 6-aminocaproic acid 
  20 % (v/v) methanol p. A. 
  in distilled water 
 
5-10 % blocking solution   5 or 10 % (w/v) skimmed milk powder or 5 % 
      BSA in PBS-T 
 
Dryls-Solution
160
    1.5 mM sodium citrate 
  1 mM NaH2PO4 
  1 mM Na2HPO4 
  1.5 mM CaCl2 
  in distilled water 
The CaCl2 solution was autoclaved separately and after cooling down it was added aseptically 
to the medium. 
 
Chemiluminescent solution   2.5 mM Luminol in DMSO 
      0.405 mM p-coumaric acid in DMSO 
      100 mM Tris-HCl, pH 8.5 
      0.011 % H2O2 
      made up to 20 mL with distilled water 
 
ICDH buffer     0.1 M tri-ethanolamine hydrochloride 
      4.6 mM isocitric acid 
      25 mM sodium carbonate 
      51.3 mM sodium chloride 
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ICDH solution    9.1 mM β-NADP 
      0.124 M MnSO4 
 
Phosphate buffered saline (PBS)  2.7 mM KCl 
  1.5 mM KH2PO4 
  137 mM NaCl 
  8 mM Na2HPO4 
  in distilled water 
 
PBS-T      0.05 % (v/v) Tween
®
20 in PBS 
 
RIPA buffer      10 mM Tris-HCl, pH 7.2 
  150 mM NaCl 
  5 mM EDTA 
  7 µM E-64 
 
Stacking gel buffer (4 x)   0.5 M Tris-HCl, pH 6.8 
  in distilled water 
 
Resolving gel buffer (4 x)   1.5 M Tris-HCl, pH 8.8 
      in distilled water 
 
SDS running buffer    25 mM Tris-HCl, pH 8.6 
  192 mM glycine 
  0.1 % (w/v) SDS 
  in distilled water 
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SDS sample buffer (4x)   200 mM Tris-HCl, pH 6.8 
  16 % (w/v) SDS 
  48 % (v/v) glycerol 
  8 % (v/v) β-mercaptoethanol 
  0.04 % (w/v) Coomassie Brilliant Blue R-250 
  in distilled water 
 
TAE buffer (50 x)    40 mM Tris 
  0,114 % (v/v) acetic acid p. A. 
  1 mM EDTA 
  in distilled water, pH 8.9 
 
Buffers for protein chromatography 
Phosphate buffer (10 mM)   15.5 mM Na2HPO4 
      4.06 mM NaH2PO4*H2O 
      in distilled water, pH 7.4 
 
Phosphate buffer (150 mM)   136 mM Na2HPO4 
      14 mM NaH2PO4H2O 
      in distilled water, pH 7.5 
 
Running buffer 1    10 mM phosphate buffer 
      5 % glycerol, pH 7.4 
 
Elution buffer 1    Running buffer 1 plus 150 mM NaCl 
 
Elution buffer 2    Running buffer 1 plus 1 M NaCl 
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Loading buffer    Running buffer 1 plus 3 % Tween
®
20 
 
Running buffer 2    10 mM phosphate buffer 
      5 % glycerol, pH 7.5 
 
Elution buffer 3    150 mM phosphate buffer 
      5 % glycerol, pH 7.5 
 
Running buffer 3    PBS 
 
Elution buffer 4    PBS 
      0.5 M methyl α-D-mannopyranoside, pH 7.4 
 
2.5 Stock solutions 
Ampicillin stock solution   100 mg/mL ampicillin in distilled water 
      working concentration: 100 µg/mL 
 
Cadmium chloride stock solution  5 mg/mL cadmium chloride in distilled water 
working concentration: 5-40 µg/mL 
 
Chloramphenicol stock solution  30 mg/mL chloramphenicol in 100 % ethanol 
      working concentration: 30 µg/mL 
 
Chymostatin     10 mM chymostatin in DMSO 
      working concentration: 10-100 µM 
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E-64      2.5 mg/mL E-64 in distilled water 
      working concentration: 7-175 µM 
 
Kanamycin stock solution   75 mg/mL kanamycin in distilled water 
working concentration: 75 µg/mL 
 
Leupeptin     10 mg/mL leupeptin in distilled water 
      50 µg/mL (120 µM) 
 
Paromomycin stock solution   130 mg/mL paromomycin sulfate 
      in distilled water 
working concentration: 150-1000 µg/mL 
 
Penicillin/Streptomycin stock solution 10 mg/mL penicillin in distilled water 
2.5 mg/mL streptomycin in distilled water 
working concentration: 250 µg/mL 
 
Zinc sulfate stock solution   1 M zinc sulfate in distilled water 
      working concentration: 2-4 mM 
 
2.6 Suppliers of antibiotic reagents 
Ampicillin     Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
Chloramphenicol    Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
Kanamycin      Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
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Paromomycin sulfate    Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Penicillin G     Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Streptomycin sulfate    Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
 
2.7 Suppliers of chemical reagents 
Acrylamide 4K-Lösung   Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
β-NADP     Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Cadmium chloride    Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Chymostatin     PeptaNova GmbH, Sandhausen, Germany 
Coomassie Brilliant Blue   Biomol GmbH, Frankfurt, Germany 
Dimethylsulfoxide (DMSO)   Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
dNTP Mix (10 mM each)   Fermentas GmbH, St. Leon-Rot, Germany 
E-64      PeptaNova GmbH, Sandhausen, Germany 
Ferrous sulphate/chelate solution (100 x) Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Isocitric acid     ICN Biomedicals GmbH, Frankfurt, Germany 
Leupeptin     PeptaNova GmbH, Sandhausen, Germany 
Luminol     Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
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Manganese sulfate    Merck KGaA, Darmstadt, Germany 
Peptone from casein    Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
Proteose peptone    BD, Franklin Lakes, NJ, USA 
Skimmed milk powder   Nordmilch eG, Bremen, Germany 
Silfar
®
      Wacker Chemie AG, Nunchritz, Germany 
SuperSignal West Pico  
chemiluminescent substrate   Thermo, Waltham, MA, USA 
Triton X-100      Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Tween
®
20     Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Wheat peptone    OrganoTechnie, La Courneuve, France 
Yeast extract     BD Biosciences, Heidelberg, Germany 
Zinc chloride     Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
2-mercaptoethanol    Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
 
Other chemicals that are not listed here were purchased from Carl-Roth GmbH & Co KG, 
Karlsruhe, Germany or from Sigma-Aldrich Laborchemikalien GmbH, Schnelldorf, Germany. 
 
2.8 Suppliers of enzymes 
Cre-Recombinase    New England Biolabs GmbH, Frankfurt,  
      Germany 
Herkulase
®
 Enhanced DNA Polymerase  Stratagene, La Jolla, Canada, USA 
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ICDH      Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
PNGase F     New England Biolabs GmbH, Frankfurt,  
      Germany 
Restriction endonucleases    New England Biolabs GmbH, Frankfurt,  
      Germany 
T4 DNA Ligase    New England Biolabs GmbH, Frankfurt,  
      Germany 
 
2.9 Suppliers of antibodies and antigens 
Influenza anti A/New Caledonia/ 
20/99 HA serum (sheep)  NIBSC, Hertfordshire, United Kingdom 
Influenza anti A/New Caledonia/ 
20/99 HA serum (guinea pig)  Sanofi Pasteur, France 
Influenza Antigen A/NewCaledonia/20/99 NIBSC, Hertfordshire, United Kingdom 
Influenza anti A/Brisbane/ 
10/2007-like HA serum  NIBSC, Hertfordshire, United Kingdom 
Influenza Antigen A/ Brisbane/ 
10/2007-like (prepared from A/ 
Uruguay/716/2007)  NIBSC, Hertfordshire, United Kingdom 
Influenza anti B/Florida/4/2006  NIBSC, Hertfordshire, United Kingdom 
Influenza Antigen B/Florida/4/2006  NIBSC, Hertfordshire, United Kingdom 
Anti-sheep IgG-Peroxidase antibody 
produced in donkey    Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
Anti guinea pig IgG-Peroxidase antibody 
produced in goat    Sigma-Aldrich Laborchemikalien GmbH,  
      Schnelldorf, Germany 
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2.10 Suppliers of standards 
2.10.1 Protein standard 
PageRuler™ Plus Prestained  
Protein Ladder    Fermentas GmbH, St. Leon-Rot, Germany 
 
2.10.2 D&A standards 
GeneRuler
TM
 100 bp Ladder plus  Fermentas GmbH, St. Leon-Rot, Germany 
GeneRuler
TM
 1 kb DNA Ladder  Fermentas GmbH, St. Leon-Rot, Germany 
 
2.11 Suppliers of kits 
DNeasy blood and tissue Kit   Qiagen GmbH, Hilden, Germany 
FastPlasmid
®
 Mini Kit   5 Prime GmbH, Hamburg, Germany 
HiSpeed™ Midi Kit    Qiagen GmbH, Hilden, Germany 
Imperial™ Protein Stain Kit   Thermo, Waltham, MA, USA 
Montage™ PCR Centrifugal Filter Devices Millipore GmbH, Schwalbach, Germany 
QIAquick Gel Extraction Kit   Qiagen GmbH, Hilden, Germany 
RNeasy Plus Mini Kit   Qiagen GmbH, Hilden, Germany 
RevertAid™ First Strand cDNA 
Synthesis Kit     Fermentas, St. Leon-Rot, Germany 
 
2.12 Suppliers of consumables 
Gold particles (0.6 µm)   Seashell Technology, La Jolla, CA, USA 
Macrocarrier     Bio-Rad Laboratories GmbH, München,  
      Germany 
Nitrocellulose membrane   Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
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Rupture discs (900 psi)   Bio-Rad Laboratories GmbH, München,  
      Germany 
Stopping screen    Bio-Rad Laboratories GmbH, München,  
      Germany 
Tris-Glycin-Gele (8 & 12 %)   Anamed Elektrophorese GmbH, Groß- 
      Bieberau, Germany 
Whatman paper     Carl-Roth GmbH & Co KG, Karlsruhe,  
      Germany 
X-ray film, Fuji Super RX   BW plus Röntgen, Kamp-Lintfort, Germany 
24 well plates     TPP AG, Trasadingen, Switzerland 
96 well plates     TPP AG, Trasadingen, Switzerland 
 
Other consumables were purchased from Omnilab Laborzentrum GmbH & Co KG, Bremen, 
Germany, or Carl-Roth GmbH & Co KG, Karlsruhe, Germany. 
 
2.13 Laboratory Equipment 
Binokular      SZX-ILLD 200   (9) 
Biolistic gun      PDS1000/Helium   (3) 
Blot Apparatus    Semi Dry Blotter   (2) 
Chemiluminescence Detection system  Diana III    (9) 
Concentrator     Concentrator 5301   (6) 
Electrophoresis Apparatus (DNA)   Agagel Mini     (2) 
Electrophoresis Apparatus (Protein)   Mini Twin     (2) 
Electroporator (for E. coli)   Electroporator 2510   (6) 
Fermentor (0.5 L)    Sixfors
®
    (5) 
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Fermentor (50 L)    Biostat UD 50    (7) 
Gel documentation    AIDA     (9) 
Incubation shaker    Innova 4230    (11) 
Incubation shaker    Multitron AJ    (5) 
Microscope     CK-40     (10) 
PCR cycler     mastercycler
®
 gradient  (6) 
Photometer  PowerWaveX Select plate reader (4) 
Purification device  Kronlab    (8) 
Sonification bath  Sonorex     (1) 
Spectral photometer Libra S12    (12) 
Thermomixer      Comfort    (6) 
UV-Transilluminator    IDA     (9) 
 
Manufacturer: 
(1) Bandelin electronic GmbH & Co KG, Berlin, Germany; (2) Biometra GmbH, Göttingen, Germany; (3) Bio-
Rad Laboratories GmbH, München, Germany; (4) Bio-Tek Instruments Inc., Winooski, Vermont, USA; 
(5) Infors AG, Bottmingen, Switzerland; (6) Eppendorf AG, Hamburg, Germany; (7) Sartorius, Goettingen, 
Germany; (8) YMC Europe GmbH (Kronlab), Dinslaken, Germany; (9) Raytest GmbH, Straubenhardt, 
Germany; (10) Olympus GmbH, Hamburg, Germany; (11) New Brunswick Scientific, Edison, NJ, USA; 
(12) Biochrom AG, Berlin, Germany. 
 
2.13.1 Centrifuges 
Centrifuge, 5810R with Swing-bucket-Rotor A-4-62 Eppendorf AG, Hamburg 
Centrifuge, 5415D with Rotor F45-24-11   Eppendorf AG, Hamburg 
Centrifuge, 5417R with Rotor F45-30-11   Eppendorf AG, Hamburg 
Sorvall evolution RC      Thermo, Waltham, MA, USA 
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2.14 Databanks and Computer programs 
2.14.1 Databanks 
Tetrahymena Genome Databank (TGD): http://www.ciliate.org 
The Institute for Genomic Research: http://www.tigr.org 
PubMed of National Centers of Biotechnology (NCBI): 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
 
2.14.2 Computer software for Sequence analysis 
AIDA Image Analyzer Software 
Clone manager suite, Version 6.00  
 
2.14.3 Computer software for the calculation of theoretical molecular weights 
Compute pI/MW tool (www.expasy.ch) 
ProtParam (www.expasy.ch) 
Translate tool (www.expasy.ch) 
 
2.14.4 Computer software for data acquisition 
IRIS V 5.0 (32 bit software) (Sixfors
®
) 
Prep Con 5 (Purification device) 
 
2.14.5 Computer software for Literature index 
Reference Manager Professional Edition Version 11 
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2.14.6 Computer software for conversion of figures  
Adobe Photoshop, Version 6 
CorelDraw, Version 10.427; 2000 Corel Corporation 
 
2.14.7 Computer software for Calculation and Texts 
MS Office 2007 
 
2.15 References for D&A Sequences 
Beta-tubulin-terminator (BTU2)
161
    NCBI Accession#: L01416 
Histon-promoter (H4-1)
162
     NCBI Accession#: X00417 
Metallothionein promoter (MTT1)
134
  NCBI Accession#: AY061892 
Metallothionein promoter (MTT5)
163
  NCBI Accession#: AY884209 
Codon optimized sequences of the antigen genes and the Grl3-locus are listed in the appendix. 
 
2.16 Source of oligonucleotides 
Oligonucleotides were purchased from Invitrogen GmbH, Karlsruhe, Germany or Eurofins 
MWG Operon, Ebersberg, Germany. Oligos were diluted to a final concentration of 1 µg/µl 
with distilled water. The forward primer and the reverse primer are identified by labeling F or 
R, respectively. Where present, restriction sites are marked in lower case letters. 
 
2.16.1 Primers for cloning 
Primer for the amplification of the truncated New Caledonia derived HA (NC531 and NC344) 
NC Sac AA F  5`-TTTgagctcAAGATACTATTTGTATTGGTTATCACG-3` 
   36 bp 
NC531 R  5`-TAAagatctTCAAATTTAGTAAACTC-3` 
   26 bp 
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NC344 F  5`-ATCAAAGCTAAGTTATTAGTTTTA-3` 
   24 bp 
 
NC344 R  5`-GTCTagatctTCATCTAGATTAG-3` 
   23 bp 
 
The primers above were used for truncation of the HA of the New Caledonia influenza virus 
strain, which was codon optimized and synthesized by GeneArt AG, Regensburg, Germany. 
The forward primer contains a SacI restriction site, the reverse primer a BglII restriction site. 
Furthermore, a stop codon was included for the reverse primers. 
 
Primers for the assembly of a Grl3 knock out vector 
Grl3 5´ F  5`-AAGGTGccgcggTGGGAGAGAAAATATG-3` 
   28 bp 
Grl3 5´ R  5`-AAAggatccAAAACGATAGCTAAATTC-3` 
   27 bp 
Grl3 3´ F  5`-CACCAACGAAgtcgacTAATCCAGTC-3` 
   26 bp 
Grl3 3´ R  5`-CAAggtaccCAAAAAAAATTAAAATAC-3` 
   27 bp 
 
2.16.2 Primers for Sequencing 
Primer for sequencing of the different HAs, to verify the success of the cre-reactions and to 
analyze genomic DNA 
NC Seq 1 F  5`-CTGGTGTTTCTGCTTCTTGTTCTC-3` 
   24 bp 
NC Seq 2 R  5`-TAATTACCAATATTAGGAGGGTGG-3` 
   24 bp 
 
Materials  35 
NC Seq 3 F  5`-GAGGGAGGATGGACAGGTATGG-3` 
   22 bp 
 
UR Seq 1 F  5`-CTGGTAATGATAATTCTACTGCTA-3` 
   24 bp 
 
UR Seq 2 R  5`-ATCTAGGGCAAGCACCGTAAGT-3`  
   22 bp 
 
FL Seq 1 F  5`-GACTGCTACTTAAGGAGAAGTTA-3´ 
   23 bp 
FL Seq 2 R  5`-ACCAGTGTAGTAAGGCTTAGAC-3` 
   22 bp 
 
MTT Seq 1 F  
 5`ATATCTCGAGGATAAGTAATATATTTAGTGCACAATGTTTGAATG-3` 
   45 bp 
MTT Seq 2 F  5`-CACGATTTATGCAATGATCC-3` 
   20 bp 
MTT Seq 3 R  5`-AAATGATAGCCTAAATAATGAG-3` 
   22 bp 
 
2.16.3 Primers for cD&A analysis 
Grl3 1 F  5`-GGTGCTGGATAAAGTGCTGGTAG-3` 
   23 bp 
Grl3 2 R  5`-GGCAAGGTGCTTTTGGAGGAGAG-3` 
   23 bp 
betaHex 1 F  5`-ATGCAAAAGATACTTTTAATTACTTTC-3` 
   26 bp 
Materials  36 
betaHex 2 R  5`-TATATTTTAGGAATGTTGTAATC-3` 
   23 bp 
 
2.17 Vectors 
The used cloning plasmid and the episomal expression plasmid were kindly provided by 
Cilian AG. All constructed vectors are listed below. 
 
Cloning plasmid pDL-325 
The vector was derived from the pCR4TOPO vector where the ampicillin resistance cassette 
has been removed. The vector contains two loxP sites to enable a cre-dependant homologous 
recombination. The expression cassette consists of the MTT1 promoter (metallothionein gene 
of T. thermophila), a blasticidin resistance cassette (bsdR from the pCBM-BSD-vector) and a 
beta tubulin 2 terminator (btu2). Furthermore, a sacB gene was inserted (levansucrase of 
Bacillus subtilis), a chloramphenicol resistance cassette (CmR of the vector pDNR-LIB, 
Clontech) and a kanamycin resistance cassette (KanR of the vector pCR4TOPO) for 
propagation in E. coli
142
.  
 
Expression plasmid pAX 
The expression plasmid pAX was published by Weide et al.
142
 and used for the expression of 
all HAs. 
 
Mucocyst knock out expression plasmid pGX 
An integrative mucocyst knock out vector was developed during this work that combined the 
knock out of a Grl3 gene with the integration of an expression cassette for the recombinant 
production of NC531. This vector is based on the published pKOIX vector
142
. The 5´ and 3´ 
DHFR-TS integration flanks were replaced by parts of the 5´ and 3´ coding and non-coding 
regions of the Grl3 gene of T. thermophila. The sequence is demonstrated in appendix. 
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pDL_MTT1_NC 
The hemagglutinin (HA) of the influenza A virus strain New Caledonia/20/99 (H1N1; 
Accession number: CY033622.1) was codon optimized and synthesized by an external 
provider (GeneArt AG, Regensburg, Germany). The synthetic gene of this hemagglutinin was 
named NC HA and transferred by the external provider to the working plasmid pDL-325 by 
replacing the bsdR open reading frame. 
 
pDL_MTT1_NC531 
The antigen of the New Caledonia strain was truncated by removal of the coding sequence of 
the transmembrane domain (TMD) of the NC HA .The truncated version was generated by 
PCR and cloned into the working plasmid pDL-325 by replacing the bsdR open reading 
frame, and named NC531 HA. 
 
pDL_MTT5_NC531 
The pDL_MTT1_NC531 was modified by exchanging the MTT1 promoter to the MTT5 
promoter region of T. thermophila. 
 
pDL_MTT1_UR 
The HA of the influenza A virus strain Uruguay/716/2007 (H3N2; Accession number: 
CY035022) was codon optimized and synthesized by an external provider (GeneArt AG, 
Regensburg, Germany) and transferred to the working plasmid pDL-325 by replacing the 
bsdR open reading frame, and was named UR HA. 
 
pDL_MTT1_FL 
The HA of the influenza B virus strain Florida/4/2006 (Accession number: EU515937) was 
codon optimized and synthesized by an external provider (GeneArt AG, Regensburg, 
Germany) and transferred to the working plasmid pDL-325. This was performed by replacing 
the bsdR open reading frame, and named FL HA. 
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pAX_MTT1_NC 
The expression cassette including the MTT1 promoter, the NC antigen, the BTU2 terminator 
and the chloramphenicol resistance (CmR) were transferred via cre-dependant homologous 
recombination into the episomal expression plasmid pAX
142
. 
 
pAX_MTT1_NC531 
The expression cassette with the MTT1 promoter, the truncated NC531 antigen, the BTU2 
terminator and the CmR were transferred by a cre-dependant homologous recombination into 
the pAX vector
142
. 
 
pGX_MTT1_NC531 
The expression cassette including the MTT1 promoter, the NC531 coding region, the BTU2 
terminator and the CmR were transferred by the homologous cre-dependant recombination to 
the integrative mucocyst knock out vector pGX. 
 
pAX_MTT5_NC531 
The expression cassette comprising the coding region of the NC531 antigen including the 
MTT5 promoter, the BTU2 terminator and the CmR were transferred from the working 
plasmid to the expression plasmid pAX by cre-dependant homologous recombination
142
. 
 
pAX_MTT1_UR 
The UR expression cassette from the pDL working plasmid including the MTT1 promoter, 
BTU2 terminator and the CmR were transferred via cre-dependant homologous 
recombination into the episomal expression plasmid pAX
142
. 
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pAX_MTT1_FL 
The FL expression cassette including the MTT1 promoter, the BTU2 terminator and the CmR 
were transferred to the expression plasmid pAX by cre-dependant homologous 
recombination
142
. 
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3. Methods 
3.1 Cultivation and storage of bacteria and ciliates 
3.1.1 Strain maintenance of Escherichia coli 
Cultivation and selection of E. coli was performed using LB-agar plates supplemented with an 
appropriate antibiotic. The plates were incubated at 37 °C and afterwards stored at 4 °C. For 
long term storage, 500 µl of the E. coli culture was mixed with 500 µl (v/v) Glycerol and 
stored at -80 °C. 
 
3.1.2 Strain maintenance of Tetrahymena thermophila 
A 1.5 mL culture of T. thermophila was regenerated once a week. The cells were cultivated in 
24 well plates in 1.5 mL SPP medium under selection pressure (400 µg/mL paromomycin) 
and stored at 30 °C in an incubator. 
 
3.1.3 Long-term storage in a culture 
For long-term storage of transformed T. thermophila cultures, autoclaved water with a chick 
pea in a glass tube was used. The inoculation was performed by addition of 10 µl of  
Tetrahymena culture to the glass tube. The cultures were renewed biannually. Alternatively, 
long term storage was achieved by freezing transformed Tetrahymena cells as described 
previously
130
. In modification, SPP medium was used for initial cultivation of the target cells. 
 
3.1.4 Cultivation of E. coli 
E. coli submers culture were inoculated with a single colony from an agar plate. Cultivations 
were performed using 15 mL tubes or 100 mL flasks. Cultures were incubated at 37 °C and 
180 rpm in a shaking incubator. Selection was applied using an appropriate antibiotic. 
Cultures were harvested by centrifugation at 4,000 x g and 4 °C for 30 minutes. 
 
Methods  41 
3.1.5 Cultivation of T. thermophila 
Recombinant T. thermophila cells were cultured using a 5 mL starter culture of SPP medium 
supplemented with 400 µg/mL paromomycin. Cultures were incubated at 80 rpm and 30 °C 
for three days. Larger cultures for subsequent experiments were inoculated with 1 mL of 
starter culture in 10 mL SPP supplemented with 400 µg/mL paromomycin. The expression of 
recombinant protein was induced using cadmium chloride or zinc. Cell pellets were harvested 
by centrifugation at 1,500 x g at 10 °C for 3 minutes. Supernatants were also collected for 
analysis. 
 
3.1.6 Determination of the cell titer of T. thermophila 
The cell titer was determined using a Fuchs-Rosenthal counting chamber. The suspension of 
cells was diluted using 2.5 % (v/v) glutaraldehyde. Four big squares were counted and the 
titer was calculated using a mathematic formula: 
 
cell titer (cells/mL) = (M/64) x 8 x D x 10.000 
M = mean of the counted squares 
D = factor of dilution 
 
3.2 Transformation of bacteria and ciliates 
3.2.1 Transformation of E. coli electroporation 
Transformation of electro competent E. coli cells was performed using an Eppendorf 2510 
electroporator. One aliquot (40 µl) of electro competent cells (2.1.1.) was taken for each 
transformation, mixed with 20 µl of purified DNA, and transferred into an ice-cold cuvette 
(gap 1 mm, Eppendorf AG, Hamburg, Germany). The electroporation was done at 1,800 V. 
The regeneration of the cells was performed in 500 µl SOC medium for 1 h at 37 °C and 
450 rpm. Cells were spread after the transformation on a prewarmed selective plate and grown 
at 37 °C overnight. 
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3.2.2 Transformation of T. thermophila 
Preparation of DNA 
Plasmid DNA for transformation of T. thermophila was isolated via MIDI preparation (3.2.4) 
and concentrated to ~1 µg/µl. 
 
Conjugation and preparation of the cells 
Prior to conjugation of T. thermophila cells, cultures were starved. T. thermophila cultures of 
two different mating types growing in exponential phase were pelleted by centrifugation at 
21 °C and 900 x g for 3 minutes, washed in Dryls buffer (pH 7.4) and an additional 
centrifugational step was performed (21 °C, 900 x g, 3 min). A cell titer of 200,000 cells/mL 
in 100 mL Dryls buffer was adjusted. The resulting culture of two mating types was incubated 
for approximately 20 hours at 30 °C, shaking at 180 rpm to prevent conjugation. 
Subsequently, cells begin to conjugate. 
After 4-5 hours, conjugation rate should be high, approximately 70-80 %. Following, after 
10 hours of incubation, cells are competent, meaning the new MAC is going to be built, and 
the MAC transformation can be performed. 20-40 mL of the conjugated cells were pelleted 
(21 °C, 900 x g, 2 min) and resuspended in 1 mL of Dryls buffer. This suspension was taken 
for the transformation. 
 
Preparation of gold particles 
The preparation of the gold particles (diameter 0.6 µm) was done according to a protocol of  
Seashell Technology. DNadeI™ gold particles (S550d) were stored in binding buffer at a 
concentration of 50 mg/mL. Firstly, the gold was diluted by the addition of binding buffer to a 
concentration of 30 mg/mL and plasmid DNA was added to give a ratio of 2-5 µg per mg 
gold. After mixing, the same volume of precipitation buffer was added and the reaction was 
mixed again. Samples were mixed for 3 minutes at room temperature then centrifuged for 
10 sec at 9.3 x g. The supernatant was discarded and 500 µl ice-cold ethanol (100 %) was 
added to the pellet. After mixing, a centrifugational step was performed (room temperature, 
10 sec, 9.3 x g), the supernatant was discarded and the pellet was resuspended in 20 µl of 
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100 % ethanol. The gold was sonicated for 1-2 min and placed on a Macrocarrier. This 
Macrocarrier was dried on a filter paper on CaCl2. 
 
Transformation by biolistic bombardment 
Transformation of T. thermophila cells was done using a PDS-1000/He Biolistic
®
 Delivery 
system where an applied helium pressure accelerates the gold particles. In preparation for the 
transformation, a rupture disk (900 psi) was put into the rupture disk retaining cap and the 
fully assembled microcarrier launch assembly (with cover lid) was inserted inside the 
bombardment chamber. The microcarrier launch assembly holds the DNA/microcarrier 
preparation on a Macrocarrier sheet over the Stopping Screen in the path of the helium shock 
wave. The target shelf holds the T. thermophila cells in a Petri plate in the path of the 
accelerated DNA/microcarrier preparation. The door of the chamber was closed and the 
chamber was evacuated, the vacuum was held at the desired level of ~27 inches of mercury 
(Hg vacuum) and the fire button was continuously depressed until the rupture disk burst and 
the helium pressure gauge dropped to zero. The vacuum was released from the chamber and 
the T. thermophila cells were removed from the chamber. The transformed cells were 
regenerated in proteose peptone medium (PP 1 %) overnight at 30 °C. The detection of 
transformed cells was done afterwards under selection pressure (as described in 3.2.3). 
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Figure 5: The biolistic bombardment process (modified
113
). 
At helium pressure of 900 psi the Rupture Disk bursts and the Macrocarrier with the DNA loaded gold particles 
is accelerated. Because of the Stopping Screen, the Macrocarrier is hold. The gold particles are transported to the 
target cells and penetration and transformation takes place. 
 
3.2.3 Selection of transformed T. thermophila 
For selection of positive transformants, tranformed cells were harvested by a centrifugational 
step (3 min, 2100 rpm, 21 °C), resuspended in 50 mL of skimmed milk medium supplemented 
with 150 µg/mL paromomycin. Cells were spread in 96-well plates and after an incubation 
period of 2-3 days investigated by a light microscope. Growing cultures indicated resistance 
to the added antibiotic and therefore correct transformation. Putative transformants were 
cultivated in skimmed milk medium under selection pressure (300 µg/mL paromomycin). 
After approximately 7 days, the selection pressure was raised to 400-1000 µg/mL in skimmed 
milk medium. The strain maintenance was performed using SPP medium and the 
supplementation of 400 µg/mL of paromomycin. 
 
3.3 Cloning of D&A 
3.3.1 Purification of D&A after agarose gel electrophoresis 
QIAquick Gel extraction kit was used for the extraction of DNA. Gel slices of DNA 
fragments obtained from an agarose gel electrophoresis step (3.5) were put into a sterile 
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1.5 mL reaction tube. The extraction was performed according to the manufacturer’s manual. 
The DNA was eluted by addition of 30 µl of sterile and distilled water and stored at -20 °C. 
 
3.3.2 Purification of D&A using Montage™ PCR Centrifugal Devices  
Products of a PCR, a ligation or a restriction were purified from contaminating salts or 
oligonucleotides using Montage™ PCR Centrifugal Devices. The procedure was done in 
accordance with the manufacturer’s recommended protocol. The obtained DNA solution 
(20 µl) was stored at -20 °C. 
 
3.3.3 Isolation of total D&A from T. thermophila cells 
For the isolation of total DNA from a transformed or a wild type T. thermophila culture, the 
DNeasy blood and tissue Kit was used. The preparation was performed with slight 
modifications from the manufacturer’s protocol (Purification of Total DNA from Animal 
Blood or Cells). The harvest was done using a T. thermophila culture (~4 x 10
6
 cells) and a 
centrifugation step for 3 minutes and 1500 x g at 10 °C. The lysis of the cells with Buffer AL 
was prolonged to 30 minutes and the elution was performed using 200 µl of sterile and 
distilled water instead of Buffer AE. The samples were immediately used for the analysis of 
DNA via PCR or stored at -20 °C. 
 
3.3.4 Isolation of high purity plasmid D&A with the FastPlasmid™ Mini Kit 
The isolation of plasmids was done using the FastPlasmid™ Mini Kit. A single isolated 
colony from a freshly spread E. coli strain was inoculated into 5 mL of selective culture 
medium. The growth of bacterial cultures took place overnight at 37 °C and shaking at 
180 rpm. 1.5 mL of the cultures were harvested and the cell pellet was treated as described in 
the manufacturer’s manual. The elution was done using 50 µl of sterile distilled water and the 
isolated DNA was stored at 4 °C. Restriction analyses were performed using this DNA. 
 
3.3.5 Isolation of high purity plasmid D&A with the HiSpeed
®
 Plasmid Midi Kit 
A Midi preparation was done using the HiSpeed
®
 Plasmid Midi kit. The protocol is based on 
alkaline lysis followed by anion exchange chromatography. For the preparation, 50 mL of an 
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E. coli culture, grown overnight, was harvested. The preparation was performed according to 
the manufacturer’s manual. The obtained DNA was concentrated to 1 µg/µl using a 
concentrator and stored at 4 °C until the transformation of T. thermophila cells. 
 
3.3.6 Restriction analysis 
The restriction of DNA was done using endonucleases with the appropriate buffer. DNA 
fragments with blunt ends or cohesive ends were formed, depending on the enzyme used. The 
samples were incubated for 1 to 3 hours at the manufactuer’s recommended temperature and 
separated by agarose gel electrophoresis (3.5). 
 
3.3.7 Ligation 
The ligation of a plasmid with insert was performed by applying the T4 DNA Ligase in the 
appropriate buffer. To aid the efficiency of the ligation, the insert DNA should be present in a 
high molar ratio. DNA concentration was estimated by agarose gel electrophoresis of the 
DNA (3.5). DNA fragments for ligation were purified using the QIAquick Gel extraction kit 
(3.3.1). The ligation was performed according to the manufacturer’s recommended protocol 
and incubated overnight at 16 °C. 
 
3.3.8 Cre dependant homologous recombination 
The expression cassette of the pDL cloning plasmids was transferred to the expression 
plasmid pAX as described previously
142
. 
 
3.3.9 PCR method 
PCR is an in vitro technique capable of amplifying trace amounts of DNA of defined length 
and sequence from heterogenous nucleic acid mixtures. During the reaction, the sequence 
between specific primers is repeatedly replicated by a thermostable DNA polymerase upon 
every thermal cycling step. PCR reactions were performed using a PCR mastercycler
®
. All 
programs were set up and cycled according to the details below. 
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3.4 Sequencing of D&A 
Sequencing analysis was performed by MWG (Ebersberg, Germany). Clone manager suite 
(2.14) was used for the evaluation of sequence data. 
 
3.5 D&A agarose gel electrophoresis 
Agarose gel electrophoresis is a method to separate DNA achieved by moving negatively 
charged nucleic acid molecules through an agarose matrix within an electric field. Shorter 
molecules move faster and migrate further than longer ones. Conformation is also a factor. To 
avoid this problem linear molecules are usually separated, usually DNA fragments obtained 
from a restriction digest, or linear PCR products. A DNA plasmid that has not been cut with a 
restriction enzyme will move with different speed corresponding to the conformational forms 
of the DNA. Nicked or open circular, linearised, or supercoiled plasmid forms will separate at 
different rates, listed from slowest to fastest. Increasing the agarose concentration of a gel 
reduces the migration speed, and enables the separation of smaller DNA molecules. For the 
determination of the size of DNA fragments a standard was used (2.10). 
The electrophoresis was performed in a horizontal apparatus in TAE buffer. Depending on the 
expected size of the DNA fragments, an agarose concentration of 1-1.5 % (w/v) in TAE 
buffer was used. Samples were supplemented with loading dye (6 x, Fermentas, St. Leon-Rot, 
Germany) and applied to the gel. A voltage of 3-10 V/cm was applied. For the visualization of 
DNA bands ethidium bromide was used, that intercalates into DNA molecules and can be 
visualized with UV light. A picture of the obtained gels was taken. 
 
PCR program:      Component 
1) 95 °C    3 min   template-DNA (0.1 µg/µl) 1 µl 
2) 95 °C   1 min   Reaction buffer (10 x) 5 µl 
3) 55 °C   1 min   dNTP mix (10 mM each) 1 µl 
4) 65 °C   1-2 min, 39 x  primer 1 (1 µg/µl)  1 µl 
5) 65 °C    5-8 min   primer 2 (1 µg/µl)  1 µl 
6) 4°C    ∞    Polymerase   2.5 U 
Distilled water   ad 50 µl 
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3.6 Electrophoresis und Visualization of proteins 
3.6.1 Preparation of samples 
The cell titer of an exponential or stationary phase SPP-culture of a transformed or a 
non-transformed wild type strain were calculated using a Fuchs-Rosenthal counting chamber 
(3.1.5). 1-10 mL of the culture were harvested by centrifugation at 10 °C, 1,500 x g for 
3 minutes. Cells and supernatants were collected and frozen at -20 °C or immediately used for  
SDS-PAGE. The cells were solubilized by applying RIPA buffer and a following sonification 
step for 15 minutes. Prior to loading a SDS-gel, the cell extracts and supernatants were mixed 
with a sample buffer containing SDS and heated to 95 °C for 3 minutes. 
 
3.6.2 Denaturing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE relies on a discontinuous buffer system. Two ions of differing electrophoretic 
mobility (glycinate and chloride) form a moving boundary when voltage is applied. Proteins 
have an intermediate mobility, causing them to concentrate, or stack, into a narrow zone at the 
beginning of electrophoresis. As the boundary moves through the gel, the sieving effect of the 
polyacrylamide gel matrix causes different proteins to move at different rates. The stacking 
effect is responsible for the high resolving power of SDS-PAGE. The sample is loaded in a 
relatively broad zone, and the moving boundary concentrates the proteins into sharp bands 
prior to separation. 
Protein samples for SDS-PAGE were prepared using SDS and for some samples a thiol 
reductant, 2-mercaptoethanol was added. SDS forms complexes with proteins giving them a 
rod like shape and similar charge to mass ratio. The reductant cleaves disulfide bonds between 
and within proteins allowing complete denaturation and dissociation. Heat treatment in the 
presence of SDS and reductant effectively eliminates the effects of protein structure and 
native charge on electrophoretic mobility, so the migration distance depends primarily on 
molecular weight. 
Gels were comprised of polyacrylamide with a bisacrylamide cross linker. Each gel has a 5 % 
polyacrylamide stacking layer extending approximately 5 mm from the bottom of the loading 
well to the top of the resolving gel. The resolving gel was of 8 or 12 % polyacrylamide with 
10 lanes. Gels were bought from Anamed GmbH (Groß-Bieberau, Germany) or self made. 
Resolving gels contained a final concentration of 0.375 M Tris-HCl (pH 8.8) and 0.1 % SDS. 
Methods  49 
The 5 % stacking gel contained a final concentration of 0.125 M Tris-HCl (pH 6.8) and 0.1 % 
SDS. 
 
Following protocol was used for the preparation of four gels: 
 
The agents APS and TEMED were added immediately before the gels were cast, because they 
initiate the polymerization of the gel matrix. 
 
After the casting of the resolving gel, the gel was protected by the addition of 5 mL of 
isopropanol to hinder contact with oxygen. After 60 minutes of polymerization, the 
isopropanol was discarded and a polymerized gel could be seen. The stacking gel was 
prepared and cast on top of the resolving gel. A comb was used to form pockets for loading 
the samples. After 15 minutes of polymerization the gels were ready for SDS-PAGE. The 
separation of the samples was performed at approximately 120 V for 2-3 hours. A protein 
standard was used for the SDS-PAGE to estimate molecular weights of the separated proteins. 
3.6.3 Western blot analysis 
Protein blotting, the transfer of proteins to solid-phase membrane supports, has become a 
powerful and popular technique for the visualization and identification of proteins. Protein 
blotting involves two major phases: transfer and detection. The transfer step involves moving 
the proteins from the gel and immobilizing them on a synthetic membrane support (blot). The 
transfer was done by semi-dry blot to a nitrocellulose membrane. Proteins were detected by 
8 % resolving gel (25 mL)   5 % stacking gel (12 mL) 
9.7 mL H2O    6.74 mL H2O 
6.3 mL 4x resolving gel buffer 3 mL  4x stacking gel buffer 
6.7 mL Acrylamide solution  2 mL  Acrylamide solution 
250 µl  10 % SDS   120 µl  10 % SDS 
250 µl   10 % APS   120 µl  10 % APS 
10 µl  TEMED   20 µl  TEMED 
 
12 % resolving gel (25 mL) 
8.2 mL H2O 
6.3 mL 4x resolving gel buffer 
10 mL  Acrylamide solution 
250 µl  10 % SDS 
250 µl   10 % APS 
10 µl  TEMED 
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the application of a specific antibody followed by the use of a secondary antibody coupled by 
the enzyme of the horse radish peroxidase. Antibody localization was visualized by the 
addition of a chemical substrate and the optical signal was detected using X-ray film or a 
visualization chamber. 
In the electrophoretic transfer, the membrane and protein-containing gel were placed together 
with filter paper between two electrodes. Proteins migrate to the membrane following a 
current (I) that is generated by applying a voltage (V) across the electrodes, following Ohm’s 
law (V = I x R) where R is the resistance generated by the materials placed between the 
electrodes (that is, the transfer buffer, gel, membrane, and filter papers). The electric field 
strength (V/cm) that is generated between the electrodes is the driving force for 
electrophoretic transfer. In a semi-dry transfer, the gel and membrane are sandwiched 
between two stacks of filter paper and are in direct contact with plate electrodes
164,165
. The 
term “semi-dry” refers to the limited amount of buffer, which is confined to the two stacks of 
filter paper. The blot was performed by 1 mA/cm
2
 gel area for 1-2 hours. Following the 
membrane was washed by PBS-T and incubated in 10 % skimmed milk in PBS-T overnight at 
4 °C to block unspecific protein binding sites. The primary antibody was added in a working 
dilution in 5 % skimmed milk or BSA in PBS-T for 1 hour at room temperature and shaking. 
Afterwards, three washing steps followed by PBS-T (each 10 min), and the diluted secondary 
antibody was added for 1 hour at room temperature and shaking. After four additional 
washing steps the detection of proteins was done by addition of a chemiluminescent substrate. 
 
3.6.4 Quantitative analysis 
To estimate recombinant expression yields a quantitative analysis was performed. To load a 
SDS-gel a calibration curve by different dilutions of the purchasable antigen and dilutions of 
the recombinant expressed protein obtained during a 0.5 L or 50 L fermentation process were 
made. After separation by SDS-PAGE and the transfer of proteins to a nitrocellulose 
membrane by Western blot protein was detected by addition of a specific primary antibody 
and the appropriate secondary antibody (as described in 3.6.3.). A luminol substrate was 
added and the visualization of the quantification was performed with the CCD camera system 
DIANA III. The analysis was done using the AIDA program and yields were calculated 
thereby. 
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3.6.5 Coomassie staining 
Separated proteins after a SDS-PAGE were stained by Imperial™ Protein stain Kit as 
described by the manufacturer's manual. 
 
3.6.6 Isocitrate dehydrogenase assay 
Intracellular enzymes can be released into the culture medium due to lysis of cells. The 
enzyme of the isocitrate dehydrogenase (ICDH) is a mitochondrial enzyme and comprises a 
high cytosolic activity and stability. Therefore, it represents an ideal marker enzyme to detect 
leakage of the cells. The enzymatic activity was measured as described by the manufacturers 
manual (Biochemika, Boehringer Mannheim GmbH, Germany). The increase of the 
extinction was measured using a photometer at 339 nm. For this test an aliquot of 1 mL of a 
complete culture and 300 µl of the cell free supernatant were harvested. 
 
3.7 Glycosylation analysis 
For the deglycosylation one aliquot of purified antigen of T. thermophila was digested by 
N-glycosidase F (PNGase F). This amidase of the Flavobacterium meningosepticum 
hydrolyzes N-glycans of glycopeptides or glycoproteins between the innermost GlcNAc- and 
asparagine-residue. The enzymatic digest was done in two steps, the denaturation of the 
sample and the PNGase F digest. 
Denaturation      N-Glycosidase F-digest 
10 µl  purified NC531    20 µl  denatured sample 
2 µl  Denaturing buffer (10 x)   3 µl  G7-Puffer (10 x) 
8 µl  distilled water     3 µl  NP-40 
       2 µl  N-Glycosidase F 
       2 µl  distilled water 
Incubation: 100°C, 10 min    Incubation: 37°C, 1-24 h 
Samples were analyzed via SDS-PAGE with subsequent transfer to a nitrocellulose membrane 
by Western blot. 
 
3.8 Estimation of protein content (Bradford assay) 
The estimation of whole protein content was done by the colorimetric method of Bradford. It 
is based on the binding of the dye Coomassie Brilliant Blue G-250 in acidic milieu and the 
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associated shift of the maximum of the absorption from 465 nm to 595 nm. The determination 
of the protein content was performed according to the manufacturer’s manual (Thermo, 
Waltham, MA, USA). 30 µl of each sample was mixed with 150 µl of Coomassie Protein 
Assay Reagent in a 96-well plate and after a 5 min of incubation at room temperature the 
absorption was measured at 595 nm. Protein concentrations were calculated by interpolation 
on a calibration curve generated using BSA standards. 
 
3.9 Analysis of mucocyst knock out strains 
3.9.1 Dibucaine stimulation 
A transformed NC531 expressing Grl3 knock out strain and a non-transformed wild type 
strain were cultivated in a 5 mL cell culture under selection pressure (400 µg/mL 
paromomycin). After three days of growth the cells were harvested by centrifugation (21 °C, 
1,000 x g, 3 min) and the supernatant was discarded. The cell titer was calculated and cells 
were adjusted to a concentration of 1 x 10
6
 cells/mL. 2 mL of this cell suspension was washed 
with Dryls buffer and the excretion of mucocyst contents was initiated by the addition of 
dibucaine in a final concentration of 1.4 mM. After an additional centrifugation step (21 °C, 
1,000 x g, 3 min) the mucocyst contents were visualized by taking a picture. 
 
3.9.2 R&A analysis 
The RNA of a transformed NC531 expressing Grl3 knock out strain and a non-transformed 
T. thermophila wild type strain was isolated using the RNeasy Plus Mini Kit (Qiagen, Hilden, 
Germany). The mRNA was isolated due to the manufacturer's manual. 
 
3.9.3 cD&A synthesis 
cDNA was made by using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, St. 
Leon-Rot, Germany). The procedure was done according to the manufacturer's manual. The 
verification of the cDNA was done by PCR analysis and a subsequent agarose gel 
electrophoresis. 
 
Methods  53 
3.10 Fermentation procedures 
3.10.1 Lab-scale fermentation (0.5 L) 
For the fermentation of T. thermophila expression strains a 0.5 L fermentation process was 
done using a Sixfors
®
 multibioreactor (Infors AG, Bottmingen, Switzerland). The fermentor 
was equipped by a paddle impellor, and a digital control subunit (DCU). 
The stirrer was limited to a rotation not exceeding 800 rpm, because faster stirring lead to 
high cell damage. The concentration of dissolved oxygen was adjusted to be held at 20 % of 
the air saturation level. Thereby, the oxygen supply was regulated at first priority and the 
rotation of the stirrer as second priority. The measurement of oxygen saturation was 
performed using an O2-electrode. The temperature was maintained at 30 °C. The pH value 
was regulated during the whole fermentation procedure at 7.0 by acetic acid and NaOH. 
The complete mounted fermentor including SPP medium was autoclaved for 30 min at 
120 °C. Inoculation of the fermentor was performed sterile by using a syringe connected 
through a tube to the fermentor. The first phase of the fermentation was performed as a batch 
procedure. When cells reached the end-logarithmic phase the second phase was initiated by 
adding a feeding solution all at once. This fed-batch fermentation procedure was found out to 
best suited for the production of recombinant antigens by T. thermophila. The feeding 
solution was composed of concentrated SPP medium, so that after the feeding step the final 
concentration of 1 fold was reached within the fermentation broth. 
 
3.10.2 Up scaling fermentation process (50 L) 
The 50 L fermentation procedure was performed using a Biostat
®
 UD (Sartorius, Goettingen, 
Germany) fermentor. The fermentation procedure was performed according the 0.5 L 
fermentation process, except that the medium was autoclaved within the fermentor itself and 
inoculation was done through a membrane. 
 
3.10.3 Harvest of the cells 
Cells obtained of the 0.5 L fermentation process were transferred into a sterile and ice cold 
fernbach flask and incubated on ice for 20 min at 80 rpm. Afterwards, cells were harvested by 
centrifugation at 10 °C and 1,500 x g for 10 min (Sorvall evolution RC, SLC-6000 rotor). The 
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supernatant was discarded and the cell pellet was washed using ice cold phosphate buffer and 
resuspended. Following, the cells were pelleted by an additional centrifugational step at 10 °C 
and 2,400 x g for 8 min (SLA-1500 rotor). The washing and centrifugational step was 
repeated 3-4 times to remove mucocyst contents. Mucocyst-free cell pellets were resuspended 
in 90 mL of phosphate buffer (10 mM) and immediately frozen at -20 °C. 
The harvest of the cells from the 50 L fermentation process was achieved using a hollow fiber 
module (0.3 m
2
, 3 L/min, tube diameter 11 mm). Applying this module, the cells were 
separated from the fermentation broth. The washing steps to remove mucocyst contents were 
performed as described for the 0.5 L fermentation process. The obtained mucocyst-free cell 
pellet was frozen immediately at -80 °C. 
 
3.11 Purification via column chromatography 
3.11.1 Cell lysis 
For the purification of recombinant NC531 HA, 80 g of frozen and washed cells obtained 
from the 50 L fermentation process were resuspended in 400 mL loading buffer and 
supplemented by the cysteine protease inhibitor E-64 (70 µM). Cells were disrupted using an 
ultraturrax (IKA UT T25 + S25N-25G) at 10,000 rpm for 5 min on ice. The lysate was filled 
up to 1.8 L using loading buffer and the solubilization was performed by stirring at 4 °C for 
17 hours. This cell lysate was filtrated using a hollow fiber module (0.45 µm with 850 cm
2
 
surface) and washed three times with 2.3 L of loading buffer. The duration of this procedure 
was about 2 h at a flow rate of 1 L/min and a tube with a diameter of 8 mm. The pH dropped 
to 7.1 and was adjusted to 7.4 prior to loading onto the first column. 
 
3.11.2 First column: Capto™ Q 
The first column was a Capto™ Q column (GE healthcare Europe GmbH, Munich, Germany) 
that is a strong quaternary ammonium anion exchange medium. It is designed for capturing 
proteins from large feed volumes by packed bed chromatography. A 125 mL Capto™ Q 
column was loaded with the lysate of the cells at a flow rate of 15 mL/min and afterwards 
washed with running buffer 1. The elution was performed with elution buffer 1 by a 400 mL 
step elution and with the addition of 150 mM NaCl. To elute all protein that was not eluted 
during the 150 mM NaCl step the column was washed with 1 M NaCl in elution buffer 2. 
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Fractions of each 10 mL were taken and E-64 was added to each fraction in a final 
concentration of 175 µM. Samples were further analyzed by SDS-PAGE, Western blot and 
Bradford assay. NC531 HA positive fractions were pooled for the next column 
chromatography step. 
 
3.11.3 Second column: Ceramic Hydroxyapatite (CHT) 
Ceramic Hydroxyapatite (CHT) (Bio-Rad, Hercules, CA, USA) was used to capture 
contaminating proteins. The NC531 HA did not bind to this column but a high percentage of 
other proteins did. The pooled fractions obtained from the Capto™ Q column were 
concentrated and a buffer exchange to remove the NaCl was performed using a Labscale TFF 
module (30 kDa) with running buffer 2. The sample that was loaded onto the column, with a 
bed volume of 20 mL, had a volume of 150 mL. The pH was adjusted to 7.5 prior to loading 
onto the column and the column was loaded with a flow rate of 7 mL/min and subsequently 
washed with running buffer 2. The elution was performed by a step elution by applying 
elution buffer 3. The flow through of 200 mL was taken to load to the next column. The 
eluate and the flow through were tested by SDS-PAGE, Western blot analysis and Bradford 
assay. 
 
3.11.4 Third column: Con A 
The third column was a Con A Sepharose 4B (GE healthcare Europe GmbH, Munich, 
Germany) with a bed volume of 15 mL. The flow through of the CHT column was 
supplemented with 150 mM NaCl and applied with a flow rate of 5 mL/min to the column and 
afterwards washed with running buffer 3. The elution was done about 10 column volumes by 
applying elution buffer 4. Samples were analyzed by SDS-PAGE, Western blot and Bradford 
assay. 
3.12 Safety regulation 
Genetic modifcation experiments were performed pursuant the law "Gesetz zur Regelung von 
Fragen der Gentechnik" (Gentechnikgesetz, GenTG) of 29.07.2009 observing the formulated 
§7 Abs. 1 GenTG. Announcement of the work performed was pursuant the law § 8 Abs. 1 and 
§ 11 of Gentechnikgesetz. 
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4. Results 
As described in the introduction, none of the expression systems currently available is ideal 
for a safe, low-cost and efficient production of a vaccine. New production platforms have to 
be found and developed. Tetrahymena thermophila represents a promising expression system 
that can be advanced to an excellent production platform of recombinant therapeutics and 
subunit vaccines. Recently, it was successfully demonstrated that the expression of i-antigens 
from Ichthyophthirius multifiliis in the Tetrahymena system using a strong inducible promoter 
is feasible
134
. These proteins were targeted to the plasma membrane in their correct 
3-dimensional conformation
59
. Besides, it could be demonstrated that the GPI-anchored 
circumsporozoite protein of the malaria parasite Plasmodium falciparum was expressed and 
targeted to the surface of T. thermophila
58
. This work addresses to the expression and 
secretion of viral antigens. A production and purification process for the influenza vaccine 
component was established to reach a purity which is acceptable for industrial purposes. 
 
4.1 Expression of three different recombinant hemagglutinins 
As optimal viral vaccine component, the main antigen of the influenza virus, the 
hemagglutinin (HA), was chosen. Due to the fact that the common subunit influenza vaccine 
is composed of three HAs originating from different influenza strains, three HAs were 
intended to be produced using the T. thermophila expression system
37
. 
 
4.1.1 Design and construction of hemagglutinin expression cassettes 
The genes of three various HAs of the influenza A virus New Caledonia/20/99 (NCBI 
Accession number CY033622.1, H1N1), of the influenza A virus Uruguay/716/2007 (NCBI 
Accession number CY035022, H3N2), and of the influenza B virus Florida/4/2006 (NCBI 
Accession number EU515937) were identified and codon optimized. Therefore, the native 
codons were adapted to the codon preferences of T. thermophila. The sequences were 
optimized and synthesized by an external provider (GeneArt AG, Regensburg, Germany; see 
appendix). The obtained synthetic genes encode for 566 amino acids (aa) of the 
New Caledonia derived HA precursor protein (Figure 6 A, NC HA), for 533 aa of the 
Uruguay derived HA (Figure 6 C, UR HA) and for 537 aa of the Florida derived HA 
(Figure 6 D, FL HA), comprising the respective original ER leader sequence. All synthetic 
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genes were flanked by an EcoRV and a BglII restriction site to transfer the genes to the 
cloning plasmid pDL that was kindly provided by the Cilian AG. The cloning was performed 
by an external provider (GeneArt AG, Regensburg, Germany), and the created plasmids were 
named pDL_MTT1_NC, pDL_MTT1_UR, and pDL_MTT1_FL. The heterologous 
expression of the recombinant HAs was controlled by the application of the strong and 
cadmium inducible metallothionein 1 promoter (MTT1) system and the well established beta 
tubulin 2 (BTU2) terminator sequence
134
. The generated plasmids contained expression 
cassettes that were composed of the MTT1 promoter, the target gene, the btu2 terminator and 
a chloramphenicol resistance gene. The whole cassette was flanked by loxP sites on the 5' and 
3' ends that enabled the application of cre-dependant transfer of the expression cassette from 
the pDL cloning plasmid to the T. thermophila expression plasmid. A chloramphenicol 
resistance (CmR) was inserted between the loxP site and the BTU2 terminator to reduce 
background clones, because this CmR is only translated if a correct site-specific 
recombination between expression and cloning plasmid has been occurred. 
Regarding one target antigen, the HA of the NC strain, two different versions were planned to 
be tested. The first version comprised the whole coding region of the NC derived HA that 
included the HA1 chain, the HA2 chain, the fusion peptide and the transmembrane domain 
(TMD). The second version was a C-terminally truncated version of the NC HA coding 
region lacking the TMD and the fusion peptide. The additional analysis of the truncated NC 
protein based on the fact that the TMD anchors the HA in the native viral membrane, and is 
therefore able to anchor the HA in any T. thermophila based membrane that can result in an 
inhibition of the efficient secretion of the recombinant antigen. Furthermore, it could also 
hinder the passage through a column chromatography material. For the shortened NC derived 
HA, a PCR was performed to obtain a coding region without the TMD (aa 1-531), and to add 
a stop codon directly downstream the amplified sequence. This shortened NC HA was cloned 
using an EcoRV and a BglII restriction site via the ligation method into the cloning plasmid 
pDL, and named pDL_MTT1_NC531 (Figure 6 B, NC531 HA). 
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Figure 6: The expression modules. 
Scheme of the created HA expression modules (linear structure). The figure demonstrates the structure concept 
of the expression cassettes. For all expression cassettes the MTT1 promoter (green) and the BTU2 terminator 
(red) were used. As ER leader sequence the endogenous signal peptide of the different HAs (dark blue) was 
employed. The New Caledonia derived HA (A, NC HA, yellow), the Uruguay derived HA (C, UR HA, yellow), 
and the Florida derived HA (D, FL HA, yellow) comprised a transmembrane domain (TMD, purple), which 
anchors the HA in the viral membrane. A truncated version of the New Caledonia derived HA (B, NC531 HA, 
yellow) excluded the TMD. The expression cassettes were flanked by two loxP sites (lox, light blue) and 
contained a bacterial selection marker (CmR, chloramphenicol resistance, grey). The synthetic genes of the HAs 
were cloned in order to generate the expression cassette by EcoRV and BglII sites. 
 
Subsequently, the expression cassettes of the four created working plasmids were transferred 
to an episomal expression plasmid (pAX) that was kindly provided by the Cilian AG via 
cre-dependant homologous recombination
142
. This episomal expression plasmid carries the 
paromomycin resistance cassette (neo2) in order to select for transformed ciliates. The 
obtained expression plasmids were named with reference to the cloning plasmids as 
pAX_MTT1_NC (Figure 7 A), pAX_MTT1_NC531 (Figure 7 B), pAX_MTT1_UR 
(Figure 7 C), and pAX_MTT1_FL (Figure 7 D). In general, the transformation of the 
cre-reaction yielded in E. coli clones that were able to grow on LB-agar plates supplemented 
with chloramphenicol, ampicillin and sucrose. The purified plasmids of representative clones 
were analyzed by digestion using specific restriction endonucleases to control the success of 
the recombinase approach. For the separation of DNA fragments, a 1 % agarose gel 
electrophoresis was performed. As demonstrated in Figure 7, the restriction analysis regarding 
the clones obtained from the transformation of the cre-reaction revealed correct DNA 
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fragments for the different expression plasmids. Furthermore, the sequence of the truncated 
NC531 was verified via sequencing analysis (data not shown). 
 
Figure 7: Restriction analyses of the expression plasmids. 
Agarose gel electrophoresis of the restriction analyses using pAX_MTT1_NC (A), pAX_MTT1_NC531 (B), 
pAX_MTT1_UR (C), and pAX_MTT1_FL (D) are demonstrated. The restriction analysis of the four expression 
plasmids confirms successful generation of the expression plasmids. 
A: Examination of pAX_MTT1_NC. 
1: The restriction analysis with BstBI is shown (4826 bp, 4695 bp, 1929 bp, 669 bp, 381 bp). 2: Analysis due to a 
XhoI and a BglII site (9761 bp, 2703 bp). 
B: Testing of pAX_MTT1_NC531. 
3 and 4: The analogous approach as shown in A. Lane 3 (4826 bp, 4551 bp, 1929 bp, 669 bp, 381 bp) and lane 4 
(9761 bp, 2595 bp). 
C: Analysis of pAX_MTT1_UR. 
5: The restriction analysis with XhoI and BglII is shown (9761 bp, 2661 bp). 6: Analysis using an AccI site 
(5519 bp, 4863 bp, 2040 bp). 
D: Investigation of pAX_MTT1_FL. 
7: Analysis due to a XhoI and BglII restriction (9761 bp, 2649 bp). 8: A NotI and SacI restriction is shown 
(9346 bp, 3022 bp, 42 bp). 
A 1 kb DNA ladder was used as standard (S). 
 
4.1.2 Generation of HA expressing T. thermophila 
After the construction and assembly of the expression vectors, the generation of transformed 
Tetrahymena cells was performed. Conjugating T. thermophila wild type cells were 
transformed using biolistic bombardment, applying the four different expression plasmids and 
the successful transformation was monitored by selection against the antibiotic paromomycin 
in a final concentration of 150 µg/mL. 
After approximately three weeks of growth, paromomycin resistant clones were verified 
performing a molecular analysis. Therefore, the whole genomic DNA was extracted from 
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putative transformants and wild type cells, and the DNA was examined via PCR analysis. 
Figure 8 exhibits the verification of one representative T. thermophila culture transformed 
with pAX_MTT1_NC (A), pAX_MTT1_NC531 (B), pAX_MTT1_UR (C), or 
pAX_MTT1_FL (D). For a proper transformant, a fragment corresponding to a part of the 
MTT1 promoter and the HA coding region (PCR 1), a fragment corresponding to the entire 
HA coding sequence (PCR 2), and a fragment that reflects the MTT1 promoter (PCR 3) was 
amplified and visualized performing an 1 % agarose gel electrophoresis. For the wild type, a 
proper signal regarding the endogenous MTT1 promoter (PCR 3), but not for the HA (PCR 2) 
and MTT1-HA-fusion (PCR 1) sequence was observed, as expected. 
 
Figure 8: Analyses of representative transformed Ciliates. 
Results of the PCR analysis of T. thermophila transformed with pAX_MTT1_NC (A), pAX_MTT1_NC531 (B), 
pAX_MTT1_UR (C), or pAX_MTT1_FL (D). The 1 % agarose gel electrophoresis confirms that the analyzed 
clones contain the correct expression modules. 1: PCR 1 confirms the fusion of the MTT1 promoter to the HA 
coding region. 2: PCR 2 depicts a PCR of the coding region of the HA. 3: PCR 3 exhibits the MTT1 promoter. 4, 
5 and 6 are analogous, but applying wild type DNA. PCR approach was performed using MTT1 and target 
antigen specific primers. The negative controls show a proper signal regarding the endogenous MTT1 promoter, 
but no signals in respect to the target antigens. An 1 kb DNA ladder was used as standard (S). 
 
4.1.3 Screening of transformed ciliates for HA expression by Western blot analysis 
The verified transformants were screened for HA antigen expression and secretion. For this 
purpose, transformed T. thermophila cells were cultured in SPP medium under selection 
pressure (400 µg/mL paromomycin) for 12 hours. The expression was subsequently induced 
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by cadmium, setting up a final concentration of 5 µg/mL. Same expression strains were 
cultivated without induction of the protein expression by cadmium. To minimize digestion of 
the recombinant HA in the extracellular medium by endogenous proteases, the cysteine 
protease inhibitor E-64 was added to the cultures at point of time of cadmium induction. 
24 hours after the induction of the HA expression cells were harvested by centrifugation and 
were subsequently solubilized in an extraction buffer (RIPA-buffer). Samples of the cell free 
culture supernatant were collected, as well. For the separation of the proteins 12 % SDS gel 
electrophoresis was performed. Extracts of cells and supernatants derived from T. thermophila 
cultures transformed with vectors of the New Caledonia derived untruncated HA (NC HA, 
Figure 9 A, theoretical molecular weight 62 kDa), and C-terminally truncated HA (NC531 
HA, Figure 9 B, theoretical molecular weight 58 kDa), the Uruguay derived HA (UR HA, 
Figure 9 C, theoretical molecular weight 60 kDa), and the Florida derived HA (FL HA, 
Figure 9 D, theoretical molecular weight 57 kDa) were tested by SDS-PAGE and 
Western blot analysis. The proteins were transferred to a nitrocellulose membrane using 
semi-dry blot and recombinant HA antigens were detected using strain specific anti HA 
antibodies. A Tetrahymena wild type strain was applied as negative control. As a positive 
control a NIBSC antigen of each untruncated HA was taken. All samples were tested using 
non-reducing conditions, and reducing conditions where 2-mercapto ethanol was added to the 
sample buffer. 
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Figure 9: Expression analyses of recombinant HA in T. thermophila. 
Aliquots of a non-transformed wild type and cell extracts of clones that were transformed with the 
pAX_MTT1_NC (A), pAX_MTT1_NC531 (B), pAX_MTT1_UR (C), and pAX_MTT1_FL (D) expression 
plasmid were separated on 12 % SDS-PAGE and transferred to a nitrocellulose membrane via semi-dry blot. 
Samples of the NIBSC antigen were applied using non-reducing (A-) and reducing conditions with the addition 
of 2-mercapto ethanol (A+). Cell extracts of every expression strain were applied, taking non-reducing 
conditions with induction by cadmium (C-) and without induction by cadmium (Cni-), as well as supernatants 
with induction by cadmium (SN-) and without (SNni-). The cell extracts were also applied utilizing reducing 
conditions (C+) as well as the supernatants (SN+). Cell extracts under non-reducing conditions of a 
non-transformed wild type strain served as negative control (WT-). As protein standard the PageRuler™ Plus 
Prestained Protein Ladder (S) was applied. 
 
Analyzing the transformants of the NC expression strain HA specific bands were detected in 
the cell extracts indicating HA expression with an apparent molecular weight of 62 kDa using 
non-reducing and reducing conditions as also shown for the NIBSC NC antigen (Figure 9 A). 
Sample preparation with and without the addition of 2-mercapto ethanol was performed in 
order to test the stability of the recombinant expressed antigen. Furthermore, slight signals 
were detected in the supernatant of the pAX_MTT1_NC transformant (Figure 9 A). Applying 
the cell extract and the supernatant of wild type Tetrahymena cells and supernatants of a 
non-induced transformant (negative control) no signal was shown, as expected. Testing 
transformants of the NC531 expression strain lacking the TMD, strong bands were visualized 
in cell extracts under non-reducing and reducing conditions comprising an apparent molecular 
weight of 58 kDa (Figure 9 B). The applied positive control (NIBSC NC antigen) was the 
same as for the NC expression strain. This NIBSC antigen could be used, because the epitope 
where the antibody binds is located within the HA1 chain. Slight signals testing the 
supernatants were also visualized for the NC531 expression strain. For the non-transformed 
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wild type control and a non-induced transformant no HA specific band was detected. The 
results of the analysis of the UR expression strains are depicted in Figure 9 C. UR antigen 
specific signals appeared, analyzing cell extracts applying non-reducing and reducing 
conditions with an apparent molecular weight of 60 kDa, as well as for the NIBSC UR 
antigen. No signals were found testing the supernatants of pAX_MTT1_UR transformed 
T. thermophila, non-transformed wild type cells and the cell extract and the supernatant of the 
non-induced UR expression strain. When analyzing the cell extracts of UR transformants and 
non-transformed wild type cells, an additional signal appeared at approximately 30 kDa 
within the controls (Figure 9 C), which could be explained by a cross reaction of the used 
antibody. Testing the pAX_MTT1_FL transformants applying non-reducing conditions, a 
strong signal that points to FL derived HA was detected within the cell free culture 
supernatant (Figure 9 D). No band can be visualized applying the supernatant with reducing 
conditions. The visualized band had an apparent molecular weight of approximately 72 kDa 
testing the cadmium induced supernatants. No FL HA specific band could be visualized 
regarding the non-induced supernatant of the FL expression strain. Applying the NIBSC FL 
antigen resulted in a FL HA specific band of an apparent molecular weight of 90 kDa 
(Figure 9 D). Testing the cell extracts of the pAX_MTT1_FL transformant, nearly all bands 
that were detected were also seen in the non-transformed wild type cells. This can also be 
explained by a side reaction of the used FL HA antibody. 
The fact that signals for HA expression strains were detected for cadmium induced cultures 
but not for non-induced cultures pointed out that the expression of the recombinant HAs was 
regulated properly by the cadmium inducible metallothionein 1 promoter (MTT1) system. 
The main focus of this initial experiment was to illustrate that HA from different influenza 
virus strains can be expressed by the ciliate system. Nevertheless, to give an estimation of the 
yield of the expressed HA, quantitative Western blot analysis was performed. 
 
4.1.4 Lab-scale expression of HA (0.5 L) and quantification of the yield 
For the development of an industrial production process, the evaluation of an optimal 
fermentation procedure is of critical importance, because parameters such as medium 
components, pH values, oxygen supply and duration of the fermentation process significantly 
affects product concentration, yield and productivity. For biopharmaceuticals, medium costs 
can substantially affect the overall process economics. 
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To examine the production efficiency of the developed HA expression system on lab-scale, 
fermentation of the recombinant strains was carried out in a 0.5 L multi fermentor at 30 °C. 
Applying this multi bioreactor, different Tetrahymena clones and different cultivation 
conditions can be tested parallely. Therefore, in an initial attempt the fermentation process 
was established setting optimal growth conditions regarding the pH values and the oxygen 
supply of the cells. Testing different media components, supplemented proteose peptone 
(SPP) medium was ascertained to be optimal for the cultivation of HA transformed 
Tetrahymena cells. The cysteine protease inhibitor E-64 was added to prevent digestion of 
extracellular HA. The fermentor was controlled to maintain the broth temperature at 30 °C, 
pH 7.0, and dissolved oxygen at 20 % of the air saturation level. For the growth of the cells, a 
fed-batch culture method was chosen, because it has become a platform technology for the 
large-scale production of therapeutic and recombinant proteins due to its simplicity, flexibility 
and a high final product concentration
166
. Inoculation of the culture broth was done with a cell 
titer of 20,000 to 40,000 cells/mL obtained from a preculture of 200 mL SPP medium under 
selection pressure (paromomycin 400 µg/mL). Cells were concentrated performing a 
centrifugational step, and the fermentor was inoculated with 10 mL of concentrated cells. In 
the first phase of the fermentation process, cells were grown batch-wise for approximately 
43 hours exhibiting a cell density of approximately 1.5 x 10
6
 cells/mL. The second phase of 
the fermentation procedure was initialized by a feeding step (Figure 10, feeding) with 10 mL 
of 50 fold concentrated SPP medium, and the final volume of the culture broth was about 
0.5 L. Cells reached a cell density of approximately 1.1 x 10
6
 cells/mL for the NC HA 
expression strain, 1.5 x 10
6
 cells/mL for the NC531 HA expression strain, 2 x 10
6
 cells/mL for 
the UR HA expression strain, and 1 x 10
6
 cells/mL for the FL HA expression strain. At this 
point of time the cultures were induced by cadmium chloride in a final concentration of 
40 µg/mL after approximately 47.5 hours of growth (Figure 10, Cd). This cadmium 
concentration was defined as optimal for the recombinant HA production for all expression 
strains. Samples were taken in minimum at about 23 and 43 hours after the induction of the 
HA expression (Figure 10, harvest 1 and 2), and analyzed via Western blot. Finally, cells were 
harvested 43 h after induction of the expression. At this point of time, the NC HA expression 
strains reached a cell density of 2.6 x 10
6
 cells/mL, while the pAX_MTT1_UR and 
pAX_MTT1_FL transformed cultures reached a cell density of 2.1 x 10
6
 cells/mL for the UR 
HA strain, and 1.46 x 10
6
 cells/mL for the FL HA strain during the fermentation process. The 
harvest was carried out by a centrifugational step, and samples were collected for a pretesting 
and a following quantification and were frozen at -20 °C immediately. Figure 10 shows the 
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growth curve of an optimized fermentation process using a 0.5
pAX_MTT1_NC (blue line), pAX_MTT1_NC531 (red line), pAX_MTT1_UR (green line), 
and pAX_MTT1_FL (purple line).
Figure 10: Fed-batch fermentation of HA expressing 
line), pAX_MTT1_NC531 (red line), pAX_MTT1_UR (green line), and pAX_MTT1_FL (purple line). The 
growth curves are depicted logarithmically.
The cells were grown in a 0.5 L multi fermentor using SPP medium. The fermentatio
maintained at 30 °C, regulating a pH of 7.0, and an oxygen supply of 20
milliliter of nutrient was supplemented to the culture broth (black arrow, feeding) adding 50
SPP medium. The cadmium induction was carried out after cells reached the stationary phase (red arrow, Cd). 
The harvest (green arrow harvest 1 and orange arrow harvest
inoculation, respectively, meaning 23 and 43
densities at different points of time of
Tetrahymena expression strain. 
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high rates. This pointed out that the extracellular detected signal was based on a leakage of the 
cells. 
 
Figure 11: Analysis of the production of recombinant NC531 and NC HA during fermentation (0.5 L). 
A NC531 and a NC expression strain are shown after 70 and 90 hours of fermentation. Cell extracts and 
supernatants were applied on an 8 % SDS-PAGE. Following, Western blot analysis was performed. 
Recombinant NC antigen (A-, NIBSC, 6 ng, non-reducing conditions) served as positive control. Aliquots of 
250 cells and the supernatant corresponding to 1,000 cells were applied to the SDS-PAGE under non-reducing 
conditions. 
Within the cell extract of NC531 strains after 70 hours (C1-) and after 90 hours (C2-) of the fermentation, 
meaning 23 hours and 43 hours after induction of the expression by cadmium, strong NC531 HA specific signals 
were found. Regarding the supernatants, a signal after 23 hours (SN1-) of the induction of the expression was 
detected that increased in intensity after 43 hours (SN2-) of induction. Analyzing the NC HA strain, a signal at 
point of time of harvest of 70 hours (C3-) and 90 hours (C4-) was found regarding the cell pellet and the 
supernatants, respectively (SN3- and SN4-). Additional signals were detected at approximately 120 kDa and 
270 kDa what can be due to dimers and trimers. As protein standard the PageRuler™ Plus Prestained Protein 
Ladder (S) was applied. 
 
A first estimation of the yield of the recombinant NC531 and NC antigen was made by 
performing a quantitative Western blot analysis. To draw up a calibration curve, different 
amounts of recombinant NC antigen (5 ng, 10 ng, 20 ng, 30 ng) were applied on a SDS-gel 
and transferred to a nitrocellulose membrane using semi-dry blot. The produced HA antigen 
of transformed T. thermophila cells obtained from the established fermentation within the 
multi bioreactor after 43 hours of the induction of the expression by cadmium served as 
samples. Densitometric analysis of performed quantitative Western blot led to the estimation 
that the signals correspond to 102±25 mg/L of recombinant untruncated NC antigen, and 
185±25 mg/L of recombinant C-terminally truncated NC531 antigen. 
 
Following, the UR expression strain was tested by SDS-PAGE and Western blot analysis 
during a fermentation process. UR HA specific signals were detected regarding the cell 
extracts after the induction of the recombinant UR HA expression analyzing the cell extracts 
(Figure 12). No signals were detected in the supernatants. The determination of the yield of 
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the UR transformant was performed as mentioned above and led to an expression value of 
186±49 mg/L of UR derived HA. This is comparable to the expression value of the shortened 
New Caledonia derived HA. 
 
Figure 12: Analysis of recombinant UR HA expression during a fermentation process (0.5 L). 
Aliquots of 10,000 cells and the supernatant corresponding to 10,000 cells were applied to a 12 % SDS-PAGE 
using reducing conditions. A non-induced UR HA expression strain is shown after 47.5 hours of growth (C1+, 
SN1+), where no specific signal was detectable. Recombinant UR antigen (A+, NIBSC, 15 ng) served as 
positive control. After the induction of the UR HA expression at point of time of 54 hours of growth an UR HA 
specific signal at approximately 70 kDa was detected in the cell extract (C2+), but not in the supernatant (SN2+). 
This point of time was about 6.5 hours after induction of the expression by cadmium. After 70 hours (C3+, 
SN3+), and after 90 hours of growth (C4+, SN4+), meaning 23 hours and 43 hours after induction of the 
expression by cadmium, UR HA specific signals were found in the cell extracts. As protein standard the 
PageRuler™ Plus Prestained Protein Ladder (S) was used. 
 
Finally, the FL HA expression strain was tested for FL derived HA antigen expression and 
secretion obtained during a 0.5 L fermentation process. No FL HA specific signal could be 
visualized testing the cell extracts due to unspecific binding of the antibody (data not shown), 
however, strong FL HA corresponding signals were detected regarding the extracellular 
medium (Figure 13). Signals for recombinant expressed FL antigen (calculated molecular 
weight was about 57 kDa) were found at an apparent molecular weight of approximately 
72 kDa and 90 kDa. This increased molecular weight could be due to glycosylation or folding 
effects of the produced protein. The same effect could be detected applying the FL specific 
NIBSC antigen. 
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Figure 13: Analysis of the expression of recombinant HA of a pAX_MTT1_FL transformant peforming a 
fed-batch fermentation process (0.5 L). 
Obtained supernatants were applied to a 12 % SDS-PAGE using non-reducing conditions followed by 
Western blot analysis. The applied NIBSC FL antigen showed a signal corresponding to approximately 90 kDa 
(A-, NIBSC, 45 ng). Different points of time of harvest after the induction of the FL antigen expression (SN1- 
3.5 h, SN2- 20.5 h, SN3- 23 h, SN4- 43 h) did not lead to an accumulation of the detected extracellular HA 
derived from the Florida B strain after 20.5 h of the cadmium induction. A band at approximately 72 kDa and 
90 kDa appeared. As protein standard the PageRuler™ Plus Prestained Protein Ladder was applied (S). 
 
Additionally, a quantification of the yield applying the extracellular medium of the FL 
expression strain was performed and determined as 21±8 mg/L of recombinant expressed FL 
derived HA antigen. The measured extracellular ICDH activity was about 28 % but the 
estimated cell titer during the fermentation was constant from the point of time of induction of 
the FL antigen expression by cadmium until the harvest of the cells. Furthermore, the 
measured extracellular recombinant FL antigen appeared as a strong signal testing the 
supernatant, and no signal could be visualized analyzing the cell extracts (data not shown). 
Therefore, it can be concluded that the FL derived HA antigen was secreted despite the 
relative high measured ICDH activity. The results of the Western blot analysis are depicted in 
Figure 13. 
Figure 14 summarizes the determined expression yields of several fermentations. While 
acceptable yields of truncated recombinant NC531 antigen and the recombinant expressed UR 
antigen could be reached, the expression yield of the untruncated version, the NC antigen, was 
significantly lower. The lowest expression yield was obtained for the HA derived from the FL 
expression strain. But it is mentionable that this FL derived HA antigen was secreted using 
the T. thermophila based expression system. 
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Figure 14: Expression yields of the four di
system. 
The yield of intracellular recombinant expressed HA from a pAX_MTT1
independent 0.5 L fermentation process
intracellular NC531 HA was calculated to be 
186±49 mg/L (green bar, n=8), and of extracellular FL derived HA to be 
standard deviations are shown by error bars.
 
4.2 Development of an efficient production and purification process
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up-scaling by using a 50 L fermentation vessel
was performed as a fed-batch cultivation
scale fermentation (0.5 L). SPP medium was chosen because h
and a high productivity was shown as aforementioned (4.1.7). Inoculation was performed with 
a cell titer of 30,000 cells/mL. The feeding with 750
after 43.5 hours of the fermentation procedu
fermentor was controlled to maintain the broth temperature at 30
20 % dissolved oxygen, as found out during the 0.5
reached the stationary phase, induction of the NC531 HA expression was carried out by 
addition of cadmium chloride in a final concentration of 40
(Figure 15). Cells reached a final cell density of 0.95
90.5 hours of fermentation, meaning 42
(Figure 15). 
Figure 15: Fed-batch fermentation of the NC531 HA
is depicted in logarithmic scale. 
The cells were grown in a 50 L fermentor using SPP medium. The fermentation broth temperature was 
maintained at 30 °C regulating the pH 
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After 42 hours of induction of NC531 protein expression, the culture was separated from the 
fermentation broth applying a hollow fiber module and a following centrifugational step. To 
enhance the yield of the recombinant expressed NC531 antigen and to ease the purification 
process, the harvest was optimized by an additional step. Cells were shocked on ice and 
washed with ice cold phosphate buffer after the separation of the cells from the fermentation 
broth to remove mucocyst contents and remaining media components. Mucocysts, extrusomes 
of Tetrahymena and other ciliates, have the capacity to secrete a dozen acidic polypeptides. 
The function of these organelles in Tetrahymena is unknown, but nutrient trapping has been 
proposed as a possibility along with membrane accretion and defense against predators. These 
expanding protein structures would interfere with the purification using column 
chromatography. Finally, the washed and pelleted cells were frozen at -80 °C, immediately. 
In order to determine the expression yield, samples corresponding to 10, 50 and 100 cells and 
aliquots of the supernatant were analyzed by an 8 % SDS-PAGE and a following Western blot 
analysis using non-reducing conditions. The cell extract (Figure 16) and the supernatant of a 
non-transformed wild type strain served as negative control and the recombinant NIBSC NC 
antigen (NIBSC, 6 ng) as positive control. NC531 HA corresponding signals were detected at 
approximately 57 kDa within all samples. In addition, the formation of putative dimers and 
trimers was shown when applying 100 cells per lane. Extracellular recombinant NC531 HA 
was detected as well, but the performed ICDH activity assay exceeded 50 %, indicating that 
the extracellular located NC531 HA was dependant on cell lysis. Quantitative Western blot 
analysis revealed intracellular HA expression values of ~150 mg/L obtained during a 50 L 
fed-batch fermentation process. 
 
Figure 16: Expression analysis of NC531 HA obtained during a 50 L fed-batch fermentation. 
An 8 % SDS-PAGE and a Western blot analysis was performed. The NC HA antigen (NIBSC, 6 ng, A) served 
as positive control, whereas the cell pellet (WTC) and the supernatant (WTSN) of a non-transformed wild type 
strain served as negative controls. Verifying the NC531 HA expression, aliquots corresponding to 10, 50 and 
100 cells/lane (C1-, C2- and C3-) were applied after 42 hours of induction by cadmium. The supernatant (SN) 
that refers to 1,000 cells is demonstrated, as well. As protein standard the PageRuler™ Plus Prestained Protein 
Ladder was used (S). 
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4.2.2 Establishment of a purification process for HA expressed by T. thermophila 
For industrial purposes, the purification strategies employed should be inexpensive, rapid, 
efficient in terms of yield, and amenable to large-scale operations. They should have the 
potential for a relatively high capacity and selectivity for the desired product. 
To establish a purification process, the harvest was optimized as mentioned above (4.2.1). 
Different columns for chromatography were tested to define the best column material to use 
for the purification of recombinant NC531 antigen. Furthermore, different buffers, different 
protease inhibitors as supplementation for the buffers and different elution strategies were 
checked. An important point during the purification process was to maintain neutral pH 
values around 7.4 in order to prevent refolding of NC531 HA (personal communication by the 
cooperation partner). 
 
Cell lysis and separation of cell debris. 
Washed and frozen cells (80 g) obtained from the 50 L fed-batch fermentation, corresponding 
to 2.1 L of original culture, were thawed in loading buffer supplemented with the cysteine 
protease inhibitor E-64 (70 µM) and disrupted using an IKA UT T25 Ultra-Turrax with a 
S25N-25G rotor at 10,000 rpm for 5 minutes. This mechanical method together with the lysis 
by Tween
®
-20 was found out to be the most efficient technique to obtain completely disrupted 
cells without losing much recombinant NC531 antigen. After 12 hours of stirring at 4 °C, 
most of the NC531 HA was soluble, and the lysate was filtrated applying a hollow fiber 
module (0.45 µm, 850 cm², 1 L/min). The pH, which dropped to about 7.1 during the stirring 
step, was readjusted to 7.4 by addition of NaOH. The cell retentate of the filtration containing 
cell debris and with this about 30 % of the total NC531 HA was discarded. 
 
1st column: 125 mL Capto™ Q. 
The solubilized and filtrated cell lysate was used to load the first column of the purification 
process. Capto™ Q is a strong anion exchange chromatography material for the capture and 
intermediate purification of proteins from large feed volumes. This anion exchanger was 
chosen because the NC531 HA should be purified at neutral pH values concerning the folding 
properties. At neutral pH values, the NC531 antigen is theoretically negatively charged 
because of its theoretical isoelectric point of 6.31. All column steps were performed at 4 °C. 
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The column comprising a bed volume of 125 mL was equilibrated and subsequently loaded 
with the obtained filtrate at a flow rate of 15 mL/min. A washing step with one column 
volume (CV) of phosphate buffer supplemented with Tween
®
-20 was done. Afterwards, the 
washing was changed to phosphate buffer without Tween
®
-20 applying 2 CV to get rid of the 
detergence. The NC531 HA was eluted by a step to 150 mM NaCl in phosphate buffer 
(elution buffer 1). This salt concentration was found to be best suited for elution. In previous 
experiments, a NaCl gradient was used to determine this salt concentration. To check for 
complete elution of NC531 HA, a final step increasing the NaCl concentration to 1 M (elution 
buffer 2) was performed. The exemplary elution profile of this column chromatography step 
and corresponding amounts of NC531 HA is shown in Figure 17. This first capturing step led 
to a concentration of the antigen in 16 fractions by eliminating contaminating proteins. 
Testing the fractions of the 1 M NaCl step, nearly no HA was detected. Each collected 
fraction was supplemented by 11 µM E-64 to exclude the digestion by endogenous proteases 
of T. thermophila. 
 
Figure 17: Elution profile of NC531 HA using a Capto™ Q column (1st column). 
The red line indicates the amount of NC531 HA [mg] quantified by Western blot analysis. The blue line shows 
the UV values at 280 nm [relative] that reflect the whole protein content measured during the column 
chromatography. The green line demonstrates the conductivity [relative] related to the salt concentration of the 
step elution. The dashed bar indicates the fractions pooled for the 2nd column. 
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Second column: 25 mL Ceramic hydroxyapatite 
Ceramic hydroxyapatite (CHT) overcomes the physical and chemical limitations of traditional 
crystalline hydroxyapatite, and provides the throughput, stability, and reproducibility required 
for industrial biopharmaceutical manufacturing. CHT interacts with biomolecules by multiple 
modes. Electrostatic interactions occur between positively charged calcium ions and 
negatively charged phosphate groups on the support and charged moieties on the 
biomolecule´s surface. Much stronger coordination complexes can form between clusters of 
carboxyl groups (on proteins) and calcium sites on CHT. Repulsion effects and the geometric 
charge distribution on CHT provide unique selectivity. Typically, proteins are bound to 
hydroxyapatite using a low ionic strength phosphate buffer. Elution is accomplished through 
the use of a phosphate gradient of increasing strength. 
Fractions 10 to 47 of the Capto Q column were pooled, and a buffer exchange using running 
buffer 2 was carried out applying the pooled fractions to a lab-scale Tangential Flow 
Filtration module (TFF, 30 kDa, Pellicon, Millipore GmbH, Schwalbach, Germany) to reach a 
final NaCl concentration below 10 mM with a final volume of 80 mL. The pH value of this 
sample was adjusted to 7.5 prior to loading to the column. The column comprising a bed 
volume of 25 mL was loaded with a flow rate of 7 mL/min. The recombinant NC531 protein 
did not bind to the column but could be detected nearly quantitatively in the flow through. 
Performing this column step, the whole protein content could be decreased because a vast 
number of contaminating proteins bound to the column, and this finally led to a purer antigen 
(see Table 1). 
 
Third column: 15 mL Concanavalin A. 
Concanavalin A (Con A) is a tetrameric metalloprotein isolated from Canavalia ensiformis. 
Con A binds molecules containing α-D-mannopyranosyl, α-D-glucopyranosyl and sterical 
related residues. The binding sugar requires the presence of C-3, C-4 and C-5 hydroxyl 
groups for reaction with Con A. Con A coupled to Sepharose is routinely used for separation 
and purification of glycoproteins, polysaccharides and glycolipids. Binding of proteins occurs 
at a neutral pH using PBS buffer supplement with NaCl. Elution of bound substances can be 
achieved applying an increasing gradient (linear or step) of α-D-methylmannoside or 
α-D-methylglucoside. 
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A 15 mL Con A Sepharose 4B (GE-Healthcare) column was used. Loading and elution were 
performed at a flow rate of 5 mL/min. After the equilibration of the column, the flow through 
of the CHT column, supplemented with 150 mM of NaCl, was loaded to the Con A column. 
The bound NC531 HA was eluted by applying a step to 0.5 M of α-D-methylmannoside in 
PBS. This high concentration of sugar was discerned to be best suited for the elution of 
NC531 HA. An overall of 30 fractions of each 5 mL were collected and quantified via 
Western blot analysis. The entire yield was determined to be about 15 mg of purified NC531 
HA. Figure 18 shows the elution diagram of the Con A chromatography, the corresponding 
NC531 HA and whole protein content. The elution was performed as a step elution. This 
applied step did not lead to an elution of the recombinant antigen in a circumscribed area but 
elutes during many fractions. Even a step to as much as 1 M α-D-methylmannoside did not 
result in an elution volume of 1-2 CV which indicated a very tight binding of HA to the 
Con A material (data not shown). The whole protein content was measured by Bradford 
assay, and is nearly similar to the content of NC531 HA in the fractions of the Con A column. 
The fractions 3 to 30, containing 0.5 M α-D-methylmannoside at a pH value of 7.4 were 
pooled. A buffer exchange to PBS buffer at a pH of 7.4 including a concentration of the 
antigen was done using a Pellicon XL biomax 50 kDa module. The starting volume was about 
130 mL of the sample and finally concentrated to 25 mL. The final protein suspension showed 
a concentration of α-D-methylmannoside beneath in theory 0.07 mM and a yield of 
recombinant and purified NC531 antigen of 15 mg. 
 
Results  76 
 
Figure 18: Elution of NC531 HA on Con A Sepharose 4B. 
The red line indicates the yield of recombinant NC531 HA [mg] quantified by Western blot analysis. The blue 
line depicts the measured UV 280 nm [relative], and the purple line shows the whole protein content determined 
by Bradford assay [mg]. The green line demonstrates the estimated step of the α-D-methylmannoside. 
 
To show the effect of the purification process, a coomassie stain was chosen to detect all 
protein bands of each sample. Figure 19 shows the coomassie stained SDS-gel of all samples 
collected during the purification process. The concentrated sample after the completed 
purification cascade is applied in lane 7. The purified protein fraction, eluted from the matrix 
and afterwards concentrated resulted in predominant bands running at a molecular weight of 
approximately 60 kDa. The size was in close agreement with the calculated molecular weight 
of NC531 HA (57 kDa). Furthermore, a band due to a NC531 HA dimer and due to a NC531 
HA trimer could be visualized. To verify this result of the purification step, aliquots of this 
sample were separated by SDS-PAGE, blotted to nitrocellulose and finally probed with anti 
New Caledonia H1N1 antibody (data not shown). A clear band was detected at the same 
height as seen in the coomassie stained SDS-gel, which argues for an efficient purification 
process. 
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Figure 19: Purification of recombinant NC531 HA. 
A coomassie stained SDS-gel (12 %) of different purification steps by Capto™ Q, Ceramic Hydroxyapatite, and 
Concanavalin A. As a marker the PageRuler™ Protein Ladder Plus (Fermentas) was applied (S). For the control 
the NC NIBSC antigen was used (A, 0.65 µg, NIBSC). The cell lysate after the solubilization and filtration step 
(lane 1, 20 µg), the flow through of the Capto™ Q column (1st column) (lane 2, 20 µg), the pooled fractions 
10-47 of the Capto™ Q column (1st column) (lane 3, 7 µg), the pooled fractions 10-47 of the Capto Q column 
after concentration and salt removal (lane 4, 7 µg), the flow through of the Ceramic Hydroxyapatite column (2nd 
column) (lane 5, 7 µg) is depicted. The flow through of the Con A column (3rd column) (lane 6, 7 µg) showed 
many protein bands regarding the coomassie stained SDS-gel. After the purification cascade nearly a single band 
at approximately 60 kDa can be detected analyzing the pooled fractions 3-30 of the Con A column (3rd column) 
(lane 7, 2 µg). A putative NC531 HA dimer and trimer can be visualized, as well. 
 
Table 1 summarizes all quantified samples of the purification process. The purity of NC531 
HA is shown in %. This purity was calculated based on a whole protein content determination 
using Bradford assay, and a quantitative HA antigen determination applying Western blot 
analysis. After all purification steps, a nearly 100 % pure Tetrahymena based NC531 HA was 
obtained. The loss of HA antigen after the concentration of the sample could be due to 
absorption of the antigen to the membrane of the concentration tool. 
Finally, an efficient purification protocol was established. The first sample that was applied 
for the Capto™ Q column yielded about 4,880 mg of whole protein, with a content of 
recombinant HA of 56 mg. Regarding the pooled and concentrated fractions of the Con A 
column, a whole protein content of 16 mg was detected with 11.4 mg of NC531 HA. 
Concluding, 20.4 % of NC531 antigen were obtained during a 3-step column chromatography 
purification process, decreasing whole protein content to 0.33 %. 
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Table 1: Summary of the NC531 HA preparation. Protein content was determined by Bradford assay and the 
NC531 HA was quantified by Western blot analysis. 
Sample Protein [mg] &C531 HA [mg] purity of &C531 HA [%] 
sample Capto™ Q 4,880 56 1.1 
flow through Capto™ Q 4,537 5 0.1 
fractions 10-47 Capto™ Q 376 57 15.2 
sample CHT 392 42.4 10.8 
sample Con A 179 33.1 18.5 
flow through Con A 192 0,1 0.1 
pooled Con A fractions 18 17.2 95.6 
pooled concentrated Con A fractions 16 11.4 71.3 
 
4.2.3 Characterization of the T. thermophila expressed &C531 antigen 
Transport through ER and Golgi compartments usually is accompanied by the addition of 
N-glycans. Because the NC531 HA comprises a signal peptide, it is assumed that the HA was 
led to the ER and gets glycosylated. This point was investigated for the purified recombinant 
antigen NC531 and a glycosylation assay was performed by applying N-glycosidase F 
(PNGase F) and denaturing conditions (Figure 20). PNGase F is an amidase that cleaves 
between the innermost GlcNAc and asparagine residues of high mannose, hybrid and complex 
oligosaccharides from N-linked glycoproteins. For the test, purified NC531 HA was applied. 
The PNGase treated samples revealed a significant band-shift on a 12 % SDS-PAGE followed 
by a transfer to a nitrocellulose membrane when compared to the PNGase F untreated control 
(C1). Additional bands were detected regarding the PNGase F treated samples (C2 and C3), 
which could be due to protein degradation. The NC NIBSC antigen (A) was used as control. 
The significant reduction of the molecular weight of intracellular extracted NC531 HA from 
T. thermophila demonstrated that it becomes glycosylated while shuttling through the ER and 
Golgi. Furthermore, comparison of C1 and A showed that the NC531 antigen from 
T. thermophila and from the native virus were running at heights of comparable molecular 
weight. The slight reduction of the Tetrahymena derived NC531 HA is due to the truncation 
of the transmembrane domain. 
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Figure 20: Deglycosylation assay of recombinant expressed and purified NC531 antigen. 
The treatment with PNGase F results in a significant band-shift (C2 and C3), when compared to non-treated 
recombinant NC531 of T. thermophila (C1) and the non treated NC NIBSC antigen (A, 30 ng). The significant 
band-shift of the recombinant HA from T. thermophila demonstrates that NC531 HA becomes glycosylated 
while shuttling through the ER and Golgi. As protein standard the PageRuler™ Plus Prestained Protein Ladder 
was applied (S). 
 
4.3 Optimization of the production process of &C531 antigen 
A high expression yield of the truncated version of the New Caledonia derived HA was 
obtained and the purification process of this antigen was established by reaching a purity of 
nearly 100 %. Nevertheless, to facilitate the purification, it was addressed to the secretion 
improvement of the NC531 antigen as a first step. Therefore, it was tested if secretion can be 
reached while expressing the HA1 chain without the hydrophobic HA2 chain, the fusion 
domain and the transmembrane domain. By this, the purification of the secreted HA would be 
facilitated, and the functionality of the antigen would be preserved because the HA1 chain is 
responsible for immunogenicity. As a second step, a knock out strain that is not able to 
produce and eject mucocyst contents would ease the purification process in terms of time 
because additional washing steps for the harvest of the cells would not be necessary. Finally, 
the strong but cadmium inducible MTT1 promoter was intended to be replaced by a novel 
promoter candidate of equal strength due to the fact that cadmium is toxic and hence 
undesirable for a large scale industrial production process. 
 
4.3.1 Improvement of the secretion of recombinant HA 
Because the purification of recombinant protein from cell culture supernatant is much more 
preferable than the purification of intracellular protein, it was tested if the secretion of the 
more truncated HA1 version without the hydrophobic HA2 chain of the recombinant protein 
is feasible. Therefore, the HA1 coding region of the influenza virus strain 
New Caledonia/20/99 (aa 1-344) was amplified via PCR and afterwards cloned to the MTT1 
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and BTU2 coding working plasmid pDL. The generated plasmid was termed 
pDL_MTT1_NC344. Finally, an episomal expression plasmid was assembled by 
cre-dependant homologous recombination
142
. Afterwards, the generated expression plasmid 
pAX_MTT1_NC344, tested by restriction analysis (data not shown), was transformed into 
T. thermophila cells via biolistic bombardment. After the selection for paromomycin resistant 
clones and the verification of the genomic DNA by PCR analysis (data not shown), the 
transformants were tested for expression and secretion of the NC344 HA chain (Figure 21). 
To ensure that the proteases in the surrounding medium of Tetrahymena cells did not degrade 
the NC344 antigen, the cysteine protease inhibitor E-64 was added to the culture at point of 
time of induction of the protein expression by cadmium. To verify the results of the 
Western blot analysis, the degree of cell lysis during the cultivation and culture harvest was 
measured by determining the activity of the intracellular ICDH. 
 
Figure 21: Expression analysis of recombinant NC344 HA in T. thermophila. 
Aliquots of pAX_MTT1_NC344 transformed T. thermophila were separated on 12 % SDS-PAGE and 
transferred to a nitrocellulose membrane via semi-dry blot. Cell extracts of different transformants showed a 
strong NC344 antigen expression using reducing conditions with an apparent molecular weight of approximately 
37 kDa (C1+ to C4+). Testing the supernatants regarding two clones a signal was detected (SN1+ and SN3+), 
and two clones showed no signal (SN2+ and SN4+). As protein standard the PageRuler™ Plus Prestained 
Protein Ladder was applied (S). 
 
NC344 HA corresponding signals were detected by Western blot analysis regarding the cell 
pellet and the supernatant of the generated transformants at an apparent molecular weight of 
approximately 37 kDa (Figure 21). In the applied supernatants, NC344 HA corresponding 
signals were detectable in some samples. After a quantitative analysis, the yield of 
intracellular NC344 HA was determined to be 22±7 mg/L, whereas the quantification of 
extracellular NC344 HA yielded about 0.8±0.4 mg/L (Figure 22). The performed ICDH assay 
revealed evidence that the detected NC344 HA of the supernatant does not originate by the 
event of secretion because ICDH activity in the extracellular medium exceeded 15 % of the 
total activity. Deductively, secretion was not reached applying the HA1 chain of the 
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Figure 23: Comparison of the application of a mucocyst knock out strain to a common expression strain. 
The purification, when using the common vector system needs additional steps prior to purification, i.e. removal 
of mucus and additional washing steps. When using a Grl3 knock out vector, T. thermophila expression strains 
excreted no mucocyst contents. Thus, no additional steps before the purification step are necessary. 
 
For the expression of NC531 HA in T. thermophila, an expression module was designed that 
combines the knock out of the Grl3 gene with the knock in of the expression cassette 
(Figure 24). The up- and downstream regions and a part of the coding region of the Grl3 gene 
were amplified by PCR to generate the integration flanks. Both flanks were about 1000 bp, 
and the cloning was performed via restriction sites that were integrated into the flanks by the 
primer sequence. The ligation into an equally restricted integrative vector pKOIX that was 
kindly provided by the Cilian AG
142
 replaced its common integration sites, so that the 
T. thermophila selection marker (neo2) and the lox sites were framed by the newly designed 
Grl3 knock out cassette (Figure 24). Making use of cre-dependant homologous 
recombination, the expression module for NC531 was integrated between the two Grl3 flanks. 
The selection of positive transformants was done using the paromomycin resistance. After the 
construction, the plasmid was transformed into at least one allele of the 45 MAC alleles of the 
Grl3 locus. For the complete replacement of all 45 wild type alleles against the disrupted 
version of the Grl3 gene, the process of allelic assortment was necessary
99
. This allelic 
assortment took place for a duration of approximately six weeks applying increasing 
paromomycin concentrations up to 1,000 µg/mL cultivating the transformants in SPP 
medium. By the application of this integrative expression plasmid, stable transformants were 
obtained after the process of allelic assortment that expressed NC531 HA without producing 
mucocyst contents. Furthermore, after the stable integration of the expression cassette into the 
Results  83 
T. thermophila genome the addition of the antibiotic is not necessary anymore. This is an 
important argument for an industrial production purpose. 
 
 
Figure 24: Grl3 knock out vector. 
The NC531 HA expression cassette and the selection marker (neo2) is flanked by Grl 3' and 5' sites that promote 
the integration into the Tetrahymena macronuclear Grl3 locus. 
 
The verification of a proper knock out of the Grl3 gene was done using RNA isolation, 
including a following analysis of the cDNA using specific primers for a PCR. Figure 25 
shows exemplarily the PCR analysis of a Grl3 knock out transformant and of a 
non-transformed Tetrahymena wild type strain. The amplification of a small fragment of an 
endogenous T. thermophila enzyme, the β-hexasominidase (β-hex), served as positive control. 
The agarose gel electrophoresis of the PCR applying the non-transformed wild type led to a 
signal for the Grl3 (WT Grl3) gene and for the β-hex (WT hex), as expected. Analyzing the 
knock out transformants, a cDNA fragment corresponding to the Grl3 gene was not detectable 
(ko Grl3), indicating that the gene was properly knocked out and the mRNA could not be 
synthesized. It could be excluded that a cDNA preparation was not successful because a 
signal for the β-hex was demonstrated properly regarding the knock out transformant 
(ko hex). 
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Figure 25: Agarose gel electrophoresis (1 %) of the isolated RNA of a Grl3 knock out transformant and a 
non-transformed wild type strain via cDNA synthesis and a following PCR. Specific primer pairs were used to 
verify the proper knock out. The use of the wild type cDNA led to a specific band for the Grl3 (WT Grl3) and 
the β-hex (WT hex). The anlogous approach was done applying the cDNA of a Grl3 knock out transformant. 
Here, a specific signal was detected reagarding the β-hex PCR (ko hex) but no signal was found for the Grl3 
PCR (ko Grl3). A 1 kb DNA ladder was used as standard (S). 
 
Additionally, it was tested if the excretion of mucocyst contents can be initiated by dibucaine 
stimulation. Synchronous secretion of mature mucocysts in Tetrahymena can be induced by 
the local anesthetic dibucaine
167,168
. The dibucaine treatment should stimulate the biosynthetic 
processes related to mucocyst biogenesis. Therefore, a non-transformed wild type strain and a 
Grl3 knock out transformant were grown in SPP medium for three days. The cells were 
harvested, washed, and subsequently stimulated by the addition of dibucaine. After an 
additional centrifugational step, no mucocysts were visible regarding the Grl3 knock out 
transformant but for the wild type control (Figure 26). 
 
Figure 26: Dibucaine stimulation of a Grl3 knock out transformant and a wild type strain. 
The addition of dibucaine to a Grl3 knock out transformant did not lead to the excretion of mucocyst contents 
(Grl3 knock out). For the non transformed wild type strain mucocyst contents could be properly visualized 
(WT). 
 
Finally, a Western blot analysis of a Grl3 knock out NC531 expression strain was performed. 
A proper signal of NC531 HA was detected intracellularly (data not shown). The yield of 
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intracellular recombinant NC531 antigen, applying an integrative knock out expression 
cassette, was determined to be 24±10 mg/L. 
 
4.3.3 Identification of promoter candidates for &C531 HA expression 
The MTT1 promoter of T. thermophila is a strong and cadmium inducible promoter. 
Nevertheless, the use of this cytotoxic heavy metal is not suitable for an industrial production 
process. For this reason, different promoter candidates were tested for the expression of 
NC531 HA. The MTT5 promoter that is strongly inducible by the addition of several heavy 
metals, was described for the homologous expression as most inducible by the addition of 
divalent zinc ions. To test if the MTT5 promoter is also applicable for the heterologous 
expression of the NC531 HA, 1200 bp of the upstream region of the macronuclear MTT5 
locus were cloned directly upstream to the coding region of NC531 HA. The native zinc 
inducible MTT5 promoter turned out to be the strongest promoter when pretested in 
small-scale. For this approach, cultures were grown using SPP medium under selection 
pressure (400 µg/mL paromomycin) and the expression of the NC531 antigen was induced 
after 12 hours of growth by the addition of zinc in a final concentration of 2 mM. Based on 
these findings, a 0.5 L fermentation was performed, applying same parameters as described in 
4.1.7 for the cultivation of the pAX_MTT1_NC531 strain. A feeding step was done after 
43 hours of growth, and after additional 4.5 hours of growth the induction of the NC531 
antigen expression was performed by the addition of zinc in a final concentration of 4 mM. 
This higher concentration of zinc turned out to be important in order to reach higher yields of 
the recombinant antigen during a fermentation procedure. Cell extracts and supernatants were 
tested by Western blot analysis, where a strong NC531 HA specific signal was detected after 
43 hours of the induction of the expression (data not shown). Following, a quantification of 
the yield was done. The yield of NC531 HA using the MTT5 promoter was determined as 
162±9 mg/L. By this, an expression rate of this antigen was reached which is comparable to 
the MTT1 based NC531 HA expression rate(185±25 mg/L, see Figure 27). Hence, a promoter 
was found to replace the MTT1 promoter. 
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5. Discussion 
Heterologous protein expression becomes more and more important in the field of the 
production of pharmaceutical relevant agents. Recently, bacterial and yeast expression 
systems are used for heterologous protein expression, due to the abundance of simple genetic 
tools and because they can be cultivated to high cell densities including short generation 
times. On the other hand these systems often fail in the field of required posttranslational 
modifications like glycosylation and disulfide bonds which are easily integrated by 
mammalian cells
76
. But, this is accompanied by high costs and the risk of contaminations by 
human and animal pathogens and prions
169
. The possibility to use the innovative 
Tetrahymena thermophila expression system for viral antigen production is based on many 
favorable features, including the large-scale fermentation using inexpensive axenic media, 
gaining high cell densities, and the ability of T. thermophila to produce and secrete complex 
homogenously glycosylated proteins. 
 
5.1 Establishment of a heterologous expression system for viral antigens 
A proven, effective way to combat influenza is through vaccination of the public using the 
trivalent vaccine produced in embryonated chicken eggs. In the current process three 
influenza strains selected by WHO/CDC are propagated in chicken eggs, chemically 
inactivated, and semi-purified. The egg-based technology, however, is unable to respond to a 
pandemic crisis. Vaccine development and production takes several months following 
identification of potential target strains and typically requires the re-assortment of the target 
strain with a high yield strain to obtain suitable growth properties
170
. Therefore, there is a 
pressing need to establish innovative and effective expression systems for the production of 
recombinant antigens. In the recent years, two new approaches, a cell-culture based and a 
recombinant protein (antigen)-based system have shown promise to replace the egg-based 
technique
170
. But, due to several limitations the development of other expression platforms is 
inevitable. The cell culture-based approach involves the production of influenza viruses in cell 
culture followed by the current (egg-based) virus inactivation and purification for the 
down-stream processing. The advantages are: cell cultures are easier to handle and can be 
scaled up in a short period of time. Additionally, the influenza vaccines produced within this 
approach have been tested in Phase I and Phase II clinical trials were found to be safe and at 
least as effective as the vaccines produced in embryonated chicken eggs
22,171,172
. A limitation 
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of the cell culture-based approach is the requirement of high-yielding re-assorted viruses. This 
process also may introduce cell line specific mutations in the genes that can lead to the 
selection of variants characterized by antigenic and structural changes in the HA protein, 
potentially resulting in less-efficacious vaccines
173,174
. Additional hurdles include that the 
production and handling of dangerous virus requires the availability of a high containment 
facility; mammalian cells can harbour animal viruses that may lead to safety concerns. 
Besides, the residues from the expressing cells may cause some unknown side-effects since 
no thorough purification process has been introduced into the manufacturing process. The 
second recombinant protein-based approach involves production of viral antigens such as 
hemagglutinin (HA) and neuraminidase (NA) in cell culture with recombinant DNA 
technology and utilization of the purified antigens as the active ingredients in the vaccine. The 
recombinant HA influenza vaccine developed using the baculovirus/insect cell expression 
system, named FluBlok
®
, has been tested in several Phase I and Phase II human clinical trials 
that demonstrated safety, immunogenicity and efficacy
175-179
. In elderly adults, this 
recombinant HA vaccine is equally or more immunogenic than the egg-based vaccine
179
. Poor 
response rates to the FluBlok
®
 were observed in the 6-35-month-old age group. One 
possibility may be the differences between FluBlok
®
 and conventional egg-derived vaccines 
in the glycosylation and cleavage of the HA molecule, which could result in less antigenicity 
and less efficient presentation to the immune system in young children
180
. HA produced in 
insect cells is generally less glycosylated than HAs produced in chicken eggs, and, more 
specifically, it has been reported the complex oligosaccharides found on HAs derived from 
vertebrate hosts are replaced by small truncated side chains on HAs derived from insect 
cells
181
. In addition, while HA produced in insect cells remains mostly in an "uncleaved" 
form, the HA present in the egg based vaccine is primarily in the form of the cleaved HA1 
and HA2 fractions
182
. 
To meet the challenge of a potential influenza pandemic, however, a reliable expression 
system and a quick, efficient downstream purification process is needed. Additional 
challenging issues are to create safe vaccines. Ciliates combine molecular genetic 
manipulations and growth characteristics of prokaryotic organisms together with the 
sub-cellular machinery for performing post-translational protein modifications. Moreover, 
ciliates have been a model organism in many research fields for decades and there is no 
evidence that they contain any viruses, endoparasites or DNA sequences with oncogenic 
potential. The differences between humans and ciliates during evolution resulted in significant 
differences concerning the codon bias and the whole genome organisation, indicating that it is 
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implausible that ciliates could be a host for human pathogens. The ciliate expression system is 
safe and ciliates are GRAS organisms (generally regarded as safe)
132
. Neither from the 
scientific literature, nor own studies argue for any bio safety problems. In addition to that, 
nothing has been reported about toxins. In expression hosts like fertilized chicken eggs and 
cell lines most of the antigens are difficult and cost intensive to produce, due to bio safety 
aspects (contaminations in mammalian cell lines), but additionally due to the missing 
up-scalability and processing time. In general, ciliates exhibit many features essential for an 
excellent expression system, but the potential to produce candidate vaccines provides 
additional and unique features that should be considered
124
. Ciliates are economical, usually 
giving higher yield and are less demanding in terms of time and effort relative to complex 
eukaryotic systems such as Chinese hamster ovary cells and baculovirus infected cell lines. 
Large cultures of ciliates can be grown in cheap and simple medium compositions to high cell 
densities up to 2 x 10
7
 cells/mL, leading to dry mass weights of 60 to 70 g per litre
131
. The 
recombinant proteins can be targeted into the cytosol (intracellular expression), into the 
medium (expression and secretion), or to the surface (surface display)
58,59,113,135
. This allows 
an easy and fast testing of different protein variants and putative vaccine candidates, 
respectively. These features along with easy maintenance, easy scale-up, and inexpensive 
growth requirements makes T. thermophila as a very useful protein expression system. 
Because of safety issues, and cost effectiveness, the Tetrahymena based expression system 
was addressed to express three different HAs, two derived from A strain influenza virus, and 
one derived from B strain influenza virus during this work. Therefore, the HA of the 
influenza A virus New Caledonia/20/99 (H1N1), the HA of the influenza A virus 
Uruguay/716/2007 (H3N2), and the HA of the influenza B virus Florida/4/2006 were chosen 
because they composite a potential trivalent vaccine against influenza. Tetrahymena is 
characterized by both very AT-rich genome and an unusual codon usage
107,108,119,183
. 
Consequently, to avoid problems in heterologous HA expression, codon adapted genes in 
which critical triplets were changed to the commonly used triplets of highly expressed genes 
in T. thermophila were used for the target antigens (see appendix). AT-rich genomes can 
cause difficulties in handling the DNA sequences. Also the AT-richness of the T. thermophila 
genome causes the main challenge in altering the ciliates phenotype. Previously described 
episomal expression plasmid consists of a pUC backbone that enables propagation in E. coli, 
two 1.9 kb parts forming the T. thermophila rDNA origin and the paromomycin resistance 
cassette (neo 2) that allows the selection for transformed ciliates. The empty vector is sized 
about 8.4 kb. Especially the rDNA origin duplicates are (3.8 kb) AT-rich sequences
147
. These 
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sequences are probably one reason why this plasmid tends to recombinate into the highly 
amplified endogenous rDNA chromosomes of the host cell
144
. Additionally, the uptake of 
ligation reactions and the subsequent amplification in E. coli often resulted in reduced and 
fragmented backbones and the loss of the expression cassette in the past
113,142
. The adaption of 
the cre-recombinase system to the ciliate expression system that comprises the assembly of 
expression modules within small cloning plasmids and the subsequent construction of final 
expression vectors by an easy and robust shuttling of the expression module was established 
by Weide et al.
142
. The cloning plasmid pDL lacks AT-rich sequences like the rDNA origin 
and the expression module of the HAs could be easily generated and afterwards transferred by 
a time-saving cre-dependant homologous recombination into the expression plasmid pAX
142
. 
The created constructs were named pAX_MTT1_NC for the New Caledonia (NC) derived 
HA, pAX_MTT1_NC531 for a C-terminally truncated version of the NC derived HA, 
pAX_MTT1_UR for the Uruguay (UR) derived HA, and pAX_MTT1_FL for the Florida 
(FL) derived HA. For the regulation of the recombinant antigen expression the strong and 
cadmium inducible metallothionein 1 promoter (MTT1), and the beta tubulin 2 terminator 
(btu2) were applied. The MTT1 promoter was chosen because it is the strongest promoter 
described for T. thermophila
134,135
. Furthermore, its inducibility is beneficial for certain 
approaches. Regulated systems are particularly useful, because they allow a control on timing 
and levels of gene expression, and are preferred to be applied in many expression systems. 
For the methylotropic yeast Pichia pastoris several promoters are described. For instance, the 
promoter of the alcohol oxidase I gene (AOX1) has been employed in most studies and 
applications
184
. Being tightly repressed by glucose, its transcription is highly induced upon 
shift to methanol as sole carbon source
185,186
. Other carbon sources which represses 
transcription from AOX1 gene are glycerol and ethanol, while very low derepression of 
transcription occurs upon carbon starvation
186
. Furthermore, some examples of yeast 
promoters are those of the MET3 gene, negatively regulated by methionine; the PHO5 gene, 
negatively regulated by inorganic phosphate; the metallothionein-encoding CUP1 gene, 
activated by Cu
2+
 ions, and the GAL1, Gal7 and Gal10 gene, activated by galactose and 
repressed by glucose
187
. The yeast metallothionein (CUP1) gene is a metallothionein gene like 
that of the Tetrahymena MTT1 promoter, that belongs to a group of promoters of 
metal-binding proteins that are widely distributed among eukaryotes
188
. 
For the expression in T. thermophila the promoter region of the metallothionein gene 1 was 
described
156
. This MTT1 promoter was shown to be able to highly overexpress both 
homologous and heterologous genes
134
. It was demonstrated that a region of approximately 
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0.9 kb of this MTT1 promoter is responsible for high transcription rates and can be used to 
increase the efficiency of most of the commonly used types of DNA-mediated transformation 
in this organism. During this work, the MTT1 promoter turned out to regulate a strong 
expression of all recombinant expressed HA antigens, without loss of viability of the cell 
cultures. Obtained expression yields during a fermentation process were 102±25 mg/L for the 
NC antigen, 185±25 mg/L for the NC531 antigen, 186±49 mg/L for the UR antigen, and 
21±8 mg/L for the FL antigen. Although the MTT1 is a strong promoter, the toxicity of 
cadmium leads to problems when applying in an industrial production process. Consequently, 
several other inducible as well as constitutive promoters were tested during this work for the 
expression of the NC531 HA to replace the MTT1 promoter. Recently, a 1.5 kb fragment 
from the copper-inducible MTT2 promoter region of T. thermophila has been shown to drive 
a reporter gene expression to levels roughly equivalent to those obtained with MTT1 in this 
system
157
. This effect could not be demonstrated for the expression of recombinant HA (data 
not shown). Besides, a 1.3 kb fragment of the copper inducible MTT4 promoter region was 
reported to act as a strong promoter in homologous protein expression
155
. Applying this 
promoter for heterologous expression of HA, no functionality could be demonstrated, neither 
by cadmium nor by copper induction (data not shown). A 1.2 kb part of the upstream region 
of the MTT5 gene of T. thermophila was also described to be useful in homologous protein 
expression
155
. During this work this zinc inducible MTT5 promoter was shown to be efficient 
in NC531 HA expression. For the first time the MTT5 promoter was shown to be highly 
productive in heterologous protein expression comprising an expression yield of NC531 HA 
of 162±9 mg/L. Likewise, this MTT5 promoter might be an excellent tool for the 
overexpression of viral antigens for biotechnological application. 
Also constitutive promoters are widely distributed for the expression of proteins. The GAP 
promoter, for instance, is derived from the P. pastoris glyceraldehydes-3-phosphate 
dehydrogenase (GAP) gene
189
. The advantage of using this promoter is that neither methanol 
is required for induction, nor it is necessary to shift cultures from one carbon source to 
another, making strain growth and protein expression more convenient and straightforward. 
The disadvantage of a constitutive promoter is that it is undesirable for the production of 
proteins that may be toxic to the host cell
190
. This could also be true for the expression of 
recombinant HA by T. thermophila. Because of the high expression yield, the recombinant 
protein is maybe toxic for the host cells, and therefore an inducible promoter like the MTT5 
or the MTT1 turned out to be more efficient for the expression of HA. The use of a 
constitutive promoter would be necessary when applying a high cell density continuous 
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fermentation procedure, as it was described before
131
. Different constitutive promoters like the 
phospholipase A1 promoter were tested during this work, but none turned out to initiate a 
comparable strong expression of HA antigen
191
. 
Technical tools that are important to establish a sophisticated system have been developed and 
improved for the T. thermophila expression system. This includes techniques for the ciliate 
transformation into vegetative and conjugating cells and set up of a promoter and secretion 
test system. Additionally, a variety of molecular biology tools and methods like new 
promoters, use of a cre dependant homologous recombination system, different episomal and 
integrative expression vectors, different markers for the selection of clones, including an 
auxotrophic marker enzyme, and the use of proprietary signal and pro peptides were 
established
136,142,144,147
. This allows easy and fast testing of different protein variants and 
putative vaccine candidates. All constructed expression plasmids enabled the transformation 
of T. thermophila cells. After a selection of paromomycin resistant clones the proper uptake 
of the episomal expression plasmids could be confirmed by testing of whole cell DNA of 
transformed Tetrahymena cells. All target genes comprised a signal peptide to target the 
antigens to the cell membrane or even to reach secretion. T. thermophila is able to secrete a 
wide range of acid hydrolases into the extracellular medium. The largest clusters of expanded 
proteases in T. thermophila are all cysteine proteases, which comprise 44 % of the total 
protease complement
108
. Evidence has accumulated for the presence of multiple forms of 
cysteine proteases in cellular extracts and secretions from Tetrahymena
192
. The most 
conclusive evidence for a predominance of cysteine proteinases came from the observation 
that E-64, an active site specific and irreversible inhibitor of cysteine proteinases, also 
strongly inhibited azocasein digestion by extracts
192
. For the protection of the recombinant 
expressed antigens protease inhibitors were added to prevent the digestion of the membrane 
bound or secreted antigens. For all antigens the addition of the cysteine protease inhibitor 
E-64 (2.5 µg/mL) turned out to be most effective for the inhibition of extracellular proteases 
of T. thermophila. Furthermore, E-64 with low cell permeability may also stabilize the 
intracellular antigen expression. Performing a protease assay, no extracellular protease 
activity was measured when adding E-64, but growth of the cells and protein production was 
not influenced (data not shown). The fact that protease inhibitors like leupeptin, antipain, a 
mix of protease inhibitors (complete™, Roche) are less effective as E-64 was confirmed 
within this work, as shown for T. thermophila before
192
. Similar results were found for the 
insect cell/baculovirus expression system. It has been demonstrated that leupeptin and E-64 
can be used to effectively inhibit the in vitro proteolysis of a human recombinant enzyme
193
. 
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Analysis of the cell extracts revealed signals by Western blot analysis due to NC and UR HA 
expression. For the HA of the FL expression strain a signal was detected analyzing the 
supernatants. The respective detected bands were appropriate to the calculated molecular 
weight, except of the FL HA. A signal with an apparent molecular weight of approximately 
90 kDa was detected; this was not in agreement with its theoretical molecular weight value of 
57 kDa. Differences between apparent and real molecular weights are not uncommon due to 
differences in folding properties and differences in protein surface charges or the 
glycosylation pattern (personal communication by Dr. Ingo Aldag, Cilian AG). The fact that 
the secreted FL antigen could be detected within the cell free supernatant when adding the 
protease inhibitor E-64, suggests evidence that the other HAs that are anchored by the 
transmembrane domain (TMD) did not go the pathway of secretion after the passage through 
the ER and Golgi apparatus. For instance, yeast organisms are favoured for producing 
heterologous proteins by recombinant DNA technology due to their ability to secrete 
expressed proteins from the cell. Secretion of the produced protein has several advantages. 
First, secretion avoids toxicity, which is often a problem when recombinant proteins 
accumulate inside the cell. Second, many proteins require passage through the secretory 
pathway in order to obtain proper conformational folding, post translational modifications, 
and full biological activity. Third, biochemical purification of the recombinant protein is 
facilitated by secretion since higher initial degrees of purity are obtained in the culture broth 
than in a cell lysate, and fewer purification steps are needed. The secreted and soluble proteins 
can be directly recovered by clarification of culture media by centrifugation as it was shown 
for the production of proteins by Pichia pastoris. Samples can be concentrated and purified by 
subjecting the supernatant to ultrafiltration, precipitation, and/or adsorption/elution 
chromatography
194
. Because secretion is an important point in the choice of a production 
platform, it was tested if the HA of the New Caledonia strain is anchored by its TMD into the 
membrane or if it is intracellularly accumulated applying the T. thermophila expression 
system. Therefore, a C-terminally truncated version of the NC derived HA was cloned, where 
the TMD and the fusion peptide were excluded. It was possible to exclude the TMD, because 
the HA1 chain contains receptor binding and major antigenetic sites which should introduce 
immunogenicity when testing in vivo
195
. For the expression of a glycoprotein in 
Saccharomyces cerevisiae the deletion of the transmembrane domain together with the 
deletion of the autologous signal sequence led to an efficient secretion of the protein
196
. 
Nevertheless, truncation of the TMD did not lead to the efficient secretion of the C-terminally 
truncated NC derived HA (NC531) applying the T. thermophila expression system but led to a 
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1.6 x enhanced intracellular protein yield of approximately 180 mg/L. Furthermore, it was 
tested if the secretion of the NC derived HA can be achieved by the additional exclusion of 
the hydrophobic HA2 chain. The HA2 chain is primarily responsible for fusion and due to its 
hydrophobicity can hinder an efficient secretion
195
. Therefore, the open reading frame of the 
NC HA was reduced to the first 344 amino acids. Cells expressing the NC344 chain were 
tested for expression and secretion. Intracellular HA of 22±7 mg/L was yielded but no 
extracellular located protein could be measured reproducibly. As shown for the FL derived 
HA, it seems to be a clone or HA strain specific phenomenon that enables secretion. 
Therefore, a clone screening has to be evaluated for the production platform of 
T. thermophila. Cell line screening is an important parameter in the generation of the final 
Chinese hamster ovary (CHO) hosts for the production of monoclonal antibodies, for 
instance. However, it is a time-consuming and labor-intensive process, with hundreds of 
clones screened over the course of many weeks
197
. Furthermore, to screen large number of 
clones, a high-throughput, flexible system is required. For the expression of recombinant HA, 
the evaluation of a clone screening remains difficult, because at the moment no suitable test is 
available and has to be established if necessary. Moreover, there is a high time pressure in 
producing influenza vaccines which argues against a time-consuming clone screening 
approach. 
A further approach to reach secretion reflects the application of an optimal ER-leader 
sequence. The mechanism of protein secretion is conserved among all eukaryotes and depends 
on the recognition of this N-terminal signal sequence and the subsequent co-translational 
insertion of the nascent polypeptide into the lumen of the ER
198
. Afterwards, the protein is 
transported through the Golgi apparatus into secretory vesicles. In T. thermophila, vesicles 
may fuse with incoming phagosomes to form phagolysosomes, which are intracellularly 
processed, and whose residual contents are finally egested. Alternatively, vesicles may fuse 
with the plasma membrane at so far unknown sites, releasing soluble enzymes into the culture 
medium. By this pathway, secretory but also membrane-bound forms of lysosomal enzymes 
may be incorporated into the plasma membrane
76
. For all HA expression constructs the 
respective native ER leader sequence was applied during this work. The usage of the original 
signal peptide for recombinant protein production in T. thermophila was shown before and 
resulted in an efficient protein secretion
113,135
. For all expressed HA antigens no secretion was 
shown using this native signal peptide, except surprisingly for the Florida derived HA antigen 
containing its TMD. For many secreted proteins, cleavage of the signal peptide results in 
production of the mature form of the protein. However, there are other secreted proteins, 
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including, e.g., human insulin-like growth factor-I, that require, when they are intended to be 
secreted by yeast cells, a sequence between the carboxy-terminus of the signal peptide and the 
amino-terminus of the mature protein that is commonly known as "pro" sequence. In the 
absence of a pro sequence some proteins are retained as intracellular, inactive precursors
199
. In 
order to test, if the secretion of recombinant HA by T. thermophila can be achieved using a 
T. thermophila based pro sequence, the pro sequence of the phospholipase A1 gene that led to 
the secretion of a functional human enzyme, the DNAse I, was tested
113,135
. The 
phospholipase A1 gene comprises a pre and a pro sequence. For the expression of the 
recombinant HA, it did not lead to secretion. The choice of the right ER leader sequence 
remains a complex field, where many sequences have to be tested for every heterologous 
expressed protein. Recently, it was shown that special combinations of a N-terminal region of 
the mature P. pastoris acid phosphatase gene, in combination with signal and cleavable spacer 
sequences, was most effective for directing high expression and secretion levels
200
. Therefore, 
it could be obtained an efficient secretion for antigens by T. thermophila, when determining 
the appropriate signal sequence. 
Because of the high intracellular expression values of HA, purification of intracellular located 
recombinant protein was aimed to be established. To facilitate the purification process, a 
strain was developed, that is not able to excrete mucocyst contents into the surrounding 
medium because of a stable integration of a Grl3 gene knock out cassette into the 
macronuclear genome of T. thermophila. Mucocysts or dense core granules (DCGs) are 
vesicles specialized for storage of highly concentrated proteins, which can be secreted via 
exocytotic fusion with the plasma membrane in response to extracellular stimuli
201
. DCGs 
cargo in T. thermophila consists principally of a family of granule lattice (Grl) proteins. Upon 
exocytosis, the lattice remains intact, but undergoes expansion to propel the DCG cargo from 
the cell
82
. The disruption or silencing of any of the core protein showed, that these proteins act 
as an essential structural element of the formation of the granule cores
202
. The Grl3 gene was 
chosen to be best suited for the disruption during this work because of its non redundant role 
in core formation. Additionally, the disruption of Grl3 just partially inhibited Grl1 protein 
processing and more important, the transport from ER to the Golgi apparatus of other proteins 
was not disturbed
92
. By contrast, the disruption of other mucocyst proteins encoding genes 
like the Grl4 gene leads to the failure of the Grl1 protein to reach the post-trans Golgi network 
processing compartment due to its retention in the ER. For the Grl6 knock out the mucus after 
dibucaine treatment was reduced to 40-70 %, whereas for the Grl3 knock out, no mucus could 
be detected
92
. Therefore, a vector was constructed that combined the knock out of the Grl3 
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gene with a knock in of the HA expression cassette. This integrative vector had the advantage 
that after the process of allelic assortment it is stably integrated into the genome of the host 
cell and no addition of an antibiotic is necessary in terms of large-scale production. This 
reduces the costs of a production process of the recombinant antigen. Furthermore, the 
addition of an antibiotic is not desirable for the production of a vaccine. Nevertheless, the 
process of the allelic assortment needs additional time because all 45 Grl3 alleles have to be 
replaced by the disrupted copy. After the cells were transformed with the Grl3 knock out 
vector, T. thermophila cells underwent the process of allelic assortment for at least 200-300 
fissions. Following analysis by RNA isolation and a PCR analysis of the cDNA, confirmed a 
proper knock out of the Grl3 gene. Resultant, these strains were not able to excrete mucocyst 
contents upon stimulation by dibucaine. Secretion of mature mucocysts in Tetrahymena can 
be induced by the local anesthetic dibucaine
167,168
. The dibucaine treatment should stimulate 
the biosynthetic processes related to mucocyst biogenesis. Although the expression of the 
NC531 was reduced to 24±10 mg/L this strain can ease the production and purification 
process, because additional washing steps are not necessary to get rid of the mucus produced 
by wild type T. thermophila cells that could hinder the passage of the proteins through a liquid 
column chromatography. Furthermore, mucus is able to adsorb target protein which gets lost 
in the subsequent washing steps (personal communication of Prof. Dr. A. Tiedtke). For large 
scale production, integration of the recombinant DNA into the chromosome is preferred in 
order to avoid DNA loss during growth of the cultures. By contrast, problems of genetic 
instability with episomal templates occur because selective pressure cannot be maintained in 
large volume cultures due to high costs of the added antibiotic. This results in a reduction in 
episome copy number due to the selective growth advantage of plasmid-free cells. Generally, 
a disadvantage associated with integrative systems is low gene dosage, which in turn leads to 
poor expression
200
. In the knock out strain the gene for the expression of the recombinant HA 
was present at 45 copies, whereas the episomal expression plasmid in former expression 
strains was present with about 9,000 copies
109,110
. Gene copy number is the first critical 
parameter of an expression system, and is therefore also a valuable indicator for potential 
bottlenecks downstream. This effect may explain the reduction of the expression yield to 
about 13 %. Numerous examples have been published indicating that an increase of gene copy 
number can significantly increase productivity. Examples for P. pastoris have been described, 
where a linear correlation between copy number and expression up to a definite upper limit 
was found
203
. Nevertheless, performing a clone screening approach better transformants 
comprising higher expression yields could be detected. 
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5.2 Fermentation process 
Besides, another argument to use a ciliate based system is the improved fermentation 
technology. Batch, fed-batch as well as continuous fermentation techniques are available. Cell 
densities in continuous cultures of T. thermophila can reach up to 2 x 10
7
 cells/mL, leading to 
dry mass weights of 60 to 70 g per Liter
131
. The up-scalability has already been shown by 
demonstrating the cultivation of T. thermophila in an 1.5 m
3
 airlift bioreactor
133
. Like yeast 
cells, T. thermophila has a short generation time (1.5 to 3 hours) and is capable of growing in 
simple and cheap media. A further advantage is the possibility to use standard bioreactor 
infrastructure designed for micro organisms (yeast or E. coli) to cultivate 
T. thermophila
76,131,132,204
. Up-scalability is one of the most important problems in producing 
vaccines, because millions of vials are necessary to start and continue vaccination programs, 
as for example it has already been done for measles or the hepatitis B virus. 
Producing an influenza vaccine, all HA expressing T. thermophila strains were cultivated 
using a fermentation process. To obtain high yields in a scalable and cost-effective system, 
the choice of the production process is of great importance. Fed-batch technology has become 
a platform technology for the large-scale production of therapeutic and recombinant proteins 
due to its simplicity of operation, flexibility to be implemented and a high final product 
concentration. Fed-batch culture is a frequently used technology for the industrial 
manufacturing of cell-culture based subunit vaccines. It was demonstrated before that the 
productivity of the cell culture process was increased dramatically by optimizing the 
fed-batch technology and particularly improving the formulation and the feeding strategy. For 
instance, an antibody production was 40-fold improved using a fed-batch process
166
. An 
important consequence of this increase in productivity is the decrease in product 
manufacturing cost. The four different HA expressing T. thermophila strains of NC HA, 
NC531 HA, UR HA and FL HA were tested applying a 0.5 L fermentor. Different conditions 
for the cultivation were tested using a Sixfors
®
 multifermentor. This fermentor comprises the 
possibility to test up to six different culture conditions in parallel. The best fermentation 
medium was found out to be SPP medium. Using skimmed milk medium or wheat peptone 
medium turned out to be less effective for the HA production process (data not shown). 
Firstly, the fermentation was performed as a batch process, and induction of the HA 
expression by cadmium in a final concentration of 20 µg/mL was done. This procedure 
neither leads to high expression yields, nor to high cell densities. Therefore, the fermentation 
process was changed to a fed-batch fermentation process. The best suited feeding solution 
was concentrated SPP medium, which was added to the fermentation broth when cells 
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reached the end logarithmic phase. The final concentration of this feeding solution was 
tenfold. This feeding step together with an induction of the HA expression by cadmium in a 
final concentration of 40 µg/mL turned out to be ideal for obtaining high expression yields. 
Thus, an intracellular expression yield for recombinant NC HA was estimated to be 
102±25 mg/L, for NC531 HA 185±25 mg/L, and for UR HA 186±48 mg/L. These high 
expression yields depict an advantage of the T. thermophila expression system. Indeed, some 
mammalian cell-based influenza vaccines have obtained license for commercialization, but 
low production yields are often the major limitations of using this technology
205
. Insect cell 
culture-based technology is an alternative for manufacturing candidate influenza vaccines. It 
takes advantages of the progress in recombinant DNA technology and the safety profile of 
insect cell cultures to successfully produce sub-unit vaccines such as Virus Like Particle 
(VLP) or recombinant viral proteins
56
. When applying the insect cell/baculovirus expression 
system expressing the NC derived HA an expression yield of 47±2 mg/L in an optimized 
fed-batch culture was determined
205
. This means, that using the T. thermophila expression 
platform a 4-fold increased expression with the New Caledonia truncated version of the HA 
and a 2-fold increased expression by applying the untruncated NC antigen was reached in 
comparison to the insect cell/baculovirus expression system. Consequently, production costs 
are lowered by the T. thermophila expression system. The major advantage of the insect 
cell/baculovirus expression system derived sub-unit vaccine is that the manufacturing of the 
HA protein does not require the cultivation and subsequent inactivation of functional 
influenza viruses as required for embryonated eggs or mammalian cell production systems
12
. 
This is also an advantage of the T. thermophila expression system. During this work high 
expression levels were demonstrated and safety issues are low when using Tetrahymena as a 
production platform. Furthermore, it was possible to demonstrate secretion for the 
recombinant expressed HA of the Florida strain, what is not common for proteins comprising 
a TMD. The estimation of the yield led to 21±8 mg/L of recombinant FL HA. When applying 
the recombinant insect cell/baculovirus expression system, the recombinant HA is expressed 
and transported to the cell membrane. To extract the HA from the cell membranes, a 
non-ionic detergent is necessary, what could result in problems in terms of folding properties 
of the recombinant protein
11
. This step is not needed when purification of a secreted HA 
antigen would be performed. 
In conclusion, a simple, reliable and robust fed-batch process was successfully developed for 
HA production by T. thermophila cells. An important feature of the established fed-batch 
process is a simple formulation of the single feeding solution. It is added to the culture in only 
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one pulse to sustain high cell viability and recombinant HA productivity. The fed-batch 
process was extended to produce four different HA proteins. One protein, the Florida derived 
HA was successfully secreted into the surrounding medium what could facilitate a 
purification process. 
 
5.3 Down-stream processing 
High-cell-density processes are one of the most effective ways of increasing cell efficiency as 
well as product yield. To obtain sufficient material to establish a purification process the 
fermentation was scaled up to 50 Liter. As production strain the pAX_MTT1_NC531 turned 
out to be best suited because of the high yield, and because the excluded TMD may facilitate 
the extraction of the recombinant antigen from the cells. During this work, the 50 L 
fermentation process was done by setting optimal parameters defined during the 0.5 L 
fermentation. The cells reached 0.95 x 10
6
 cells/mL what is less as achieved during the 
small-scale fermentation procedure. This cell density may be increased by changing the 
feeding solution, what was demonstrated for instance for the insect cell/baculovirus 
expression system. An optimized feeding solution, a different feeding strategy as well as an 
optimized cell density at infection maximized the final recombinant HA production yield 
between 2- and 3-fold, meaning an expression yield of 47±2 mg/L applying the 
insect cell/baculovirus expression system
205
. This optimization process has still to be 
performed for the HA expression strain of NC531 in large-scale. Nevertheless, a high 
expression yield (150 mg/L) was determined using the T. thermophila expression platform 
and sufficient material was obtained from the fermentation process to establish a purification 
strategy with high consistency of the starting material for every purification batch. 
A purification process has been developed to quickly purify the recombinant HA from the 
bulk harvested of the bioreactor while retaining its biological activity. In a few instances, a 
single liquid chromatography step accompanied by other non chromatographic separation 
techniques may be enough to accomplish protein purifications with a purity ≥95 %, but in 
most circumstances, a combination of several liquid chromatography steps has to be used
206
. 
A crucial point for the purification of proteins is the careful retention of their structure during 
the purification process. For example, the pH had to be fixed to neutral values during the 
whole purification process to prevent its characteristical conformational change at low pH 
values which may interfere with subsequent in vivo testing of the recombinant HA (personal 
communication by the cooperation partner). 
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The main advantage of ion exchange column chromatography (IEC) in purifying proteins, 
which was used as first purification step for the T. thermophila expressed NC531 HA, is that 
most of the proteins remain bioactive, indicating its usefulness for recombinant protein 
purification
206
. This first purification step led to an entire concentration of the HA by 
eliminating contaminating proteins. As material Capto™ Q was defined to be best suited for 
the first capturing step of the NC531 antigen. Capto™ Q is a strong ion exchange media 
especially for capture and intermediate purification of proteins. It provides fast, reproducible 
and easy separations in a convenient format. Furthermore, Capto™ Q leads to a moderate 
enrichment of target protein. Applying this column chromatography step whole protein 
contents decreased about 92 %. Nearly no NC531 antigen was lost during this 
chromatography step. When testing a hydrophobic interaction chromatography material, 
phenyl sepharose, no purification was possible. Using this column, the pH had to be dropped 
to acidic pH values, what was not possible for the purification of HA. Applying the cell 
extracts at neutral pH values, the NC531 antigen did not bind. Testing a size exclusion 
chromatography, no enrichment of the NC531 antigen was feasible (data not shown). 
Additionally, size exclusion would not be suited for large industrial-scale processes, because 
of volume limitations. The second purification step using Ceramic Hydroxyapatite (CHT) as 
column material was done to capture contaminating protein. The use of a CHT column allows 
the adaption to industrial-scale columns. The NC531 antigen did not bind to this column 
material, but was quantitatively detected in the flow through. This depicts another big 
advantage of this column, because no addition of salt for an elution is necessary and the 
sample can be loaded directly without performing a buffer exchange to the next column. The 
whole protein content could be decreased about 45 % applying the CHT chromatography step, 
and the NC531 antigen decreased just to 80 %. As a last column a Concanavalin A column 
was chosen. Con A represents the separation principle of proteins by affinity chromatography 
what is based on the interactions between a protein and the affinity chromatography stationary 
phase, which has a high selectivity or specifity. It is only one of the non-universal types of 
liquid chromatography. The selective interaction may occur between protein and low 
molecular mass substance or between several biopolymers
206
. The disadvantages are high cost 
and the risk of fouling and irreversible chemical denaturation and notable proteolytic 
degradation. Con A requires for binding to a glycoprotein at least two non-substituted 
α-mannosyl residues or extended residues with free hydroxyl groups at C3, 4 and 6 position 
like in biantennary glycosylated structures. The influenza HA possesses some of such 
structure
207
. T. thermophila is able to add oligo mannose structures to the HA that possesses 
Discussion  101 
3-9 N-linked glycosylation sites
208
. Therefore, Con A binds the recombinant HA and the most 
significant enrichment of the NC531 antigen was reached. Other T. thermophila based 
proteins did not bind to this column, because maybe the bulk of glycosylated proteins was 
present in the extracellular medium. Furthermore, the NC531 antigen is highly expressed 
intracellularly and other contaminating protein is removed during the two purificational steps 
before. By performing the purification procedure of the NC531 HA a purity of 95 % was 
reached. Only some minor bands in a coomassie stain were not related to the recombinant 
NC531 antigen. The HA purity was determined by the combination of Bradford assay (whole 
protein content) and Western blot analysis. After the concentration of the purified NC531 
antigen and a buffer exchange a 71 % pure protein was obtained, and an overall yield of 20 % 
was reached, decreasing whole protein content to 0.03 %. The reduced purity after the 
concentration step was maybe due to a binding of HA to the membrane of the spin filter and a 
consequent loss of the recombinant antigen. Even putative dimers and trimers of the purified 
NC531 antigen were detected in the coomassie stain, what may enhance the immunogenicity 
of the antigen when testing in vivo. Additionally, a simple test regarding the glycosylation of 
the NC531 was also shown during this work. The HA monomer consists of a globular head 
and a fibrous stalk domain, both being N-glycosylated. Typically, 3-9 N-linked glycans are 
attached to the intact HA protein backbone
208
. Further, it is known that N-linked 
oligosaccharides attached to the stalk region are highly conserved, whereas those at the tip of 
the molecule vary considerably in structure and number among different influenza viruses
209
. 
Applying a PNGase F treatment to the Tetrahymena expressed NC531 HA a reduction in 
molecular weight was detected. Therefore, it seems that the recombinant antigen becomes 
glycosylated while shuttling through the ER and Golgi apparatus. Glycosylation is of interest 
since it is involved in protein folding, the stability of the protein in the bloodstream, and 
protein-protein interactions, as well as contributing to the activity of some proteins
210
. Subtle 
differences in glycan structure can cause an immune response, as evidenced by the generation 
of antibodies towards that protein in human sera
211
. 
In comparison it was also reported a rapid process for production of the NC derived HA with 
the insect cell/baculovirus system comprising a 95 % pure NC antigen. Three columns were 
used for the purification of HA derived by the insect cell/baculovirus system, reaching an 
overall yield of 53 %. The first step was an ion exchange chromatography combined with a 
Sepharose column material in tandem, combining two chromatographic steps into one. The 
second was a CHT column followed by a buffer exchange and concentration step via 
ultrafiltration
11
. The starting material was lower than in the here presented work. An amount 
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of 12 mg of recombinant HA was loaded to the first column. For the extraction and loading to 
the first column a pH of 5.89 was needed
11
. This argues for problems regarding the folding 
properties of HA. 
A recombinant protein-based vaccine, such as the T. thermophila based HA antigen or the 
insect cell/baculovirus HA, has some advantages over the traditional egg-based vaccines. It 
consists solely of three antigens (proteins) stored in sterile phosphate buffered-saline and 
without preservatives such as thimerosal (a mercury derivative currently used in the 
egg-based vaccine), antibiotics or adjuvants. Unlike the egg-based vaccines, no functional 
influenza viruses, biocontainment facilities or harsh chemicals such as formaldehyde are used 
in manufacturing. Therefore, a reliable, effective, and affordable recombinant protein-based 
influenza vaccine can be and should be developed to meet the challenge of a potential 
influenza pandemic. 
 
5.4 Development of a production process for vaccines by T. thermophila 
Current influenza vaccines are administered to targeted "high risk" groups in order to protect 
against subtypes of influenza that circulate in humans, namely influenza A subtypes H1N1 
and H3N2 and influenza B. Because of the high mutation rate of influenza virus resulting in 
antigenic drift, each of the three components in the trivalent influenza vaccine is updated 
regularly to match the vaccine antigens closely to the predominant or emerging strains. For 
each influenza A subtype, a seed reassortant virus is generated in the laboratory and a 
"backbone" virus with suitable growth properties for high growth in eggs has to be found. The 
subsequent selection of the desired reassortant virus can be time consuming and unpredictable 
and for influenza B virus no suitable high growth strain has been identified
212
. It has long 
been known that propagation of human influenza isolates in eggs often leads to the selection 
of mutations, some of which give rise to mismatch in antigenicity between the egg-grown 
virus and the naturally circulating virus
174,213
. For influenza B viruses, this often manifests as 
changes in the glycosylation pattern of the HA which may affect the antigenicity
174,214
. 
Moreover, for some viruses, propagation in eggs is altogether impossible and in this case, 
reliance on eggs for vaccine manufacturer may result in the exclusion of the most suitable 
strain from incorporation into the vaccine or a delay in vaccine manufacture. Several cell lines 
are currently being explored as alternative substrates for influenza vaccine production because 
of these reasons. These include the MDCK, Vero and PER.C6 cell lines
212
. The application of 
cell culture systems would add substantial flexibility to the influenza vaccine production 
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process, particularly important in times requiring rapid scale-up, such as onset of a pandemic. 
Furthermore, the use of eukaryotic cell lines for propagation of vaccine strains reduces 
likelihood of selecting variants with altered antigenicity since HA mutations are not 
necessarily selected during replication in cell culture. Moreover, the recombinant protein 
expressed by cell lines like T. thermophila or insect cells are highly purified and do not 
contain egg protein, which should eliminate hypersensitivity reactions in egg-sensitive 
individuals. While there is an already existing recombinant cell culture based expression 
system, the insect cell/baculovirus system, there are some disadvantages by this platform. In 
clinical trials there were poor response rates to the insect cell/baculovirus derived vaccine 
observed in the 6 to 35-month-old age group and expression yields were low. In addition, high 
license fees have to be paid when using this system. 
The main advantages when using the here developed T. thermophila expression system are 
that it is cost effective. Further advantages of the system include the strong inducible MTT 
promoters, which have transcription characteristics useful for regulating heterologous protein 
expression, the well-developed methods for classical and molecular-genetic manipulation of 
the organism and the technology for the growth of an expression strain in large high-densitiy 
fermentor cultures. Furthermore, secretion of hemagglutinin was shown for the first time 
using a heterologous expression system. This feature can ease the purification process, and 
therefore lowers the costs of the production process. In addition, the glycosylation added by 
T. thermophila generates more homogenous protein what could be an advantage for the 
immunogenicity in younger human. The high expression yields shown in this work for three 
different HAs, one of the B strain and two of A strain influenza viruses, comprise a big 
advantage over all other expression systems currently used for the production of influenza 
vaccines. 
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5.5 Future prospects 
First in vivo testings in mice were performed by the cooperation partner to examine the 
immunogenicity of the NC531 antigen produced by Tetrahymena thermophila. Preliminary 
results indicated slight immunogenicity when testing the NC531 antigen. Hence, 
T. thermophila offers a big potential for producing foreign eukaryotic proteins. However, 
further development has to be done to deplete some problems and enable a highly efficient 
application of T. thermophila. Following points may be considered for this purpose: 
 1. Enhancement of the transformation rate of the host organism. 
 2. Identification of new strong inducible and constitutive promoters. 
 3. Optimization of the secretion. 
 4. Analysis of the glycosylation pattern of the expressed antigen. 
 5. Establishment of an enhanced fermentation and purification process. 
Transformation of T. thermophila can be carried out by e.g. electroporation or the biolistic 
bombardment. Nevertheless, the transformation rate is relatively low
136
. Therefore, the design 
of smaller sized expression vectors would be necessary as a first point. Moreover, the 
utilization of stronger constitutive promoters for the selection marker would enhance the 
transformation rate. Recently, the replacement of the histone (H4-1) promoter within the 
Neo2 cassette was tested in order to obtain a higher transformation rate. First promising 
results indicated an enhancement of the transformation rate. 
In addition to the availability of optimal techniques, also the strain improvement and a 
fermentation process optimization including the improvement of the downstream process are 
very important. Experience shows that choices made early in the process of development 
often are difficult to change due to regulatory constraints and process modification. This may 
hamper the profitability and increase costs. Consequently, during this work a strong and zinc 
inducible promoter was applied to control a high expression level of hemagglutinin and to 
replace the cadmium inducible MTT1 promoter. In order to obtain a production process where 
the addition of any heavy metal is necessary, further promoter candidates have to be 
identified. For instance, heat inducible promoters of the hsp family could be an alternative. 
Besides, high cell density fermentation procedure applying continuous fermentation was 
successfully established for the cultivation of T. thermophila cells
131
. In order to produce a 
vaccine applying continuous fermentation process, strong constitutive promoters have to be 
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identified. Some candidates were proven to be functional during this work, but up to now 
none of the tested promoters were strong enough to drive high antigen expression levels. 
An optimization of the secretion of specific enzymes by T. thermophila was obtained due to 
the development of hypersecretory mutants through random mutagenesis
158,215
. During this 
work one target antigen was also transported via the secretory pathway and was detected in 
the extracellular medium comprising high expression levels. To establish an efficient 
production process for a trivalent vaccine maybe the identification of novel ER-leader 
sequences that are capable of directing the secretion of the two resting HA antigens is 
feasible. Additionally, for better understanding of the localization of currently intracellularly 
expressed HAs immunofluorescent studies could be done. Moreover, the amino acid sequence 
of the secreted antigen could be analyzed and optimized in terms of the deletion of the 
transmembrane domain and hydrophobic regions. Besides, a codon harmonization can be 
done in order to obtain a more optimized folding of the recombinant protein and maybe a 
facilitated secretion of the antigen. 
Furthermore, the glycosylation pattern of the recombinant Tetrahymena based antigens could 
be analyzed. Most human proteins are glycosylated: they have one or more oligosaccharide 
chains attached to the polypeptide backbone. To analyze the glycosylation pattern, a method 
was published by Schwarzer et al.
216
. This method could be used for the T. thermophila 
expressed hemagglutinin, giving more insights regarding the glycosylation machinery of this 
ciliate. Besides, the folding properties of the recombinant expressed protein could be 
investigated. 
Additionally, the production process could be improved in order to maximize the capability of 
the expression strains. Strategies commonly employed to optimize the fermentation process 
are testing of different compositions of cultivation media and point of time of induction of the 
expression. First results indicated, that the choice of the medium is of critical importance, 
especially for the secreted FL antigen. Moreover, for the applied fed-batch fermentation 
procedure, the composition of the feeding solution has further to be developed. Moreover, it 
could be considered a continious feeding strategy. By testing different feeding strategies, the 
insect cell/baculovirus expression system was able to increase the yield 2- to 3-fold
205
. The 
development of an optimized downstream process plays a critical role in recombinant protein 
production. Therefore, the purification process should further be advanced by identifying 
more convenient column materials and elution strategies. First of all, an elution of the antigen 
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in one column volume is intended to be reached. Besides, the concentration of the sample 
combined by a buffer exchange should be optimized to minimize the losses during this step. 
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6. Summary 
Within this work, the expression of three different hemagglutinins (HAs) representing the 
composition of a trivalent influenza vaccine was successfully shown applying the 
Tetrahymena thermophila based expression platform. The three different hemagglutinins, 
originated from the influenza A virus strain New Caledonia 20/99 (H1N1), from the influenza 
A virus strain Uruguay/716/2007 (H3N2), and from the influenza B virus strain 
Florida/4/2006 and were produced using a codon optimized synthetic gene. 
Secretion of about 21±8 mg/L HA of the influenza B virus strain Florida/4/2006 was reached, 
while the HA of the influenza A strain was expressed intracellularly, as expected. High 
protein yields of about 102±25 mg/L and 186±49 mg/L were attained, expressing the HA of 
the influenza A virus strain New Caledonia 20/99 and of the HA of the influenza A virus 
strain Uruguay/716/2007, respectively. 
In further analyses, it was demonstrated that the expression of C-terminally truncated HA of 
the New Caledonia strain, showing no transmembrane domain does not support the export of 
the recombinant protein but does lead to higher intracellular expression yields of about 
185±25 mg/L. 
The optimized truncated HA version was finally used to establish an efficient production and 
purification process. Within the framework of the process, optimization the strong but 
cadmium-inducible MTT1 promoter could be replaced by the zinc-inducible MTT5 promoter, 
showing nearly the same expression yield of about 162±9 mg/L. 
Furthermore, a Tetrahymena thermophila expression strain was designed and developed to 
ease the purification of intracellular located target proteins due to its inability to produce the 
undesirable mucocyst proteins. 
Concurrently, the fermentation process was optimized and scaled up to 50 L. The truncated 
New Caledonia derived HA was successfully purified, comprising a purity of 95 % and an 
overall yield of 20 %. The purified antigen was glycosylated, which is an important feature to 
introduce neutralizing antibodies during an immunogenicity study. 
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8. Appendix 
 
8.1 Alignment of the influenza A virus strain &ew Caledonia/20/99 (H1&1) 
hemagglutinin 
 
 
  M  D  I  K  A  K  L  L  V  L  L  C  T  F  T  A  T  Y  A  D  T  I  C  I  G 
atg------aaagcaaaactactggtcctgttatgtacatttacagctacatatgcagacacaatatgtataggc 
atggatatcaaagctaagttattagttttactttgtactttcactgctacttatgctgatactatttgtattggt 
 
  Y  H  A  N  N  S  T  D  T  V  D  T  V  L  E  K  N  V  T  V  T  H  S  V  N 
taccatgccaacaactcaaccgacactgttgacacagtacttgagaagaatgtgacagtgacacactctgtcaac 
tatcacgctaataattctactgatactgttgatactgttttagaaaaaaatgttactgttactcactctgttaat 
 
  L  L  E  D  S  H  N  G  K  L  C  L  L  K  G  I  A  P  L  Q  L  G  N  C  S 
ctacttgaggacagtcacaatggaaaactatgtctactaaaaggaatagccccactacaattgggtaattgcagc 
cttttagaagattctcacaatggtaaattatgtttacttaaaggtattgctcctttataacttggtaattgttct 
 
  V  A  G  W  I  L  G  N  P  E  C  E  L  L  I  S  K  E  S  W  S  Y  I  V  E 
gttgccggatggatcttaggaaacccagaatgcgaattactgatttccaaggaatcatggtcctacattgtagaa 
gttgctggttggattcttggtaatcctgaatgtgaattacttatttctaaagaatcttggtcttatattgttgaa 
 
  T  P  N  P  E  N  G  T  C  Y  P  G  Y  F  A  D  Y  E  E  L  R  E  Q  L  S 
acaccaaatcctgagaatggaacatgttacccagggtatttcgccgactatgaggaactgagggagcaattgagt 
actcctaatcctgaaaatggtacttgttatcctggttatttcgctgattatgaagaattaagagaataactttct 
 
  S  V  S  S  F  E  R  F  E  I  F  P  K  E  S  S  W  P  N  H  T  V  T  G  V 
tcagtatcttcatttgagagattcgaaatattccccaaagaaagctcatggcccaaccacaccgtaaccggagta 
tctgtttcttcatttgaaagattcgaaattttccctaaagaatcttcttggcctaatcacactgttactggtgtt 
 
  S  A  S  C  S  H  N  G  K  S  S  F  Y  R  N  L  L  W  L  T  G  K  N  G  L 
tcagcatcatgctcccataatgggaaaagcagtttttacagaaatttgctatggctgacggggaagaatggtttg 
tctgcttcttgttctcataatggtaaatcttcattctatagaaatcttttatggttaactggtaaaaatggttta 
 
  Y  P  N  L  S  K  S  Y  V  N  N  K  E  K  E  V  L  V  L  W  G  V  H  H  P 
tacccaaacctgagcaagtcctatgtaaacaacaaagagaaagaagtccttgtactatggggtgttcatcacccg 
tatcctaatctttctaaatcttatgttaataataaggaaaaagaagttttagttctttggggtgttcaccaccct 
 
  P  N  I  G  N  Q  R  A  L  Y  H  T  E  N  A  Y  V  S  V  V  S  S  H  Y  S 
cctaacatagggaaccaaagggccctctatcatacagaaaatgcttatgtctctgtagtgtcttcacattatagc 
cctaatattggtaattaaagagctttatatcacactgaaaatgcttatgtttctgttgtttcttctcactattct 
 
  R  R  F  T  P  E  I  A  K  R  P  K  V  R  D  Q  E  G  R  I  N  Y  Y  W  T 
agaagattcaccccagaaatagccaaaagacccaaagtaagagatcaggaaggaagaatcaactactactggact 
agaagattcactcctgaaattgctaaaagacctaaagttagagattaagaaggtagaattaactattattggact 
 
  L  L  E  P  G  D  T  I  I  F  E  A  N  G  N  L  I  A  P  W  Y  A  F  A  L 
ctgctggaacctggggatacaataatatttgaggcaaatggaaatctaatagcgccatggtatgcttttgcactg 
ttattagaacctggtgatactattattttcgaagctaatggtaatcttattgctccttggtacgctttcgcttta 
 
  S  R  G  F  G  S  G  I  I  T  S  N  A  P  M  D  E  C  D  A  K  C  Q  T  P 
agtagaggctttggatcaggaatcatcacctcaaatgcaccaatggatgaatgtgatgcgaagtgtcaaacacct 
tctagaggtttcggttctggtattattacttctaatgctcctatggatgaatgtgatgctaaatgttaaactcct 
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  Q  G  A  I  N  S  S  L  P  F  Q  N  V  H  P  V  T  I  G  E  C  P  K  Y  V 
cagggagctataaacagcagtcttcctttccagaatgtacacccagtcacaataggagagtgtccaaagtatgtc 
taaggtgctattaattcttctttacctttctaaaacgttcaccctgttactattggtgaatgtcctaaatatgtt 
 
  R  S  A  K  L  R  M  V  T  G  L  R  N  I  P  S  I  Q  S  R  G  L  F  G  A 
aggagtgcaaaattaaggatggttacaggactaaggaacatcccatccattcaatccagaggtttgtttggagcc 
agatcagctaaattaagaatggttactggtttaagaaatattccttctatctaatctagaggacttttcggtgct 
 
  I  A  G  F  I  E  G  G  W  T  G  M  V  D  G  W  Y  G  Y  H  H  Q  N  E  Q 
attgccggtttcattgaaggggggtggactggaatggtagatgggtggtatggttatcatcatcagaatgagcaa 
attgctggtttcattgagggaggatggacaggtatggttgatggttggtacggttatcaccaccaaaatgaataa 
 
  G  S  G  Y  A  A  D  Q  K  S  T  Q  N  A  I  N  G  I  T  N  K  V  N  S  V 
ggatctggctatgctgcagatcaaaaaagtacacaaaatgccattaacgggattacaaacaaggtgaattctgta 
ggttctggttatgctgctgattaaaagtctactcaaaacgctattaatggtattactaacaaagttaattctgtt 
 
  I  E  K  M  N  T  Q  F  T  A  V  G  K  E  F  N  K  L  E  R  R  M  E  N  L 
attgagaaaatgaacactcaattcacagctgtgggcaaagaattcaacaaattggaaagaaggatggaaaactta 
attgaaaaaatgaatacttaattcactgctgttggtaaagaattcaataagttagaaagaagaatggaaaatctt 
 
  N  K  K  V  D  D  G  F  L  D  I  W  T  Y  N  A  E  L  L  V  L  L  E  N  E 
aataaaaaagttgatgatgggtttctagacatttggacatataatgcagaattgttggttctactggaaaatgaa 
aataagaaagttgatgatggtttcttagatatttggacttataatgctgaattattagttcttttagaaaatgaa 
 
  R  T  L  D  F  H  D  S  N  V  K  N  L  Y  E  K  V  K  S  Q  L  K  N  N  A 
aggactttggatttccatgactccaatgtgaagaatctgtatgagaaagtaaaaagccaattaaagaataatgcc 
agaactttagatttccacgattctaatgttaaaaatctttatgaaaaagttaaatcttaacttaagaataatgct 
 
  K  E  I  G  N  G  C  F  E  F  Y  H  K  C  N  N  E  C  M  E  S  V  K  N  G 
aaagaaataggaaacgggtgttttgaattctatcacaagtgtaacaatgaatgcatggagagtgtgaaaaatgga 
aaagaaattggtaatggttgtttcgaattctatcacaaatgtaataatgaatgtatggaatctgttaagaatggt 
 
  T  Y  D  Y  P  K  Y  S  E  E  S  K  L  N  R  E  K  I  D  G  V  K  L  E  S 
acttatgactatccaaaatattccgaagaatcaaagttaaacagggagaaaattgatggagtgaaattggaatca 
acttatgattatcctaaatattctgaagaatctaagttaaatagagaaaaaattgatggtgttaaattagaatct 
 
  M  G  V  Y  Q  I  L  A  I  Y  S  T  V  A  S  S  L  V  L  L  V  S  L  G  A 
atgggagtctatcagattctggcgatctactcaactgtcgccagttccctggttcttttggtctccctgggggca 
atgggagtttactaaattcttgctatctattctactgttgcttcttctttagttttattagtttctttaggtgct 
 
  I  S  F  W  M  C  S  N  G  S  L  Q  C  R  I  C  I  Q  R  S 
atcagcttctggatgtgttccaatgggtctttgcagtgtagaatatgcatctga------ 
atttctttctggatgtgttctaatggttctttataatgtagaatttgtatttgaagatct 
 
 
The upper line shows the non-optimized original sequence of the hemagglutinin of the 
Influenza A strain New Caledonia/20/99 (H1N1). The lower line shows the codon-optimized 
sequence (lower case letters). Differences are highlighted in yellow. The ER-leader sequence 
is depicted in blue letters, and the transmembrane domain in green letters as amino acid 
sequence (in capital letters). The added EcoRV restriction site (gatatc) and the BglII 
restriction site (agatct) are shown in red letters. The stop codon is highlighted in red, and the 
start codon is highlighted in purple. 
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8.2 Alignment of the C-terminally truncated influenza A virus strain 
&ew Caledonia/20/99 (H1&1) hemagglutinin (&C531) 
 
 
  M  D  I  K  A  K  L  L  V  L  L  C  T  F  T  A  T  Y  A  D  T  I  C  I  G 
atg------aaagcaaaactactggtcctgttatgtacatttacagctacatatgcagacacaatatgtataggc 
atggatatcaaagctaagttattagttttactttgtactttcactgctacttatgctgatactatttgtattggt 
 
  Y  H  A  N  N  S  T  D  T  V  D  T  V  L  E  K  N  V  T  V  T  H  S  V  N 
taccatgccaacaactcaaccgacactgttgacacagtacttgagaagaatgtgacagtgacacactctgtcaac 
tatcacgctaataattctactgatactgttgatactgttttagaaaaaaatgttactgttactcactctgttaat 
 
  L  L  E  D  S  H  N  G  K  L  C  L  L  K  G  I  A  P  L  Q  L  G  N  C  S 
ctacttgaggacagtcacaatggaaaactatgtctactaaaaggaatagccccactacaattgggtaattgcagc 
cttttagaagattctcacaatggtaaattatgtttacttaaaggtattgctcctttataacttggtaattgttct 
 
  V  A  G  W  I  L  G  N  P  E  C  E  L  L  I  S  K  E  S  W  S  Y  I  V  E 
gttgccggatggatcttaggaaacccagaatgcgaattactgatttccaaggaatcatggtcctacattgtagaa 
gttgctggttggattcttggtaatcctgaatgtgaattacttatttctaaagaatcttggtcttatattgttgaa 
 
  T  P  N  P  E  N  G  T  C  Y  P  G  Y  F  A  D  Y  E  E  L  R  E  Q  L  S 
acaccaaatcctgagaatggaacatgttacccagggtatttcgccgactatgaggaactgagggagcaattgagt 
actcctaatcctgaaaatggtacttgttatcctggttatttcgctgattatgaagaattaagagaataactttct 
 
  S  V  S  S  F  E  R  F  E  I  F  P  K  E  S  S  W  P  N  H  T  V  T  G  V 
tcagtatcttcatttgagagattcgaaatattccccaaagaaagctcatggcccaaccacaccgtaaccggagta 
tctgtttcttcatttgaaagattcgaaattttccctaaagaatcttcttggcctaatcacactgttactggtgtt 
 
  S  A  S  C  S  H  N  G  K  S  S  F  Y  R  N  L  L  W  L  T  G  K  N  G  L 
tcagcatcatgctcccataatgggaaaagcagtttttacagaaatttgctatggctgacggggaagaatggtttg 
tctgcttcttgttctcataatggtaaatcttcattctatagaaatcttttatggttaactggtaaaaatggttta 
 
  Y  P  N  L  S  K  S  Y  V  N  N  K  E  K  E  V  L  V  L  W  G  V  H  H  P 
tacccaaacctgagcaagtcctatgtaaacaacaaagagaaagaagtccttgtactatggggtgttcatcacccg 
tatcctaatctttctaaatcttatgttaataataaggaaaaagaagttttagttctttggggtgttcaccaccct 
 
  P  N  I  G  N  Q  R  A  L  Y  H  T  E  N  A  Y  V  S  V  V  S  S  H  Y  S 
cctaacatagggaaccaaagggccctctatcatacagaaaatgcttatgtctctgtagtgtcttcacattatagc 
cctaatattggtaattaaagagctttatatcacactgaaaatgcttatgtttctgttgtttcttctcactattct 
 
  R  R  F  T  P  E  I  A  K  R  P  K  V  R  D  Q  E  G  R  I  N  Y  Y  W  T 
agaagattcaccccagaaatagccaaaagacccaaagtaagagatcaggaaggaagaatcaactactactggact 
agaagattcactcctgaaattgctaaaagacctaaagttagagattaagaaggtagaattaactattattggact 
 
  L  L  E  P  G  D  T  I  I  F  E  A  N  G  N  L  I  A  P  W  Y  A  F  A  L 
ctgctggaacctggggatacaataatatttgaggcaaatggaaatctaatagcgccatggtatgcttttgcactg 
ttattagaacctggtgatactattattttcgaagctaatggtaatcttattgctccttggtacgctttcgcttta 
 
  S  R  G  F  G  S  G  I  I  T  S  N  A  P  M  D  E  C  D  A  K  C  Q  T  P 
agtagaggctttggatcaggaatcatcacctcaaatgcaccaatggatgaatgtgatgcgaagtgtcaaacacct 
tctagaggtttcggttctggtattattacttctaatgctcctatggatgaatgtgatgctaaatgttaaactcct 
 
  Q  G  A  I  N  S  S  L  P  F  Q  N  V  H  P  V  T  I  G  E  C  P  K  Y  V 
cagggagctataaacagcagtcttcctttccagaatgtacacccagtcacaataggagagtgtccaaagtatgtc 
taaggtgctattaattcttctttacctttctaaaacgttcaccctgttactattggtgaatgtcctaaatatgtt 
 
  R  S  A  K  L  R  M  V  T  G  L  R  N  I  P  S  I  Q  S  R  G  L  F  G  A 
aggagtgcaaaattaaggatggttacaggactaaggaacatcccatccattcaatccagaggtttgtttggagcc 
agatcagctaaattaagaatggttactggtttaagaaatattccttctatctaatctagaggacttttcggtgct 
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  I  A  G  F  I  E  G  G  W  T  G  M  V  D  G  W  Y  G  Y  H  H  Q  N  E  Q 
attgccggtttcattgaaggggggtggactggaatggtagatgggtggtatggttatcatcatcagaatgagcaa 
attgctggtttcattgagggaggatggacaggtatggttgatggttggtacggttatcaccaccaaaatgaataa 
 
  G  S  G  Y  A  A  D  Q  K  S  T  Q  N  A  I  N  G  I  T  N  K  V  N  S  V 
ggatctggctatgctgcagatcaaaaaagtacacaaaatgccattaacgggattacaaacaaggtgaattctgta 
ggttctggttatgctgctgattaaaagtctactcaaaacgctattaatggtattactaacaaagttaattctgtt 
 
  I  E  K  M  N  T  Q  F  T  A  V  G  K  E  F  N  K  L  E  R  R  M  E  N  L 
attgagaaaatgaacactcaattcacagctgtgggcaaagaattcaacaaattggaaagaaggatggaaaactta 
attgaaaaaatgaatacttaattcactgctgttggtaaagaattcaataagttagaaagaagaatggaaaatctt 
 
  N  K  K  V  D  D  G  F  L  D  I  W  T  Y  N  A  E  L  L  V  L  L  E  N  E 
aataaaaaagttgatgatgggtttctagacatttggacatataatgcagaattgttggttctactggaaaatgaa 
aataagaaagttgatgatggtttcttagatatttggacttataatgctgaattattagttcttttagaaaatgaa 
 
  R  T  L  D  F  H  D  S  N  V  K  N  L  Y  E  K  V  K  S  Q  L  K  N  N  A 
aggactttggatttccatgactccaatgtgaagaatctgtatgagaaagtaaaaagccaattaaagaataatgcc 
agaactttagatttccacgattctaatgttaaaaatctttatgaaaaagttaaatcttaacttaagaataatgct 
 
  K  E  I  G  N  G  C  F  E  F  Y  H  K  C  N  N  E  C  M  E  S  V  K  N  G 
aaagaaataggaaacgggtgttttgaattctatcacaagtgtaacaatgaatgcatggagagtgtgaaaaatgga 
aaagaaattggtaatggttgtttcgaattctatcacaaatgtaataatgaatgtatggaatctgttaagaatggt 
 
  T  Y  D  Y  P  K  Y  S  E  E  S  K  L  N  R  E  K  I  D  G  V  K  L  E  S 
acttatgactatccaaaatattccgaagaatcaaagttaaacagggagaaaattgatggagtgaaattggaatca 
acttatgattatcctaaatattctgaagaatctaagttaaatagagaaaaaattgatggtgttaaattagaatct 
 
  M  G  V  Y  Q  I  L  Q  R  S  A  I  Y  S  T  V  A  S  S  L  V  L  L  V  S 
atgggagtctatcagattctg---------gcgatctactcaactgtcgccagttccctggttcttttggtctcc 
atgggagtttactaaattctttgaagatct--------------------------------------------- 
 
  L  G  A  I  S  F  W  M  C  S  N  G  S  L  Q  C  R  I  C  I  Q 
ctgggggcaatcagcttctggatgtgttccaatgggtctttgcagtgtagaatatgcatctga 
--------------------------------------------------------------- 
 
 
The upper line shows the non-optimized original sequence of the hemagglutinin of the 
Influenza A strain New Caledonia/20/99 (H1N1). The lower line shows the codon-optimized 
sequence (lower case letters). Differences are highlighted in yellow. The ER-leader sequence 
is depicted in blue letters, and the transmembrane domain in green letters as amino acid 
sequence (in capital letters). The added EcoRV restriction site (gatatc) and the BglII 
restriction site (agatct) are shown in red letters. The stop codon is highlighted in red, and the 
start codon is highlighted in purple. The truncation of the HA is demonstrated. 
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8.3 Alignment of the C-terminally truncated influenza A virus strain 
&ew Caledonia/20/99 (H1&1) hemagglutinin (&C344) 
 
 
  M  D  I  K  A  K  L  L  V  L  L  C  T  F  T  A  T  Y  A  D  T  I  C  I  G 
atg------aaagcaaaactactggtcctgttatgtacatttacagctacatatgcagacacaatatgtataggc 
atggatatcaaagctaagttattagttttactttgtactttcactgctacttatgctgatactatttgtattggt 
 
  Y  H  A  N  N  S  T  D  T  V  D  T  V  L  E  K  N  V  T  V  T  H  S  V  N 
taccatgccaacaactcaaccgacactgttgacacagtacttgagaagaatgtgacagtgacacactctgtcaac 
tatcacgctaataattctactgatactgttgatactgttttagaaaaaaatgttactgttactcactctgttaat 
 
  L  L  E  D  S  H  N  G  K  L  C  L  L  K  G  I  A  P  L  Q  L  G  N  C  S 
ctacttgaggacagtcacaatggaaaactatgtctactaaaaggaatagccccactacaattgggtaattgcagc 
cttttagaagattctcacaatggtaaattatgtttacttaaaggtattgctcctttataacttggtaattgttct 
 
  V  A  G  W  I  L  G  N  P  E  C  E  L  L  I  S  K  E  S  W  S  Y  I  V  E 
gttgccggatggatcttaggaaacccagaatgcgaattactgatttccaaggaatcatggtcctacattgtagaa 
gttgctggttggattcttggtaatcctgaatgtgaattacttatttctaaagaatcttggtcttatattgttgaa 
 
  T  P  N  P  E  N  G  T  C  Y  P  G  Y  F  A  D  Y  E  E  L  R  E  Q  L  S 
acaccaaatcctgagaatggaacatgttacccagggtatttcgccgactatgaggaactgagggagcaattgagt 
actcctaatcctgaaaatggtacttgttatcctggttatttcgctgattatgaagaattaagagaataactttct 
 
  S  V  S  S  F  E  R  F  E  I  F  P  K  E  S  S  W  P  N  H  T  V  T  G  V 
tcagtatcttcatttgagagattcgaaatattccccaaagaaagctcatggcccaaccacaccgtaaccggagta 
tctgtttcttcatttgaaagattcgaaattttccctaaagaatcttcttggcctaatcacactgttactggtgtt 
 
  S  A  S  C  S  H  N  G  K  S  S  F  Y  R  N  L  L  W  L  T  G  K  N  G  L 
tcagcatcatgctcccataatgggaaaagcagtttttacagaaatttgctatggctgacggggaagaatggtttg 
tctgcttcttgttctcataatggtaaatcttcattctatagaaatcttttatggttaactggtaaaaatggttta 
 
  Y  P  N  L  S  K  S  Y  V  N  N  K  E  K  E  V  L  V  L  W  G  V  H  H  P 
tacccaaacctgagcaagtcctatgtaaacaacaaagagaaagaagtccttgtactatggggtgttcatcacccg 
tatcctaatctttctaaatcttatgttaataataaggaaaaagaagttttagttctttggggtgttcaccaccct 
 
  P  N  I  G  N  Q  R  A  L  Y  H  T  E  N  A  Y  V  S  V  V  S  S  H  Y  S 
cctaacatagggaaccaaagggccctctatcatacagaaaatgcttatgtctctgtagtgtcttcacattatagc 
cctaatattggtaattaaagagctttatatcacactgaaaatgcttatgtttctgttgtttcttctcactattct 
 
  R  R  F  T  P  E  I  A  K  R  P  K  V  R  D  Q  E  G  R  I  N  Y  Y  W  T 
agaagattcaccccagaaatagccaaaagacccaaagtaagagatcaggaaggaagaatcaactactactggact 
agaagattcactcctgaaattgctaaaagacctaaagttagagattaagaaggtagaattaactattattggact 
 
  L  L  E  P  G  D  T  I  I  F  E  A  N  G  N  L  I  A  P  W  Y  A  F  A  L 
ctgctggaacctggggatacaataatatttgaggcaaatggaaatctaatagcgccatggtatgcttttgcactg 
ttattagaacctggtgatactattattttcgaagctaatggtaatcttattgctccttggtacgctttcgcttta 
 
  S  R  G  F  G  S  G  I  I  T  S  N  A  P  M  D  E  C  D  A  K  C  Q  T  P 
agtagaggctttggatcaggaatcatcacctcaaatgcaccaatggatgaatgtgatgcgaagtgtcaaacacct 
tctagaggtttcggttctggtattattacttctaatgctcctatggatgaatgtgatgctaaatgttaaactcct 
 
  Q  G  A  I  N  S  S  L  P  F  Q  N  V  H  P  V  T  I  G  E  C  P  K  Y  V 
cagggagctataaacagcagtcttcctttccagaatgtacacccagtcacaataggagagtgtccaaagtatgtc 
taaggtgctattaattcttctttacctttctaaaacgttcaccctgttactattggtgaatgtcctaaatatgtt 
 
  R  S  A  K  L  R  M  V  T  G  L  R  N  I  P  S  I  Q  S  R  Q  R  S  G  L 
aggagtgcaaaattaaggatggttacaggactaaggaacatcccatccattcaatccaga---------ggtttg 
agatcagctaaattaagaatggttactggtttaagaaatattccttctatctaatctagatgaagatct------ 
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  F  G  A  I  A  G  F  I  E  G  G  W  T  G  M  V  D  G  W  Y  G  Y  H  H  Q 
attgccggtttcattgaaggggggtggactggaatggtagatgggtggtatggttatcatcatcagaatgagcaa 
--------------------------------------------------------------------------- 
  N  E  Q  G  S  G  Y  A  A  D  Q  K  S  T  Q  N  A  I  N  G  I  T  N  K  V 
tttggagccggatctggctatgctgcagatcaaaaaagtacacaaaatgccattaacgggattacaaacaaggtg 
--------------------------------------------------------------------------- 
 
  N  S  V  I  E  K  M  N  T  Q  F  T  A  V  G  K  E  F  N  K  L  E  R  R  M 
aattctgtaattgagaaaatgaacactcaattcacagctgtgggcaaagaattcaacaaattggaaagaaggatg 
--------------------------------------------------------------------------- 
 
  E  N  L  N  K  K  V  D  D  G  F  L  D  I  W  T  Y  N  A  E  L  L  V  L  L 
gaaaacttaaataaaaaagttgatgatgggtttctagacatttggacatataatgcagaattgttggttctactg 
--------------------------------------------------------------------------- 
 
  E  N  E  R  T  L  D  F  H  D  S  N  V  K  N  L  Y  E  K  V  K  S  Q  L  K 
gaaaatgaaaggactttggatttccatgactccaatgtgaagaatctgtatgagaaagtaaaaagccaattaaag 
--------------------------------------------------------------------------- 
 
  N  N  A  K  E  I  G  N  G  C  F  E  F  Y  H  K  C  N  N  E  C  M  E  S  V 
aataatgccaaagaaataggaaacgggtgttttgaattctatcacaagtgtaacaatgaatgcatggagagtgtg 
--------------------------------------------------------------------------- 
 
  K  N  G  T  Y  D  Y  P  K  Y  S  E  E  S  K  L  N  R  E  K  I  D  G  V  K 
aaaaatggaacttatgactatccaaaatattccgaagaatcaaagttaaacagggagaaaattgatggagtgaaa 
--------------------------------------------------------------------------- 
 
  L  E  S  M  G  V  Y  Q  I  L  A  I  Y  S  T  V  A  S  S  L  V  L  L  V  S 
ttggaatcaatgggagtctatcagattctggcgatctactcaactgtcgccagttccctggttcttttggtctcc 
--------------------------------------------------------------------------- 
 
  L  G  A  I  S  F  W  M  C  S  N  G  S  L  Q  C  R  I  C  I  Q 
ctgggggcaatcagcttctggatgtgttccaatgggtctttgcagtgtagaatatgcatctga 
--------------------------------------------------------------- 
 
The upper line shows the non-optimized original sequence of the hemagglutinin of the 
Influenza A strain New Caledonia/20/99 (H1N1). The lower line shows the codon-optimized 
sequence (lower case letters). Differences are highlighted in yellow. The ER-leader sequence 
is depicted in blue letters, and the transmembrane domain in green letters as amino acid 
sequence (in capital letters). The added EcoRV restriction site (gatatc) and the BglII 
restriction site (agatct) are shown in red letters. The stop codon is highlighted in red, and the 
start codon is highlighted in purple. The truncation of the HA is demonstrated. 
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8.4 Alignment of the influenza A virus strain Uruguay/716/2007 (H3&2) hemagglutinin 
 
 
  M  D  I  K  T  I  I  A  L  S  Y  I  L  C  L  V  F  T  Q  K  L  P  G  N  D 
atg------aagactatcattgctttgagctacattctatgtctggttttcactcaaaaacttcccggaaatgac 
atggatatcaagactattattgctctttcttacattctttgccttgttttcacttaaaagttacctggtaatgat 
 
  N  S  T  A  T  L  C  L  G  H  H  A  V  P  N  G  T  I  V  K  T  I  T  N  D 
aacagcacggcaacgctgtgccttgggcaccatgcagtaccaaacggaacgatagtgaaaacaatcacgaatgac 
aattctactgctactttatgccttggtcaccacgctgttcctaatggtactattgttaagactattactaacgat 
 
  Q  I  E  V  T  N  A  T  E  L  V  Q  S  S  S  T  G  E  I  C  D  S  P  H  Q 
caaattgaagttactaatgctactgagctggttcagagttcctcaacaggtgaaatatgcgacagtcctcatcag 
caaattgaagttactaatgctactgaacttgtttaatcttcttctactggtgaaatttgcgattctcctcactaa 
 
  I  L  D  G  E  N  C  T  L  I  D  A  L  L  G  D  P  Q  C  D  G  F  Q  N  K 
atccttgatggagaaaactgcacactaatagatgctctattgggagaccctcagtgtgatggcttccaaaataag 
attcttgatggtgaaaattgcactcttattgatgctttacttggtgatccttaatgtgatggtttccaaaacaag 
 
  K  W  D  L  F  V  E  R  S  K  A  Y  S  N  C  Y  P  Y  D  V  P  D  Y  A  S 
aaatgggacctttttgttgaacgcagcaaagcctacagcaactgttacccttatgatgtgccggattatgcctcc 
aagtgggatcttttcgttgaaagatcaaaggcttactctaattgctacccttacgatgttcctgattacgcttct 
 
  L  R  S  L  V  A  S  S  G  T  L  E  F  N  N  E  S  F  N  W  T  G  V  T  Q 
cttaggtcactagttgcctcatccggcacactggagtttaacaatgaaagcttcaattggactggagtcactcaa 
cttagaagtcttgttgcttcttctggtactcttgaattcaataatgaatctttcaattggactggtgttactcaa 
 
  N  G  T  S  S  A  C  I  R  R  S  N  N  S  F  F  S  R  L  N  W  L  T  H  L 
aacggaacaagctctgcttgcataaggagatctaataacagtttctttagtagattgaattggttgacccactta 
aacggtacttcttctgcttgcattagaagatcaaataattctttcttctctagacttaattggcttactcacctt 
 
  K  F  K  Y  P  A  L  N  V  T  M  P  N  N  E  K  F  D  K  L  Y  I  W  G  V 
aaattcaaatacccagcattgaacgtgactatgccaaacaatgaaaaatttgacaaattgtacatttggggggtt 
aagttcaagtaccctgctcttaatgttactatgcctaataatgaaaagttcgataagctttacatttggggtgtt 
 
  H  H  P  G  T  D  N  D  Q  I  F  L  Y  A  Q  A  S  G  R  I  T  V  S  T  K 
caccacccgggtacggacaatgaccaaatcttcctgtatgctcaagcatcaggaagaatcacagtctctaccaaa 
caccaccctggtactgataatgatcaaattttcctttacgcttaagcttctggtagaattactgtttctactaag 
 
  R  S  Q  Q  T  V  I  P  N  I  G  S  R  P  R  V  R  N  I  P  S  R  I  S  I 
agaagccaacaaactgtaatcccgaatatcggatctagacccagagtaaggaatatccccagcagaataagcatc 
agatcataacaaactgttattcctaatattggttctagacctagagttagaaatattccttctagaatttctatc 
 
  Y  W  T  I  V  K  P  G  D  I  L  L  I  N  S  T  G  N  L  I  A  P  R  G  Y 
tattggacaatagtaaaaccgggagacatacttttgattaacagcacagggaatctaattgctcctaggggttac 
tactggactattgttaaacctggtgatattcttcttattaactctactggtaatcttattgctcctagaggatac 
 
  F  K  I  R  S  G  K  S  S  I  M  R  S  D  A  P  I  G  K  C  N  S  E  C  I 
ttcaaaatacgaagtgggaaaagctcaataatgagatcagatgcacccattggcaaatgcaattctgaatgcatc 
ttcaaaattagaagtggtaaatcttctattatgagatcagatgctcctattggtaaatgcaattctgaatgcatt 
 
  T  P  N  G  S  I  P  N  D  K  P  F  Q  N  V  N  R  I  T  Y  G  A  C  P  R 
actccaaacggaagcattcccaatgacaaaccattccaaaatgtaaacaggatcacatacggggcctgtcccaga 
actcctaatggttctattcctaatgataagcctttccaaaacgttaatagaattacttacggtgcttgccctaga 
 
  Y  V  K  Q  N  T  L  K  L  A  T  G  M  R  N  V  P  E  K  Q  T  R  G  I  F 
tatgttaagcaaaacactctgaaattggcaacagggatgcgaaatgtaccagagaaacaaactagaggcatattt 
tacgttaagcaaaacactcttaagcttgctactggaatgagaaatgttcctgaaaagtaaactagaggaattttc 
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  G  A  I  A  G  F  I  E  N  G  W  E  G  M  V  D  G  W  Y  G  F  R  H  Q  N 
ggcgcaatcgcgggtttcatagaaaatggttgggagggaatggtggatggttggtacggtttcaggcatcaaaat 
ggtgctattgctggtttcattgaaaatggttgggaaggaatggttgatggttggtacggtttcagacaccaaaac 
 
  S  E  G  I  G  Q  A  A  D  L  K  S  T  Q  A  A  I  D  Q  I  N  G  K  L  N 
tctgagggaataggacaagcagcagatctcaaaagcactcaagcagcaatcgatcaaatcaatgggaagctgaat 
tctgaaggtattggttaagctgctgatcttaagtctacttaagctgctattgatcaaattaatggaaagcttaac 
 
  R  L  I  G  K  T  N  E  K  F  H  Q  I  E  K  E  F  S  E  V  E  G  R  I  Q 
aggttgatcgggaaaaccaacgagaaattccatcagattgaaaaagaattctcagaagtcgaagggagaattcag 
agacttattggtaaaactaacgaaaagttccactaaattgaaaaagaattctctgaagttgaaggtagaatctag 
 
  D  L  E  K  Y  V  E  D  T  K  I  D  L  W  S  Y  N  A  E  L  L  V  A  L  E 
gaccttgagaaatatgttgaggacaccaaaatagatctctggtcatacaacgcggagcttcttgttgccctggag 
gatcttgaaaaatacgttgaagatactaagattgatctttggtcttacaatgctgaacttcttgttgctcttgaa 
 
  N  Q  H  T  I  D  L  T  D  S  E  M  N  K  L  F  E  K  T  K  K  Q  L  R  E 
aaccaacatacaattgatctaactgactcagaaatgaacaaactgtttgaaaaaacaaagaagcaactgagggaa 
aattaacacactattgatcttactgattctgaaatgaataagcttttcgaaaagactaagaagtaacttagagaa 
 
  N  A  E  D  M  G  N  G  C  F  K  I  Y  H  K  C  D  N  A  C  I  G  S  I  R 
aatgctgaggatatgggcaatggttgtttcaaaatataccacaaatgtgacaatgcctgcataggatcaatcaga 
aacgctgaagatatgggtaatggttgcttcaagatataccacaagtgcgataatgcttgcattggttctattaga 
 
  N  G  T  Y  D  H  D  V  Y  R  D  E  A  L  N  N  R  F  Q  I  K  G  V  E  L 
aatggaacttatgaccacgatgtatacagagatgaagcattaaacaaccggttccagatcaagggcgttgagctg 
aatggtacttacgatcacgatgtttacagagatgaagctcttaacaatagattctaaattaagggtgttgaactt 
 
  K  S  G  Y  K  D  W  I  L  W  I  S  F  A  I  S  C  F  L  L  C  V  A  L  L 
aagtcaggatacaaagattggatcctatggatttcctttgccatatcatgttttttgctttgtgttgctttgttg 
aagtctggttacaaggattggattctttggatttctttcgctatttcttgcttccttctttgcgttgctctttta 
 
  G  F  I  Q  R  S 
gggttcatcatg------ 
ggtttcatttgaagatct 
 
 
The upper line shows the non-optimized original sequence of the hemagglutinin of the 
Influenza A strain Uruguay/716/2007 (H3N2). The lower line shows the codon-optimized 
sequence (lower case letters). Differences are highlighted in yellow. The ER-leader sequence 
is depicted in blue letters, and the transmembrane domain in green letters as amino acid 
sequence (in capital letters). The added EcoRV restriction site (gatatc) and the BglII 
restriction site (agatct) are shown in red letters. The stop codon is highlighted in red, and the 
start codon is highlighted in purple. 
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8.5 Alignment of the influenza B virus strain Florida/4/2006 hemagglutinin 
 
 
  M  D  I  K  A  I  I  V  L  L  M  V  V  T  S  N  A  D  R  I  C  T  G  I  T 
atg------aaggcaataattgtactactcatggtagtaacatccaatgcagatcgaatctgcactggaataaca 
atggatatcaaggctattattgttcttcttatggttgttacttctaatgctgatagaatttgcactggtattact 
 
  S  S  N  S  P  H  V  V  K  T  A  T  Q  G  E  V  N  V  T  G  V  I  P  L  T 
tcttcaaactcacctcatgtggtcaaaacagccactcaaggggaggtcaatgtgactggtgtgataccactaaca 
tcatctaattctcctcacgttgttaagactgctacttaaggagaagttaacgttactggtgttattcctcttact 
 
  T  T  P  T  K  S  Y  F  A  N  L  K  G  T  R  T  R  G  K  L  C  P  D  C  L 
acaacaccaacaaaatcttattttgcaaatctcaaaggaacaaggaccagagggaaactatgcccagactgtctc 
actactcctactaagtcttacttcgctaatcttaagggtactagaactagaggaaaactttgccctgattgcctt 
 
  N  C  T  D  L  D  V  A  L  G  R  P  M  C  V  G  T  T  P  S  A  K  A  S  I 
aactgcacagatctggatgtggctttgggcagaccaatgtgtgtggggaccacaccttcggcgaaagcttcaata 
aattgcactgatcttgatgttgctcttggtagacctatgtgtgttggtactactccttctgctaaggcttctatt 
 
  L  H  E  V  K  P  V  T  S  G  C  F  P  I  M  H  D  R  T  K  I  R  Q  L  P 
ctccacgaagtcaaacctgttacatccgggtgctttcctataatgcacgacagaacaaaaatcaggcaactaccc 
cttcacgaagttaagcctgttacttctggttgcttccctattatgcacgatagaactaagattagataacttcct 
 
  N  L  L  R  G  Y  E  N  I  R  L  S  T  Q  N  V  I  D  A  E  K  A  P  G  G 
aatcttctcagaggatatgaaaatatcaggctatcaacccaaaacgtcatcgatgcggaaaaggcaccaggagga 
aatcttcttagaggttacgaaaacattagactttctactcaaaacgttattgatgctgaaaaggctcctggtggt 
 
  P  Y  R  L  G  T  S  G  S  C  P  N  A  T  S  K  S  G  F  F  A  T  M  A  W 
ccctacagacttggaacctcaggatcttgccctaacgctaccagtaagagcggatttttcgcaacaatggcttgg 
ccttacagacttggtacttctggttcttgtcctaatgctacttctaagtctggtttcttcgctactatggcttgg 
 
  A  V  P  K  D  N  N  K  N  A  T  N  P  L  T  V  E  V  P  Y  I  C  T  E  G 
gctgtcccaaaggacaacaacaaaaatgcaacgaacccactaacagtagaagtaccatacatttgtacagaaggg 
gctgttcctaaggataacaataagaatgctactaatcctcttactgttgaagttccttacatttgcactgaagga 
 
  E  D  Q  I  T  V  W  G  F  H  S  D  D  K  T  Q  M  K  N  L  Y  G  D  S  N 
gaagaccaaatcactgtttgggggttccattcagatgacaaaacccaaatgaagaacctctatggagactcaaat 
gaagatcaaattactgtttggggtttccactctgatgataagacttaaatgaagaatctttacggtgattctaat 
 
  P  Q  K  F  T  S  S  A  N  G  V  T  T  H  Y  V  S  Q  I  G  S  F  P  D  Q 
cctcaaaagttcacctcatctgctaatggagtaaccacacactatgtttctcagattggcagcttcccagatcaa 
ccttaaaagttcacttcttctgctaatggtgttactactcactacgtttcttaaattggttctttccctgattaa 
 
  T  E  D  G  G  L  P  Q  S  G  R  I  V  V  D  Y  M  M  Q  K  P  G  K  T  G 
acagaagacggaggactaccacaaagcggcaggattgttgttgattacatgatgcaaaaacctgggaaaacagga 
actgaagatggtggtttaccttaatctggtagaattgttgttgattacatgatgtaaaagcctggtaaaactggt 
 
  T  I  V  Y  Q  R  G  V  L  L  P  Q  K  V  W  C  A  S  G  R  S  K  V  I  K 
acaattgtctaccaaagaggtgttttgttgcctcaaaaggtgtggtgcgcgagtggcaggagcaaagtaataaaa 
actattgtttactaaagaggtgttcttcttccttaaaaagtttggtgcgcttctggtagatcaaaagttattaag 
 
  G  S  L  P  L  I  G  E  A  D  C  L  H  E  K  Y  G  G  L  N  K  S  K  P  Y 
gggtccttgcctttaattggtgaagcagattgccttcatgaaaaatacggtggattaaacaaaagcaagccttac 
ggttctcttcctcttattggtgaagctgattgcttacacgaaaagtacggtggtcttaataagtctaagccttac 
 
  Y  T  G  E  H  A  K  A  I  G  N  C  P  I  W  V  K  T  P  L  K  L  A  N  G 
tacacaggagaacatgcaaaagccataggaaattgcccaatatgggtgaaaacacctttgaagcttgccaatgga 
tacactggtgaacacgctaaggctattggtaattgccctatttgggttaagactcctttaaagcttgctaatggt 
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  T  K  Y  R  P  P  A  K  L  L  K  E  R  G  F  F  G  A  I  A  G  F  L  E  G 
accaaatatagacctcctgcaaaactattaaaggaaaggggtttcttcggagctattgctggtttcctagaagga 
actaagtacagacctcctgctaagttacttaaagaaagaggattctttggtgctattgctggtttccttgaagga 
 
  G  W  E  G  M  I  A  G  W  H  G  Y  T  S  H  G  A  H  G  V  A  V  A  A  D 
ggatgggaaggaatgattgcaggctggcacggatacacatctcacggagcacatggagtggcagtggcggcggac 
ggttgggaaggaatgattgctggttggcacggttatacttctcatggtgctcacggtgttgctgttgctgctgat 
 
  L  K  S  T  Q  E  A  I  N  K  I  T  K  N  L  N  S  L  S  E  L  E  V  K  N 
cttaagagtacgcaagaagctataaacaagataacaaaaaatctcaattctttgagtgagctagaagtaaagaat 
cttaagtctacttaagaagctattaacaagattactaagaatcttaattctctttctgaacttgaagttaaaaat 
 
  L  Q  R  L  S  G  A  M  D  E  L  H  N  E  I  L  E  L  D  E  K  V  D  D  L 
cttcaaagactaagtggtgccatggatgaactccacaacgaaatactcgagctggatgagaaagtggatgatctc 
ctttaaagactttctggtgctatggatgaacttcacaatgaaattcttgaacttgatgaaaaagttgatgatctt 
 
  R  A  D  T  I  S  S  Q  I  E  L  A  V  L  L  S  N  E  G  I  I  N  S  E  D 
agagctgacactataagctcgcaaatagaacttgcagtcttgctttccaacgaaggaataataaacagtgaagat 
agagctgatactatttcttcttaaattgaacttgctgttcttctttctaatgaaggtatcattaactctgaagat 
 
  E  H  L  L  A  L  E  R  K  L  K  K  M  L  G  P  S  A  V  E  I  G  N  G  C 
gagcatctattggcacttgagagaaaactaaagaaaatgctgggtccctctgctgtagagataggaaatggatgc 
gaacaccttcttgctcttgaaagaaagcttaagaagatgcttggtccttctgctgttgaaattggtaatggttgc 
 
  F  E  T  K  H  K  C  N  Q  T  C  L  D  R  I  A  A  G  T  F  N  A  G  E  F 
ttcgaaaccaaacacaagtgcaaccagacctgcttagacaggatagctgctggcacctttaatgcaggagaattt 
ttcgaaactaagcacaagtgcaattaaacttgccttgatagaattgctgctggtactttcaatgctggtgaattc 
 
  S  L  P  T  F  D  S  L  N  I  T  A  A  S  L  N  D  D  G  L  D  N  H  T  Q 
tctctccccacttttgattcactgaacattactgctgcatctttaaatgatgatggattggataaccatactata 
tctcttcctactttcgattctcttaacattactgctgcttctcttaatgatgatggtcttgataatcacacttga 
 
  R  S 
------ 
agatct 
 
 
The upper line shows the non-optimized original sequence of the hemagglutinin of the 
Influenza B strain Florida/4/2006. The lower line shows the codon-optimized sequence (lower 
case letters). Differences are highlighted in yellow. The ER-leader sequence is depicted in 
blue letters, and the transmembrane domain in green letters as amino acid sequence (in capital 
letters). The added EcoRV restriction site (gatatc) and the BglII restriction site (agatct) are 
shown in red letters. The stop codon is highlighted in red, and the start codon is highlighted in 
purple. 
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8.6 Sequence of the Grl3 gene with 5´and 3´flanking region 
 
aaggtgctgctatgggagagaaaatatgtttttttaatcaaataaagaatcgtttttaattttgctgccttttat
ttcttcatctaaaattttgaatgcataaacattctggtaacatctaatgcaaaatcaataaatattatttaatgc
tcataaaatttcattcattttatcaagtgattgtatgcattattaagtatttattttatatttattattaacaat
ataaggcaatcattttattttagcttttaaacataatctttctccaatataacgtttaaattgttgaagaggtat
ggaaatttaagtaggtatccttaaacaaagaacatatttcatgctcataaatttttatcacagtttagtattttc
atctttgtaataacaacaatacctaccatttttgtatttaaaagcatatccgggttaaggggtaatttgaatcca
tttttgaaaaacaaatttatatttgaagttttgagtgctcctaagtgcgttattgaatatttttttggacatgat
aaaatgggatgatgctattgagagggcttcaattataataatgaaagataaaagcgtcaattatctaaatagaat
aagattcgtttaagaaaatttgattaaggaaaatgaatggaagcatacaaaatacaaggaattagatttctacgt
tttaacttaatatctgtttcggaaaacggctaaaaaacaaagaggtttaatagaataggattttttgttatcaac
tggctttctcccccgactttccttttgtttttctttattaattaaagcaatcttcattatttattttcaaaagag
aatgaaaaaaataaattaattaataagcaaaaactcattttttatataaacaaaaaagaaaaataaattaaaaaa
aacgaaaaaaaaaaacaaaagaaaagtaatattcgattccttgcgatgaagaatttagctatcgttttggctact
ttgtgcatttttgctcaagccacaagtgtcttcgagacccctgctttccttgaagtaagctatttcttaatctaa
taaagagatcagaccaaatatgagataaagcattttatcttcccacctactttcactttctcctcacctgataat
ttaattattaataacttctcatggagcaacgagaagttacaactaagttaaatttgatgtttaatcaatcgaata
cacaaaaggagtatcgcgttgcataaaaaaagaaatatatggaggatacagctcttcacattcaaaaattttttt
atttaagatttccactcttacccccaaagaatataaaaagaagatcgcttatcctcttaagattaaacaaacaaa
caaacaaacatacagaatgaggttttctataatttaagtgtgaaaagaaatgcgaaaagtaaaaacaactaatca
aataaacgtcaatcaaaaccaactgcatttaattgaactagctttaattttgctaaattaaagatgattcattca
ttaatccctcagtttttttaacttctttaattttacaattaaagcttttttattcttttcacataaacgttttgg
aaatcaatcaaattgcaaccaacaaactctttccttaatggtatatcaggtgcttgtttgagatttgttttaagc
taattgaaccttttattcatctagcctttaacacagaatatacccaccatattatttttttaagctcactaattt
attgaaactctgaagaaggtgtttattcatttaaaataaatacaaccataaagttgaatgaatatgctttaatta
attaattaattttcttctgtctgtctgactctctttttaaaatatttaaaatgtttaatacttttattaacatta
aatttttttattaatagattaagagcaaccccttcggtcacaccgttgcttctttggtttaattaaacttaggtg
ctggataaagtgctggtagattagatgctattgctgaagccttgaacactattgaagcttaactcgaaaatacca
gagatcacaatgatgctgaaatccaaagacaaagaggctggtgcagtgatcaagaagctaccatctaagctaaca
ttgattaagctgaaagtgatttgagcaactactaaaacgaataaacttaaagaaactaagccgttgctgacctca
cccaaaacttaaacaacgaataataatccctcgctgaaaactaaaataacttagccaacgcctaataggaattag
atgatgaaaactcttcttatgctgaatcctctaaggactacgctgatgctattgctgcttgtgaataagctctca
agctcttagccaccttgtaaactaacccctccggtttcatctaatctaaggctagattcggtaacgttgttactc
tcctccaaaagcaccttgccaacaagtcttccaacttcgttcaacccatcttgaacgtcttgactgaaatggcta
gctccaccaacgaagttgactaatccagtcttgctaaggttgtttctctcattaacgatttattagaagaattaa
gaaactaaagtgctgctaatgactaaagacactaataagttgttgatagcctcacctccaacattgcaaatctcg
aacaacttattgataattctaacaaccttatttcataatactaaggttaaatctaagaaaatgaagacagattag
cctaacttgctggtcttatccaacaaacctaagctatccttgactaagccaactaaaatcttagctaagtttaag
attaatgcgctggatacgatcaagaatatgcttctttcaagaacgaagtgtaattaatctatttattcattcatt
tctccatattttcatttatttattttactcctacttataatgaataatttatttaattatatttatattaatagt
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gatcaataactcgctaccttataagccctcaaggaatatttcaagagcaaggttgttcctgctgttgaaaacatt
aacgattctgcttatgctgatgaattaactgttgatgtttgatttctctaatatacaagcaaaatttaaggttat
tcctataatcgatattacttcaaatagctttgagtatttatgatttgaagaagaatattaaaatatatgtttacg
aaacaacaattcatatcatggtctatgttgtacttctttcttacttttttatgaatcaatatcattactttttac
aaatcatatctttttaaattccattaatatttgtttgtctattcgaaatttgataattaatacattaaatttcat
acatatatataaacacacaatcattcattttttgatttattaattcattcatttttttgtttatttatttaaaaa
tatattcattcacattttttgaaattcatttaattaaaatgcaaaattaaatcccaaaatcttttatctttttat
taataaaataaattactcaaacagttaagccaaaatttttatcaatagataatttagttaataaaacaataattg
aatacaaaatgtattttaattttttttgggta 
 
The 5´flanking region of the Grl3 gene is shown in green, the 3´flanking region in red. The 
Grl3 gene is shown in black letters. 
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